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Abstract 
Dendritic cells (DCs) are potent antigen presenting cells and are crucially involved in the 
induction of the adaptive immune response. Multiple DC subsets exist in the body at rest 
and during inflammation with unique tissue origins and development. The main function of 
DCs is the uptake of antigen from the peripheral tissue by endocytosis, and the transfer of 
this antigen to T cells within the lymph nodes (LNs) to generate an immune response 
against the antigen. Given the potency of the potential T cell response, DCs are an 
attractive cell type for therapeutic use in contexts such as cancer. Over 20 years of clinical 
trials have developed DCs for this purpose: although significant progress has been made, 
DC clinical trials still show subclinical and variable T cell responses in patients. Numerous 
strategies have been tested to improve this, including use of specific DC subsets, ex vivo 
activation and maturation of the cells using cytokines, different antigen loading strategies 
and different routes of injection. These, however, do not sufficiently take into 
consideration the migration capability of these injected cells, which severely limits the 
potential cell function.  
CCR7 is the chemokine receptor crucially involved in DC homing to LNs and is a marker 
of DC maturity, but it has been shown that ex vivo-generated cells do not consistently 
express this receptor. Using a novel sorting methodology to isolate DCs expressing CCR7, 
it is possible to improve the maturity and function of the injected cells, as well as in vivo 
migration. CCR7-expressing cells are more capable of generating mature T cell responses 
in vitro due to the expression of co-stimulatory molecules such as CD80 and CD86 and the 
production of T cell-attracting chemokines. The B16F10 mouse melanoma was used to 
assess the potential improvement in therapeutic DC use following CCR7-sorting. In the 
subcutaneous model after a single injection, or multiple prophylactic injections, of CCR7-
sorted DCs there was significant control of the tumour growth and this resulted in a longer 
survival duration. This was attributed to the increased T cell response induced by DCs 
reaching the LN, as more antigen-specific T cells were present in the CCR7-expressing 
DC-receiving animals and that the T cell phenotype was more mature by surface marker 
expression. In the metastatic model, however, there was no difference in the overall tumour 
burden between groups despite having a significantly improved antigen-specific T cell 
response following injection of the CCR7-sorted DCs. Finally, it was shown that this 
CCR7-sorting methodology is directly translatable to clinical use using the clinical grade 
MACSQuant Tyto cell sorter, and that CCR7-sorted human monocyte-derived DCs were 
also more potent activators of T cells in vitro.   
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1 Introduction  
Introduction 20 
 
1.1 Overview 
The aim of this thesis is to investigate the mechanisms involved in dendritic cell (DC) 
migration, and in particular the expression of the chemokine receptor CCR7. This 
introduction will first discuss dendritic cell development, migration and function and the 
role that CCR7 plays in these. It will then discuss the development of tumours, in 
particular the immunological aspect of this process and why targeting the immune system 
is a viable route for therapy. Lastly, the current state of DC clinical use will be discussed in 
the context of cancer therapy with the potential improvements which could be made to DC 
therapies to increase their clinical efficacy. 
1.2 Dendritic cells 
DCs are the most potent antigen presenting cells (APCs) in the body and mediate the 
adaptive immune response between inflammation and tolerance. Since their discovery by 
Steinman and Cohn in the 1970s, several distinct subsets of DCs have been characterised 
(Steinman and Cohn, 1973). DCs can be identified by their expression of the 
haematopoietic lineage marker cluster of differentiation (CD) 45, major histocompatibility 
complex (MHC) class II, and CD11c in both mice and humans. DCs are environmental 
sensors: involved in the sampling and uptake of antigen in peripheral tissues and transfer of 
this antigen to secondary lymphoid organs (SLOs) such as the lymph nodes (LNs) by 
presentation to T cells, B cells and natural killer (NK) cells (Schmid et al., 2000). Since 
their first description in the 1970s, DCs have been identified in almost all tissues in the 
body. Under homeostatic conditions, uptake of antigen from barrier tissues such as the skin 
and gut leads to the development of immune tolerance. This suppresses T cell responses to 
innocuous antigens from food or commensal microorganisms (Marelli-Berg et al., 2008). 
In comparison, with accompanying inflammation such as infection or cancer, presentation 
of antigen can instead induce an immunogenic T cell response. While particular DC 
subsets are specialised for a role in homeostasis, including Langerhans cells (LCs), 
conventional DCs (cDCs) and plasmacytoid DCs (pDCs), most DC subsets can contribute 
to an inflammatory response and include ‘emergency’ monocyte-derived DCs (MoDCs). 
Ontogeny and function of these cells will be described in this section.  
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1.2.1 Development of DC subsets 
1.2.1.1 Langerhans cells 
The earliest appearance of cells in the body which resemble DCs is during embryonic 
development. LCs are exceptional among DC subsets, being derived by primitive 
myelopoiesis from the yolk sac and foetal liver (Romani et al., 2003). Early embryonic 
macrophage-erythrocyte precursors (EMPs) respond to signals from interleukin (IL) -34 
using the macrophage-colony stimulating factor (M-CSF) receptor during early embryonic 
development (Wang et al., 2012). Since EMPs also give rise to tissue-specific 
macrophages during embryogenesis, there has been significant debate on whether LCs 
represent a tissue-specific macrophage or DC. The LC population is maintained by a pool 
of local self-renewing precursors in the dermis with some contribution of bone marrow-
derived cells at rest (Kissenpfennig and Malissen, 2006). These precursors in the skin, 
explored in adoptive transfer studies using the Id2-/- knockout mice which prevent 
development of cells expressing the conventional LC marker langerin, are replaced by 
short-term monocyte-derived LCs (Seré et al., 2012).  
During homeostasis, LCs reside in the stratified epithelium of tissues such as the 
epidermis, cornea, oral cavity, esophagus and vagina in an immature state, and comprise 
between 2-3% of the total cells in these tissues. LCs have been historically identified in the 
tissue by the expression of the C-type lectin langerin, but also express E-cadherin, CD1a 
and CD1c; and lack the typical monocyte marker CD14 (Larregina et al., 2001). The ‘LC 
paradigm’ describes the role of LCs in surveillance of the tissue; where they recognise 
potential exposure to pathogens through uptake and transfer of antigens to T cells in the 
cutaneous-draining LNs. Integration of pathogen antigens and inflammatory context of the 
tissue allows LNs to effectively instruct the magnitude and phenotype of the adaptive 
response to the antigen (Villadangos and Heath, 2005). In the absence of inflammation, 
LCs promote immune tolerance, but have been shown to be able to prime cytotoxic T cell 
responses in response to tissue inflammation (Kissenpfennig and Malissen, 2006).  
While the phenotypic identity of LCs remains controversial, cell function more closely 
aligns them with true DCs than macrophages. As discussed, LCs uptake antigen in the 
periphery, undergo a classic maturation protocol resulting in migration to the LNs, and 
present antigen to T cells during both normal homeostasis and inflammatory conditions. 
This functionally aligns them with other DC subsets. Hierarchical clustering studies also 
align LCs with other conventional DC subsets by transcriptional profile (Carpentier et al., 
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2016). In addition to this, it will be shown that LCs can be used for this purpose in a 
clinical context.  
1.2.1.2 Conventional DCs  
Conventional, or myeloid DCs (cDCs) are a population of blood-borne DCs which 
circulate both lymphoid and nonlymphoid tissue during homeostasis. cDCs are produced 
by the bone marrow, through definitive myelopoiesis from macrophage/dendritic cell 
precursors (MDPs). Signaling through FMS-related tyrosine kinase 3 ligand (Flt3-L) in the 
bone marrow microenvironment commits MDPs to the common dendritic cell precursor 
(CDP) lineage. This gives rise to both cDC1 and cDC2 subsets through a common pre-
cDC precursor stage following granulocyte macrophage colony stimulating factor (GM-
CSF) (Lutz et al., 2017).  
cDC1 and cDC2 subsets can be distinguished by surface marker expression, which in mice 
are CD103 and CD11b, respectively. In humans the same subset can be distinguished by 
CD141 and CD1c expression, respectively. CD103+ cDCs are present primarily in 
connective tissues, and express additional markers depending on the tissue in which they 
reside. In the Peyer’s patches, lymphoid organs in the intestine, CD103+ cDCs express 
CD8 and relatively low levels of MHC class II (Varol et al., 2009). In the lamina propria of 
the intestine, however, CD103+ cDCs coexpress CD11b. In other epithelial tissues such as 
the dermis of the skin, CD103+ cDCs can also express langerin (Merad, Ginhoux and 
Collin, 2008). CD11b+ cDCs are comprised of both true tissue cDCs and macrophages due 
to the expression of CD11b, although other markers such as CD64 can be used to 
distinguish the two in tissues such as the muscle (Langlet et al., 2012). 
Nonlymphoid cDCs in these tissues constantly migrate through the tissue to collect 
antigens and integrate inflammatory cues within the microenvironment to cells in the 
tissue-draining LNs (Randolph, Angeli and Swartz, 2005). This migration occurs in both 
the steady state and during inflammation, although uptake of antigen in the context of 
tissue inflammation highly upregulates MHC class II and T cell co-stimulatory molecules 
and produce inflammatory cytokines to induce a potent adaptive immune response. 
Significant experimental evidence suggests that cDCs may be superior at these processes 
than other DC subtypes (Villadangos and Schnorrer, 2007).  
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1.2.1.3 Plasmacytoid DCs 
pDCs originate from myeloid and lymphoid precursors in the bone marrow, although the 
myeloid CDP lineage is the predominant mechanism. Along with Flt3-L, the transcription 
factor E2-2 favours the development of pDCs from CDP precursors (Cisse et al., 2008). 
These cells can be identified by their unique surface marker profile; expressing CD4, 
CD303 (also known as BDCA2) and relatively low levels of CD11c (Cao, 2009). Unlike 
cDCs which at least partly develop during dissemination into tissues, pDCs exit the bone 
marrow as fully developed cells (Shortman and Naik, 2007). In the steady state, pDCs 
circulate the body through the blood and lymphoid organs, and can be detected in the LNs, 
spleen and thymus at rest (Takeuchi and Furue, 2007).  
pDCs also express toll like receptors (TLRs) 7 and 9, which are specifically involved in 
recognition of viral RNA and DNA. While they make up only 0.2-0.5% of cells in the 
peripheral blood at rest, pDCs produce almost 95% of the total Type I interferon (IFN) 
(also known as IFNα) by PBMCs (Siegal et al., 1999) to generate an antiviral defence. 
Antigen-inexperienced pDCs are already primed to respond rapidly upon detection of viral 
antigens, with IFN-production preceding maturation of the DC through production of 
IFNα. After exposure to antigen, pDCs undergo a classic DC maturation which includes 
upregulation of MHC class I and II and T cell costimulatory molecules, but lose the 
capacity to produce Type I IFN (Sozzani et al., 2010). Mature pDCs are phenotypically 
and functionally comparable to cDCs (Grouard et al., 1997; Shortman and Naik, 2007). 
1.2.1.4 Monocyte-derived DCs 
MoDCs, or inflammatory DCs, are a transient DC population derived by monocytic 
precursors in the blood or by emergency myelopoiesis from the bone marrow. As such, 
they are present in the blood at extremely low numbers at rest, but are detectable at a low 
level in the epithelia and mucosa (Jakubzick et al., 2013). Unlike other DC subsets, which 
require the Flt3-L growth factor for development, Flt3-L and its receptor Flt3 are 
dispensable for development of MoDCs (Mckenna et al., 2000). Instead, monocytes 
develop from common monocytic progenitors (cMoP) in the bone marrow using M-CSF 
and GM-CSF (Lutz et al., 2017). While GM-CSF knockout mice display no loss of MoDC 
generation or function in vitro, the deficiency of the M-CSF receptor significantly impairs 
this (Greter et al., 2012). In humans however, MoDCs do not require M-CSF for 
differentiation from PBMCs in vitro, making the role of these two growth factors difficult 
to fully elucidate (Lutz et al., 2017). 
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Although the phenotype of MoDCs is likely context dependent, murine inflammatory DCs 
can be identified by expression of CD11b, MHC class II and intermediate levels of CD11c 
in addition to the Ly6C monocyte marker (Domínguez et al., 2010). Extravasation into 
inflamed tissues downregulates Ly6C expression, making them difficult to distinguish 
from CD11b cDCs in situ. Inflammatory and infectious stimuli recruit monocytes into 
tissues, which can then differentiate into inflammatory DCs and can migrate to LNs and 
prime T cell responses (Zigmond et al., 2012). Since monocytes can also give rise to 
macrophages under the appropriate conditions, there is a significant transcriptional overlap 
between MoDCs and macrophages, but functionally this results in a more versatile T cell 
stimulatory capacity in MoDCs than subsets of cDCs (Lutz et al., 2017) 
1.2.1.5 Summary 
A summary of the development and function of LCs, cDCs, pDCs and MoDCs is shown in 
Figure 1.1, below. 
 
Figure 1.1 - Development of DC subsets from embryonic and adult tissues. 
Abbreviations: cDC = conventional DC; CDP = common DC precursor; CLP = common lymphoid 
progenitor; cMoP = common monocyte precursor; LC = Langerhans cell; MDC = macrophage and 
DC precursor; MoDC = monocyte-derived DC; pDC = plasmacytoid DC (Adapted from: Lutz et al., 
2017).  
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1.2.2 Antigen uptake and presentation 
DCs are the most potent APC in the body and can uptake antigens for presentation using a 
number of different mechanisms. Uptake of self or non-self antigens is followed by 
processing of the antigen by intracellular mechanisms and loading of the processed 
antigens onto MHC molecules presented on the cell surface. MHC molecules are 
subdivided into MHC class I and MHC class II, which are differentially expressed by DC 
subsets and stages of maturity, as described previously. DCs are capable of responding to a 
number of different potential antigen types, including pathogenic microorganisms, 
macromolecules such as proteins and other soluble antigens, and even cells undergoing 
apoptosis (Guermonprez et al., 2002). Maturation of DCs involves downregulation of 
endocytosis to modulate the uptake of further antigens after activation and during 
migration (Kamphorst et al., 2010). 
Immature DCs exhibit the most variety in antigen uptake mechanisms, although these are 
modulated during maturation. Nonspecific antigen uptake is possible by macropinocytosis, 
where DCs can rapidly sample surrounding fluid and internalise it through 
macropinosomes (West et al., 2000). Although significant in vitro evidence exists to 
support this phenomenon, its in vivo relevance is unclear as the majority of DC subsets 
sample antigen in the tissue with limited extracellular fluid. Phagocytosis is triggered by 
engagement of complement receptors, integrins or surface molecules such as CD36 for 
uptake of microorganisms, macromolecules and dying cells with varying efficiency 
between DC subsets (Guermonprez et al., 2002). Both pinocytosis and phagocytosis 
require intracellular actin polymerisation and membrane ruffling for the formation of 
vacuoles containing the antigen. 
Receptor-mediated endocytosis is another method of endocytosis which requires the 
expression of surface receptors such as lectins, scavenger receptors and pathogen 
receptors. Langerin, for example, is a C-type lectin expressed on LCs is a surface receptor 
used for phagocytosis (Valladeau et al., 2000). Expression of langerin creates the 
characteristic LC organelle known as Birbeck granules, which improve capture and 
processing of antigens. In contrast to phagocytosis, expression of receptors involved in 
receptor-mediated endocytosis signal vesicle formation for internalisation through clathrin-
coated pits (Slepnev and De Camilli, 2000).  
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After uptake of antigen, DCs must present this antigen in the context of MHC molecules 
on the cell surface to induce a T cell response in the LNs. DCs must therefore migrate from 
the site of the antigen uptake to the LNs, which they can do by entry into the lymphatics, or 
from the circulation.  
1.2.3 DC migration 
1.2.3.1 Chemokines and chemokine receptors 
Migration of immune cells is crucial in developmental biology, activation of innate and 
adaptive immune responses, and the repair of damaged tissue (Griffith, Sokol and Luster, 
2014). Leukocyte migration is primarily controlled by chemokines which are small 
molecules which orchestrate immune cell migration and positioning within the body. 
Almost 50 functional chemokines are functionally divided into two groups: inflammatory 
and homeostatic (Rot and von Andrian, 2004). Expression of the inflammatory, or 
inducible, chemokines is triggered through local release of inflammatory cytokines such as 
IFNγ and tumour necrosis factor alpha (TNFα) (Rollins, 1997), but can be triggered by 
infection, chronic tissue inflammation and autoimmunity (Gerard and Rollins, 2001). 
Many of these chemokines are also produced homeostatically by secretion from barrier 
tissues as a component of sweat, saliva and tears, which may take advantage of natural 
antimicrobial properties of chemokines such as CCL28 (Hieshima et al., 2003; Söbirk et 
al., 2013). The homeostatic chemokines, on the other hand, are expressed constitutively at 
discrete, typically lymphoid, sites within the body. Their expression allows migration of 
leukocytes within the lymphatic system, and is crucial for the development of primary, 
secondary and tertiary lymphoid structures (Ansel and Cyster, 2001). This group of 
chemokines, however, can also be upregulated during inflammation (Rot and von Andrian, 
2004). 
Chemokines exert their function through interaction with specific G-protein-coupled 
receptors (GPCRs) expressed on the surface which have seven transmembrane-spanning 
domains. There are 19 known chemokine receptors, which bind and internalise 
chemokines, and signal β-arrestin recruitment and typical downstream signalling for 
GPCRs (Zlotnik and Yoshie, 2000). There are also 5 ‘atypical’ chemokine receptors, 
which bind chemokines but are defined by their lack of subsequent signalling; this allows 
the receptors to act as chemokine scavengers. Cells which express these receptors can 
sequester chemokines by internalisation; reducing local chemokine availability and thus 
controlling the course of an inflammatory response (Nibbs and Graham, 2013). Given that 
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very few chemokines interact exclusively with one receptor, this implicates the binding of 
each chemokine to multiple receptors and therefore the ability to signal cell types with 
differential receptor expression, as well as to signal the same cell through different 
receptors. Although this would suggest a significant amount of redundancy within the 
system, studies using individual receptor knockout cells and neutralising antibodies have 
shown otherwise (Weber et al., 2001; Zernecke et al., 2006). Signalling through CCR7 will 
be discussed here; and is one of the best examples of differential signalling by the 
chemokines CCL19 and CCL21 acting through the same receptor.   
Chemokines play a crucial role in the development of DCs. Signalling by receptor ligation 
does not appear to directly induce cellular differentiation in DCs, unlike T cells, which can 
use CCR2 and CXCR3 as differentiation signals (Luther and Cyster, 2001; Kurachi et al., 
2011), and non-haematopoietic cells such as astrocytes through CXCL12/CXCR4 
interactions (Bajetto et al., 2001). However, guiding the migration of haematopoietic cells 
to the microenvironments capable of supporting particular differentiation pathways is a 
potential indirect method by which chemokines control differentiation. Monocytes express 
classical inflammatory receptors including CCR1, CCR2 and CCR5 and use these to exit 
the vasculature into inflamed tissue (Vanbervliet et al., 2002). These cells can go on to 
differentiate into inflammatory MoDCs in response to cytokines, and sample antigens 
present in the tissue, which triggers a downregulation of these chemokine receptors and a 
reciprocal upregulation of CCR7 (Sallusto et al., 1998). Mature DCs, including MoDCs 
but also LCs and cDCs, can then respond to CCR7 ligands expressed by the lymphatic 
vasculature, allowing the cells to exit the inflamed tissue and move to the LNs where they 
can interact with T cells and facilitate the adaptive immune response (Randolph et al., 
1999).  
1.2.3.2 Lymph node entry from the blood 
pDCs have been shown to migrate directly from the blood into the LNs through specialised 
blood vessels known as high endothelial venules (HEVs). This haematogenous route is 
available almost exclusively to pDCs, and is accessed using chemokine receptors such as 
CCR5 and CCR7, the latter of which is expressed even on immature pDCs (Seth et al., 
2011). Once in the HEV, entry to the LN is achieved through expression of L-selectin (also 
known as CD62L) and E-selectin for attachment and to the endothelium with support of 
integrin ligation (Diacovo et al., 2005).  
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1.2.3.3 Lymph node entry from the tissue 
The function of DCs occurs in two stages and is regulated spatially and temporally by 
chemokine receptor expression. Both entry into and within the tissue is mediated by 
expression of chemokine receptors such as CCR1, CCR2 and CCR5 (Shi and Pamer, 
2014). Antigen capture, along with inflammatory context-dependent cues induce 
maturation of the DC, which triggers downregulation of these chemokine receptors and 
upregulation of CCR7 (Sallusto, Palermo, et al., 1999). Interaction of CCR7 with its ligand 
CCL21, produced by cells of the lymphatic vasculature, instructs DC LN migration and 
induces further cell activation by upregulating markers associated with T cell stimulation 
(Marsland et al., 2005). Although both CCR7 ligands are involved in the migration of DCs 
to LN sinus, it has been shown in experimental models that only CCL21 is required for 
extravasation into the lymphatics due to its expression and presentation by lymphatic 
endothelial cells. CCL19, in comparison, is primarily involved in ‘fine-tuning’ cell 
migration within the LN proper (Weber et al., 2013). This process is summarised in Figure 
1.2, below. 
 
 
 
Figure 1.2 - The role of CCR7 in dendritic cell migration and function. 
Mature, antigen-loaded DCs migration from the site of inflammation to the lymph nodes by 
transmigration into the lymphatic vessels and migration using chemotactic cues from CCL21. Once 
in the LN proper, DCs use CCL19 for positioning in proximity to T cells for activation. 
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In the absence of antigen uptake and inflammation, cells such as LCs remain restricted to 
the epidermis. Immature LCs constitutively express the chemokine receptor CCR6 which 
allows the cell to respond to CCL20 expressed by keratinocytes for intra-epidermal 
migration and surveillance (Spiekstra et al., 2005). CCR6 expression is downregulated 
after antigen encounter and the induction of maturation. While migration of other DC 
subsets to the LNs after maturation is relatively fast, the migration of LCs to LNs is much 
slower. Unlike pDCs, cDCs and MoDCs which utilise CCR7 for migration to the LNs, the 
layered structure of the skin requires LCs to use both CXCR4 and CCR7 to access the 
lymphatics in a model of two-step migration (Villablanca and Mora, 2008). During LC 
maturation, upregulation of CXCR4 expression precedes CCR7, allowing migration from 
the epidermis to the dermis using CXCL12 produced by dermal fibroblasts (Ouwehand et 
al., 2008). As CCR7 expression increases during this time, upon reaching the dermis LCs 
are primed to respond to lymphotactic chemokines and migrate into the lymphatic 
vasculature. 
1.2.4 Induction of the adaptive immune response 
Upon uptake of antigen and subsequent arrival in the LN microenvironment, DCs are 
critical for T cell activation and the development of an effector T response through 
induction of T helper (Th)-1, Th2, Th17 or regulator T cell (Treg) differentiation. During 
maturation, DCs upregulate the molecules necessary for this induction, and provide three 
distinct signals to T cells known as Signal 1, 2 and 3. 
Antigen presentation by MHC molecules on the DC surface bind T cells which recognise 
the antigen through T cell receptor (TCR), which provides Signal 1. MHC class I 
molecules are expressed by all nucleated cells for the purpose of presenting endogenous 
peptides. These peptides are the result of cytosolic degradation of proteins produced by 
each cell and presented on MHC class I molecules by translocation into the endoplasmic 
reticulum (ER) (Vyas, Van der Veen and Ploegh, 2008). MHC class I-peptide complexes 
bind TCRs on CD8 T cells specific for the presented peptide and lead to stimulation. MHC 
class II presentation functions similarly to MHC class I although is primarily the role of 
professional APCs such as DCs. Exogenous antigens which are taken up by DCs are 
processed internally as described previously, and presented on MHC class II molecules 
through the ER (Neefjes et al., 2011). MHC class II-peptide complexes bind TCRs on CD4 
T cells. As DCs mature, their expression of MHC class I and II changes; MHC class I 
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complexes on the cell surface are rapidly replaced to reflect current antigen load, and MHC 
class II presentation is increased (Delamarre, Holcombe and Mellman, 2003). One other 
important presentation mechanism to discuss in this context is known as cross-
presentation; where exogenous antigens are presented on MHC class I molecules instead 
(Sathe et al., 2011). Most DC subsets have been shown experimentally to cross-present 
antigens, but cDC1s have superior cross-presentation function (Bachem et al., 2010). 
Upregulation of additional cell surface molecules in response to the inflammatory context 
allows DCs to give additional signals to T cells which can support or restrict T cell 
activation, which provides Signal 2. As the MHC-TCR interaction is transient, effective 
activation requires the integration of multiple signaling pathways through DC surface 
molecules. These molecules are known as co-receptors and can be broadly divided into two 
categories: the Ig superfamily, and the TNF receptor superfamily.  
CD80 and CD86, which are expressed on the DC surface are members of the Ig 
superfamily, and interact with T cells through CD28 (Sharpe and Freeman, 2002). Ligation 
of CD28 on T cells augments the TCR signal by reducing the threshold of TCR 
engagement required for activation of the T cell but does not alone support phenotypic 
commitment of the cell (Lucas et al., 1995). In addition to this, activated T cells can further 
respond to CD28 signaling by secretion of IL-2 which strongly supports T cell survival. In 
the absence of CD28 co-stimulation, T cells can become anergic, where T cells cannot 
effectively respond to stimulation, or undergo apoptosis (Alegre, Frauwirth and Thompson, 
2001). Cytotoxic T-lymphocyte antigen 4 (CTLA-4) is another member of the Ig 
superfamily which, in comparison, binds CD80 with much greater affinity, but is strongly 
inhibitory unlike CD28. It inhibits T cell function by reducing expression of the IL-2 
receptor, required for T cell survival, and arresting dividing T cells in the cell cycle (Teft, 
Kirchhof and Madrenas, 2006). In vivo ligation of CTLA-4 leads to the induction of T cell 
tolerance towards antigens and can programme T cell anergy and apoptosis (Greenwald et 
al., 2001).  
The TNF receptor superfamily involvement in the initiation of the T cell response is 
exemplified by expression of CD70, which binds CD27 constitutively expressed by naïve 
T cells. Interaction between CD27 and CD70 amplifies T cell activation, which shows a 
certain redundancy when compared to CD80/CD86, and has been shown to increase IL-2 
and IFNγ production to increase cytotoxicity (Rowley and Al-Shamkhani, 2004). CD40 is 
another member of the TNF receptor superfamily and is an essential part of the T cell 
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response. In addition to stabilising the TCR for more potent cell communication, 
interaction of CD40 on the DC surface with CD40L (otherwise known as CD154) on the T 
cell surface has been shown to reciprocally activate cytokine production and co-
stimulatory molecule upregulation by DCs (Elgueta et al., 2013).  
The secretion of pro- or anti-inflammatory cytokines by immature and mature DCs of each 
subset are different and are crucial in commitment to particular T cell phenotypes, which 
provides Signal 3. While most cytokines can support the development of the CD8 T cell 
response, the development of CD4 T cell subsets are cytokine-specific. IL-12, for example, 
is produced by cDCs activated by infectious agents and has been shown in vitro and in vivo 
to induce the development of T cells secreting high amounts of IFNγ for pathogen defence 
(Trinchieri, 2003). In particular, the IL-12p70 subunit can induce both cytotoxic (CD8) T 
lymphocyte (CTL) and Th1 responses which are strongly cytotoxic to pathogens and 
tumour cells (Zobywalski et al., 2007). This has been shown to be produced by cDCs as 
well as MoDCs (Ratzinger et al., 2004). In combination with transforming growth factor-
beta (TGF-β), IL-6 has been shown to induce the development of a Th17 cell phenotype 
(Veldhoen et al., 2006). Local IL-6 secreted by inflamed stromal tissue can be trans-
presented by DCs to T cells, which requires expression of the IL-6 receptor (Heink et al., 
2017). Th17 cells can be identified by their production of IL-17, which is involved in the 
protection of mucosal barrier tissue and accumulation of neutrophils at sites of 
inflammation (Chen et al., 2003; Liu et al., 2016). In the absence of IL-6, TGF-β leads to 
the development of the anti-inflammatory Treg subset along with IL-2 (Golubovskaya and 
Wu, 2016). Unlike cytotoxic T cells, Tregs are involved in antigen tolerance and actively 
suppress the immune response against their cognate antigens (Jin et al., 2010).  
1.3 Tumour initiation and development 
1.3.1 Primary tumour development 
Tumour development has historically been thought to be a cell-autonomous disease, in 
which the driving force behind the induction and growth of the malignancy is genetic 
abnormality. In general, abnormalities are acquired by dividing cells, whether the cells 
acquire these by ‘normal’ means such as during cell division or are induced by infectious 
agents, chronic inflammatory processes, inhaled or ingested carcinogens, or even 
ultraviolet (UV) light (Blackadar, 2016). As a consequence of these abnormalities, cells are 
released from requiring extracellular control by the body and tumour development is 
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initiated. For many cancer types, the most common mutations are known and can be 
classified according to the six hallmarks of cancer, proposed by Hanahan and Weinberg 
(2000; revised 2011). This posits six key changes a cell must undergo for malignant 
growth: sustaining cell proliferation, evasion of growth suppressors, activation of invasion 
and metastasis, induction of angiogenesis, replicative immortality, and resistance to cell 
death by apoptosis (Hanahan and Weinberg, 2000).  
Acquisition of these hallmark characteristics occurs differently between cancers, both in 
terms of the actual genetic changes and in the order in which they are acquired; in some 
cases, a genetic change may enable multiple capabilities simultaneously. An example of 
this is p53, encoded by the TP53 gene, which is thought to be the most commonly mutated 
gene in human cancer (Kandoth et al., 2013). p53 is a protein with potent tumour 
suppressor function which acts through modulation of the expression of genes involved in 
the repair of deoxyribonucleic acid (DNA), cell division and control of cell death by 
apoptosis (Carson and Lois, 1995). Both loss of this protein through mutation as well as 
gain-of-function mutations can lead to malignancy; resulting in changes in cell 
proliferation, invasion and metastasis, and angiogenesis (summarised in Muller and 
Vousden, 2014). 
The developing tumour is comprised of more than just one proliferative mass of tumour 
cells. Tumours have been described as “wounds that do not heal” (Dvorak, 1987), and as 
such tumour growth is not tumour cell-intrinsic but is influenced by a number of cells 
types which are involved in wound repair and become functionally subverted by the 
tumour (Whiteside, 2008). After the first genetic changes that initiate tumour development, 
tumour-derived signals begin to affect the local stromal cells and immune cells responding 
to this tumour development. Fibroblasts within the tissue are normally activated during 
wound repair processes (Grotendorst, Rahmanie and Duncan, 2004), but this function can 
be subverted by tumour cells to induce remodelling of the extracellular matrix (ECM), 
angiogenesis or growth factor feedback loops to support tumour cell proliferation (Busch et 
al., 2015). Cells representing the innate and adaptive immune system also respond, and 
include macrophages, NK cells, T cells and DCs, but also become either recruited to the 
tumour microenvironment (TME) or functionally suppressed (Grivennikov, Greten and 
Karin, 2011).  Understanding and accounting for other cell types which exist in the TME is 
especially important in treatment success, as overlapping compensatory and tumour 
defence mechanisms may exist and lead to variable responses between patients. 
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As APCs, DCs are responsible for the induction of the adaptive immune response against 
developing tumours. After initial cell transformation, damage signals such as damage-
associated molecular patterns (DAMPs) or cytokines can be produced which attract the 
attention of the innate immune system and patrolling DCs. Innate immune cells such as 
neutrophils and macrophages can protect against tumour development without requirement 
of the adaptive immune system, but this is dependent on the experimental model 
(Schreiber, Old and Smyth, 2011). At this stage, DCs can uptake tumour antigens and 
present these to T cells in the LNs. In most cases, production of IFNs and cytokines by 
activated cytotoxic T cells are capable of tumour elimination (Vesely et al., 2011). Long-
term control of tumour growth, known as the equilibrium phase, proceeds this phase if the 
tumour is not completely eradicated. The phase is a balance between tumour cell 
proliferation and destruction by the immune system, primarily mediated by T cells through 
production of IFNγ (Constantino et al., 2017).  
DCs function as immunogenic in early tumour development by presenting tumour antigens 
and activating tumour-specific T cell responses. In late tumour development, however, and 
despite their presence in the TME, antigen presentation and DC maturation becomes 
limited by the effect of the TME (Veglia and Gabrilovich, 2017). A number of different 
mechanisms contribute to this phenomenon. IL-10 produced by tumour-associated 
macrophages (TAMS) in the TME suppresses the maturity and production of IL-12 by 
DCs leading to a tolerogenic phenotype (Ruffell et al., 2014). Expression of molecules like 
programmed cell death (PD)-1 by tumour infiltrating lymphocytes (TILs) and tumour cells 
themselves directly suppress DC function. Therapeutic block of either PD-1 or its ligand 
PD-L1 has been shown to reverse this suppressed DC phenotype and restore cytokine 
secretion in the TME (Salmon et al., 2016). The presence of pDCs in the TME has also 
been shown to be immune tolerising through production of tumour-supporting T cell 
phenotypes through inducible T cell co-stimulator ligand (ICOSL). These cells then 
contribute to the suppressive TME milieu by producing cytokines such as IL-10 (Ito et al., 
2007).  
1.3.2 Metastatic tumour development 
Metastasis, the dissemination of cells from the primary tumour to a secondary site through 
the lymphatics or bloodstream, is a characteristic of malignant tumours and a major risk 
factor for cancer mortality. It is estimated that up to 90% of cancer-related deaths are 
caused by metastasis depending on the type of cancer (Chaffer and Weinberg, 2011). Sites 
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of metastasis tend to be specific to individual tumour types, such that secondary tumour 
sites can be predicted to a certain extent. Melanoma, for example, can readily metastasise 
to the lungs, brain, liver and distal skin (Eyles et al., 2010); in comparison, colorectal and 
pancreatic cancer metastasise primarily to the liver and lungs (Nguyen, Bos and Massagué, 
2009), but prostate cancer metastasis is confined to bone (Edlund, Sung and Chung, 2004). 
Despite some similarities in secondary site, there appear to be different genetic 
mechanisms directing metastases to these tissues between tumour types (Nguyen, Bos and 
Massagué, 2009). Temporal differences also exist between tumour types; although 
disseminating tumour cells can infiltrate secondary sites they may not immediately be able 
to successfully grow within this site. Lung cancers, for example, develop aggressive 
metastases quickly after diagnosis (Hoffman, Mauer and Vokes, 2000), but breast cancer 
metastases can present clinically years after complete remission as a result of the immune 
system eventually failing to control the tumour (Karrison, Donald and Meier, 1999). More 
effective treatments are being developed to treat primary tumours, but elimination of 
metastases remains challenging (Weigelt, Peterse and Veer, 2005). 
To become metastatic a tumour cell must have several key characteristics, which have 
historically been thought to be acquired over successive mutation events but evidence from 
other cancer types challenges this. The process of metastasis requires local invasion of the 
primary tissue stroma, intravasation into the blood, survival in the blood, extravasation at 
the secondary site and establishment of tumour growth. The genetic changes and immune 
system interactions which contribute to these capabilities can be grouped into initiation, 
progression and virulence (Chiang and Massagué, 2008). It is likely that genetic changes 
supporting the invasion of tumour cells into the local stroma are maintained for infiltration 
of secondary sites. Changes and assistance in motility, transition of epithelial to 
mesenchymal cell morphology (epithelial-to-mesenchymal transition; EMT), degradation 
of the ECM or the process of angiogenesis can be involved in the acquisition of an invasive 
phenotype.  
Mouse models have shown that T cells specific for the primary tumour can control 
dissemination of metastases and their growth in secondary sites (Eyles et al., 2010). 
However, changes in the tumour as a result of chronic inflammation and genetic instability 
which lead to metastasis may affect the antigen presentation by metastatic lesions. This 
could be by antigen escape, where tumour cells downregulate antigen expression by 
presenting other antigens or through the downregulation of MHC molecules (Butterfield et 
al., 2003; Constantino et al., 2017). This limits the efficacy of pre-existing T cells, 
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requiring that DCs patrolling the secondary site recognise the metastatic lesion and initiate 
a second primary antigen response. In this late stage of tumour development however, as 
discussed previously, systemic immune suppression from the primary tumour may 
suppress this potential response (Nguyen, Bos and Massagué, 2009; Busch et al., 2015). 
1.4 Therapeutic use of dendritic cells 
The inherent heterogeneity of tumours and tumour development between individual 
patients makes personalised medicine an attractive therapeutic approach. As the immune 
system is crucial to the anti-tumour defence, activation of the endogenous immune 
response or enhancing it with immune cell replacement has become a primary focus in the 
development of new therapies. Passive immunotherapy, such as the use of antibodies to 
activate immune cells or adoptive transfer of tumour-specific cytotoxic T cells, has been 
used successfully in several cancer scenarios (Palucka et al., 2007). Although successful in 
the short-term, passive immunotherapy has not been shown to induce a lasting 
immunological response or the development of cellular memory for the target tumour 
associated antigens (TAAs). Active immunotherapy, in comparison, utilises antigen-loaded 
DC ‘vaccines’ to induce both a short- and long-term anti-tumour response (Boudreau et al., 
2009). DCs do not themselves directly target tumour cells but instead target cells of the 
immune system such as T cells and NK cells which are heavily involved in the anti-tumour 
response. Unlike conventional cancer therapies, cell vaccines may not result in significant 
reduction in tumour volume but instead apply an anti-tumour effect over a prolonged 
period of time (Gulley, Madan and Schlom, 2011). 
DCs have been tested as immunotherapies in clinical trials for more than 20 years, 
particularly in cancer immunotherapy, primarily due their potency in processing and 
presenting antigens to activate T cells. The increasing understanding of DC biology during 
this time has been applied to clinical trials, which roughly separates them into 
‘generations’. The first generation of DC clinical trials used primarily patient-derived 
immature DCs, LCs or MoDCs from ex vivo culture but which were not matured before 
reinjection. The second generation of DC clinical trials used similar cells with addition of 
‘maturation cocktails’ to prime DCs for function before reinjection. The third, current, 
generation (alternatively known as ‘next generation’) DC clinical trials still use these cells, 
but also natural DC subsets derived either in ex vivo cultures using specific growth factors 
or fully mature in vivo subsets derived by patient leukapheresis. The provision of antigen 
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to the DCs has also evolved between these generations. In this section, each generation will 
be summarised and the key successes for DC therapeutic use will be highlighted. 
 
Figure 1.3 - Evolution of therapeutic DC use in cancer.  
DC therapies can be subdivided into generations based on chronology and the prevailing trial 
methodology in each generation. DCs (purple) vary by source between each generation as does 
the use of cell maturation cocktails. Antigen from cancer cells (red) also vary by preparation 
between each generation. Route of cell administration doesn’t necessarily change, with the same 
routes used in each generation. Abbreviations: cDCs = conventional DCs; IFNγ = interferon-
gamma; IL-1β = interleukin-1beta; LPS = lipopolysaccharide; MoDCs = monocyte-derived DCs; 
pDCs = plasmacytoid DCs; PGE2 = prostaglandin E2; PolyI:C = polinosinic:polycytidylic acid; TAA 
= tumour associated antigen; TNFα = tumour necrosis factor alpha (Adapted from: Garg, Coulie, et 
al., 2017). 
 
1.4.1 First generation DC therapies 
In the first generation of DC therapies, cells were derived from patient leukaphereses from 
which DC progenitors were cultured ex vivo or immature DCs were separated by density 
gradient. The tumour antigen in the first generation was typically a TAA peptide, or TAA 
proteins derived from tumour cell lysates, which targeted the in vivo T cell response 
towards antigens known to be expressed by particular tumours (Rosenberg, Yang and 
Restifo, 2004). In 1995, Mukherji et al. published data from a small study of dendritic cell 
use in patients with advanced metastatic melanoma (Mukherji et al., 1995). The literature 
at the time described patient-derived peripheral blood mononuclear cells (PBMCs) cultured 
with GM-CSF as APCs, but retrospectively at least some of these cells can be described as 
DCs. Using a peptide of the common melanoma-associated antigen 1 (MAGE-1), a 
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cancer/testis antigen normally only expressed in the testis but reactivated in melanoma 
(van der Bruggen et al., 1991), the DCs were loaded ex vivo and reinjected intradermally 
into 3 patients with advanced metastatic melanoma. Although no MAGE-1-specific CTLs 
were initially detectable in the blood or metastatic lesions of these patients, following 4 
doses of peptide-loaded DCs, these CTLs did become detectable in both tissues. Despite 
showing no therapeutic efficacy, due to insufficiency in DC number, antigen presentation 
to T cells or the suppression of the immune system in these advanced stage patients, this 
study was one of the first to highlight the safety and potential for efficacy of DC therapy.  
Development of DC culture protocols by the addition of IL-4 with the GM-CSF followed 
characterisation of the heterogeneity of cultures with GM-CSF alone, as well as in 
response to early reports of IL-4 improving DC phenotype and antigen presentation 
(Sallusto and Lanzavecchia, 1994). The first clinical trial to use this methodology in 
treatment was for melanoma in 1998 (Nestle et al., 1998). In a small trial with 16 advanced 
metastatic melanoma patients, MoDCs generated with GM-CSF and IL-4 were loaded with 
multiple melanoma-specific antigens (highlighting a desire for a multiple-antigen strategy 
to prevent antigen escape) and injected weekly for a month, and then monthly following 
this up to 10 injections. Uniquely in this early trial, DCs were injected directly into an 
uninvolved peripheral lymph node to ensure T cell contact. Results of this trial supported 
the earlier Mukherji trial, showing safety in all patients and tumour regression in 5. This 
trial also made use of the keyhole limpet hemocyanin (KLH) adjuvant. KLH is a marine-
derived glycoprotein commonly used as an immunostimulant, used in this context as an 
adjuvant for CD4+ T cell activation in particular (Wimmers et al., 2017).  
Other early trials used other DC sources, such as directly isolating DCs from peripheral 
blood by Hsu et al. (Hsu et al., 1996). Separation of mononuclear cells, including myeloid 
progenitors but also monocytes and immature DCs, is possible by density gradient 
centrifugation. In this trial for low-grade follicular B cell lymphoma, tumour biopsies 
supplied the immunoglobulin expressed specifically by the tumour as the TAA and this 
was given to DCs in culture without GM-CSF or IL-4. 4 patients were each given 3 
subcutaneous injections of this cell preparation: with a soluble antigen booster 2 weeks 
after the first DC injection, and the remaining DC injections 1 month after the first, and 
then again 6 months after this. All patients in this study completed the course of injections 
and developed T cell responses to the antigen leading to tumour regression and in one 
patient, complete remission.  
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Finally, in 2001, CD34+ progenitor cell-derived DCs were derived from patients by 
leukapheresis following GM-CSF mobilization of the bone marrow (Banchereau et al., 
2001). Culturing these cells with GM-CSF, Flt3-L and TNFα produces a myeloid cell 
population at different developmental stages but includes immature DCs, LCs and cDCs 
(Redman et al., 2008). In this trial, 18 patients with advanced metastatic melanoma were 
injected subcutaneously with the cultured CD34+ cell population 4 times in total over a 2-
month period. The cells were loaded with multiple melanoma-specific antigens including 
melanoma-associated antigen recognized by T cells (MART-1), MAGE-3 and gp100. Even 
in these heavily pre-treated patients, this study was the first to show a strong correlation 
between DC vaccination, particularly to multiple antigen preparations, and therapeutic 
outcome as 16 of these patients developed a T cell response against one or more of the 
antigens and 7 of these patients experienced either tumour regression or stable disease.  
These first generation clinical trials, as they would later be known, were important in 
showing the safety and potential efficacy of DCs in a clinical context. In 2003, Ridgway 
published a review of the “first 1000 dendritic cell vaccinees”, who were treated in 98 
individual first generation trials between 1995 and 2001 (Ridgway, 2003). The majority of 
these patients were treated with peptide-loaded DCs for either metastatic melanoma or 
prostate cancer, reflecting the naivety of DC clinical use and the techniques available 
during that time. In summary, patients in 31 of these studies experienced a partial response 
to the vaccine, and patients in 17 experienced a complete remission (CR), defined 
differently by each trial. This review highlighted the potential benefit of DC therapy, 
despite only a modest success. It was also the first to draw attention to the variety of 
methods used for the generation of the cells, and antigen loading and injection strategies. 
This was, at the time and continues to be, a challenge in assessment of DC clinical trials: as 
most early clinical trials involved small numbers of patients with little option for multiple 
study arms, making combining and comparing data from these trials difficult (Butterfield, 
2013).  
Assessing efficacy of DC vaccination was also variable between trials, and it became 
apparent that conventional success measures for cancer therapy such as tumour regression 
may not be appropriate for DC trials. A review of immunotherapies was published by 
Rosenberg et al. in 2004, which compared first generation DC trials and other 
immunotherapies such as soluble protein or viral vaccination using both conventional 
oncological criteria and a newly developed criteria known as Response Evaluation Criteria 
in Solid Tumours (RECIST) (Rosenberg, Yang and Restifo, 2004). The standard 
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oncological criteria were established for global comparability of tumour treatment using a 
50% decrease in patient tumour burden as the threshold for objective response (OR) 
(Miller et al., 1981), compared to RECIST which uses a 30% decrease. Using these 
slightly more accommodating criteria, it was shown that peptide-loaded DCs resulted in 
tumour regression in 7.1% of patients, which was higher than alternative vaccination 
strategies, and was used to support the continued use of DCs in clinical trials.  
1.4.2 Second generation DC therapies 
The safety and potential efficacy shown in small first generation DC clinical trials opened 
the doors to larger clinical trials using more novel modifications of these basic clinical 
protocols. After the first generation of trials, insight into the control of DC development 
and function highlighted the need for fully mature DC to use in therapy (de Vries, 
Lesterhuis, et al., 2003). A number of studies in the early 2000s showed key differences 
between immature DCs, cells which were used in many first generation trials, and 
cytokine-matured DCs. Successive studies in 1999 and 2000 from the same centre 
compared DCs generated by standard culture supplemented with monocyte-conditioned 
media (MCM) alone or MCM with TNFα (Thurner et al., 1999; Schuler-Thurner et al., 
2000). Clinical responses to the vaccine were shown to be significantly better if the DCs 
were generated with TNFα in patients with metastatic melanoma following subcutaneous 
and IV injection, despite both DC groups expressing the basic conventional DC markers 
CD86 and the human leukocyte antigen (HLA)-DR, and CD83. Jonuleit et al. directly 
compared injection of immature DCs and mature DCs intranodally, each presenting 
different antigens for comparison of the T cell response (Jonuleit et al., 2001). Only mature 
DCs, generated by the addition of IL-1β, TNFα, IL-6 and PGE2 into the culture media, 
were able to induce CTL formation in vivo despite both DC populations being able to 
induce this in vitro. Interestingly, patients receiving unpulsed immature DCs developed 
delayed-type hypersensitivity (DTH) responses, suggesting that these cells stay at the 
injection site or went on to potentiate unwanted inflammatory effects.  
The Jonuleit maturation cocktail of IL-1β, TNFα, IL-6 and PGE2 went on to become the 
standard maturation protocol used in clinical trials (Constantino et al., 2016), but there 
were several alternative factors also assessed. While this common cocktail enhanced 
activity of DC vaccines, assessed by in vitro T cell stimulation, it was shown that these 
DCs do not secrete the cytokine IL-12. The role of IL-12 in the development of a T cell 
response was shown by Dubois et al. in 1998, and therefore was thought to be crucial to 
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DC efficacy (Dubois et al., 1998). Rescue of the IL-12 secretory DC phenotype has been 
shown following ligation of CD40, and exposure to IFNγ or bacterial products such as 
lipopolysaccharide (LPS) or polyinosinic:polycytidylic acid (PolyI:C) which mimic 
environmental stimuli during endogenous maturation (Snijders et al., 1998; Nicolette et al., 
2007; Fučíková et al., 2011). Importantly, the mature DC phenotype was shown to be 
stable in vitro following cytokine removal, suggesting that the phenotype will not reverse 
when reinjected into the patients who may have a high level of inhibitory cytokines in the 
serum (Zobywalski et al., 2007). 
The second generation of DC therapies also began to expand the sources of tumour 
antigen, which in the first generation had been mostly antigenic peptides. Multiple sources 
of antigen such as antigen peptides, tumour ribonucleic acid (RNA), and tumour lysates 
were all shown to be capable of eliciting an antitumour response in vitro and in vivo when 
combined with DCs (Constantino et al., 2016). It also highlighted the differences in 
downstream T cell responses as a result of different antigen sources, both improving the 
potential therapeutic response to DC vaccines and complicating comparison between 
studies. A number of trials during this period used bulk tumour cell RNA, or TAA-
encoding RNA derived from tumour biopsies. RNA can be prepared from biopsies by 
simple molecular extraction techniques, amplified by polymerase chain reaction (PCR) and 
DCs can be electroporated with this RNA in place of natural antigenic peptide uptake. 
Expression of the tumour RNA in the cytosol allows the full polypeptide chain to be 
degraded and so multiple peptides can be presented (Schaft et al., 2005). While this 
strategy relies on the accessibility of the tumour for biopsy, which is not always possible, it 
allows the presentation of multiple individual TAAs without the need for expensive 
molecular characterisation of TAAs.  
Direct comparison between tumour RNA electroporation and irradiated tumour cells, 
which result in a mixture of apoptotic and necrotic cells, suggests that DCs with tumour 
RNA are more effective in animal models (Benencia, Courrèges and Coukos, 2008). In 
comparison to antigenic short peptides, which bind directly to MHC class molecules, other 
antigen sources rely on uptake and processing for presentation on these molecules. Protein 
sources, such as tumour cell lysates, require endocytosis by DCs for presentation, as 
described previously; apoptotic and necrotic tumour cells require the same process but can 
be affected by the method of inducing cell death. Both freeze/thaw and irradiation with UV 
light can induce tumour cell death and release of antigenic proteins, but apoptotic DNA 
produced during the process can bind directly to the MHC molecules on the DC surface 
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(Filaci et al., 2002). UV irradiation can also lead to degradation of important antigen 
epitopes, but studies have shown the susceptibility is antigen-dependent (Labarrière et al., 
2002). 
While the use of common melanoma TAAs such as the MAGE antigens, gp100 and New 
York esophageal squamous cell carcinoma 1 (NY-ESO-1) remained high (Bloy et al., 
2014), there was a shift in focus to developing new methods to target other tumours in the 
absence of a specific, defined antigen. A study by Hobo et al. published in 2013 showed 
that RNA encoding MAGE-3, Survivin and a B cell maturation antigen (BCMA) was a 
suitable TAA source for the induction of tumour-specific T cells by DC vaccination in a 
small cohort multiple myeloma patients after chemotherapy and autologous stem cell 
therapy (Hobo et al., 2013). The DCs were injected intravenously and intradermally in this 
study and highly expressed conventional markers of DC activation such as CD40, CD86 
and MHC class II. Although it was reported that more than 60% of the cells expressed 
CCR7, surface expression was shown to be low by flow cytometry. A third of the patients 
in this study had detectable anti-MAGE-3 and anti-BCMA T cells after the course of DC 
injections, and almost half of the patients in the study had a stable disease at the 26-month 
follow-up.  
Bulk tumour RNA from glioblastoma biopsies was shown in 2013 to be able to induce a 
protective T cell response when presented by DCs (Vik-Mo et al., 2013). This study by 
Vik-Mo et al. used RNA from autologous cultured glioblastoma biopsy organoids, 
containing cancer stem cells (CSCs), to load DCs. After a course of 7 intradermal 
injections, each a month apart, 5 of the 7 patients in the study survived for almost 2 years 
longer than the matched control patient cohort. 3 of these patients were alive almost 4 
years after the therapy. Isolation of T cells from the blood showed an increase in the 
number of T cells specific for TAAs and control peptides in the DC treated patients, 
highlighting the role for these cells in control of the tumour growth. In addition, with the 
DCs targeting T cells directly to the CSCs and not the whole tumour, there was no 
significant initial decrease in the tumour volume when assessed by magnetic resonance 
imaging (MRI). As additional chemotherapy regimens were used, as part of the trial, the 
tumour volume did decrease over time as rapidly proliferating cells were destroyed and 
there were no CSCs to replace them. RNA electroporation subverts normal antigen 
presentation mechanisms; since RNA requires translation into proteins for presentation, 
this allows MHC class I presentation without the requirement for cross-presentation and 
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therefore does not necessarily require the most efficient cross-presenting DC subset 
(Bachem et al., 2010). 
Additional complexity arises from the observation that different antigen loading methods 
are affected by the maturation cocktail being developed in these clinical trials. Early 
elegant studies by Zobywalski et al. showed that although tumour RNA electroporation 
allowed successful antigen presentation by DCs matured using TNFα, IL-1β, IFNγ and 
PGE2, the addition of polyI:C to this cocktail inhibited presentation (Zobywalski et al., 
2007). There is also an implication for the timing of each step in the in vitro production of 
the cells. RNA transfection, for example, has been shown to be more effective in antigen 
presentation after cell maturation (Schaft et al., 2005). Using the MAGE antigen family, it 
was shown that if transfected after DC maturation, the cells more strongly generated CTL 
responses. This closely reflects natural DC biology, where MHC-peptide complexes 
present on the immature cell surface are rapidly internalised and replaced during 
maturation (Lelouard et al., 2002). This highlights RNA transfection as potentially superior 
antigen loading method since endocytosis is also reduced during maturation but is required 
for antigen presentation from TAA peptides or tumour lysates. 
Most notably, novel maturation cocktails and antigen loading approaches introduced 
during the second generation improved the efficacy of DC therapy in clinical trials. The 
use of maturation cocktails in the treatment of prostate and renal cell carcinoma using DCs 
showed a significant number of patients had detectable TAA-specific T cells after the 
treatment (Draube et al., 2011). Direct comparison between immature and mature DCs in 
these trials strongly supported the improved clinical efficacy of mature DCs. Comparative 
evaluation of clinical trial data from patients receiving antigenic peptide vaccines with 
patients receiving tumour lysate vaccines showed an increase in objective response rate 
(ORR) from 3.6% to 8.1% (Neller, López and Schmidt, 2008), which led to an increase of 
up to 20% in survival duration depending on the type of cancer against matched controls 
(Anguille et al., 2014).  
Sipuleucel-T was developed during this time for use in prostate cancer patients. This DC 
vaccine, also known and licenced as Provenge, is exceptional being the only one to be 
approved by the US FDA for clinical use. The majority of prostate cancer patients respond 
to hormone depravation therapy, but eventually become hormone refractory and go on to 
develop metastatic disease which leads to death in almost all cases (Small et al., 2006). 
Sipuleucel-T is comprised of autologous PBMCs activated in vitro with a fusion protein 
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known as PA2024, which is a prostate-specific antigen (prostatic acid phosphatase - PAP) 
fused to the cytokine GM-CSF (Small et al., 2000). Like many antigens used clinically, 
PAP is highly expressed in prostate tissue and prostate carcinoma with minimal expression 
in other tissues which limits potential off-target effects (Graddis et al., 2011). DCs 
presenting PAP alone produce a weaker T cell response in vivo than DCs loaded with 
PA2024 suggesting that incorporation of GM-CSF during activation. In addition to this, 
DCs loaded with PA2024 have been shown to limit tumour development and prolong 
survival in animal models. In early clinical trials, Provenge was shown to be well-tolerated 
following intravenous (IV) injection in agreement with previous DC trials, as well as 
improving the anti-PAP T cell response and decreasing prostate cancer-associated antigen 
detectable in patient serum (Small et al., 2006). These clinical responses correlated with 
therapeutic efficacy compared to control therapies, and Provenge has been able to improve 
overall survival (OS) of patients but has had no significant effect on delaying the time to 
disease progression (Kantoff et al., 2010). Importantly, leukapheresis and the short 2-day 
culture time results in a significant number of T cells as well as B cells and NK cells in the 
bolus, which may limit efficacy (Wesley et al., 2012). The approval of Sipuleucel-T for 
commercial healthcare use by the US FDA was a significant milestone in DC therapy and 
led to further modifications to cell production to improve efficacy.  
1.4.3 Third/next generation DC therapies 
The licencing of Sipuleucel-T by the FDA and the improved clinical responses to second 
generation therapies highlighted the potential of further improving DC vaccines. In concert 
with a better understanding of the complexities of DC biology, and the development of 
more sophisticated molecular techniques, the scope of the field was broadened.  
One of the major focuses in the current generation of DC therapies is in the use of in vivo 
DC subsets – which have no requirement for costly ex vivo culture protocols. 
Transcriptional profiling of in vitro DCs such as CD34+ and CD14+ cell-derived DCs 
showed that although these cells are technically DCs based on phenotypic and functional 
criteria, they are transcriptionally different from their in vivo counterparts such as pDCs 
and cDCs, described previously (Lundberg et al., 2013). Certain functionality may be 
unique to particular in vivo DC subsets: pDCs are strong producers of Type I IFNs, where 
myeloid cDCs have more potent uptake of apoptotic cells and debris and presentation of 
this antigen (Schreibelt et al., 2010; Hagberg et al., 2011). Given their more specialised 
functions, natural DC subsets have different surface and cytokine phenotypes when mature 
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and respond differently to inflammatory stimuli in maturation cocktails (Piccioli et al., 
2009). pDCs, for example, do not express common bacterial pattern recognition receptors 
(PRRs), which precludes maturation using bacterial products such as LPS. Natural DC 
subsets interact with T cells differently to one another and to ex vivo DCs. This can 
therefore implicate particular DC subsets as the most immunogenic in the context of 
cancer. While these DCs are relatively scarce in the blood at rest, clinical trial data has 
shown that both pDCs and cDCs can be reliably isolated in a sufficient number for 
therapeutic use when isolated using novel magnetic bead-based sorting methodologies.  
pDCs are primarily involved in antiviral defence through the production of Type I IFNs, 
but have been shown to efficiently stimulate cytotoxic T cells in a melanoma context (Salio 
et al., 2003).  Despite their relative inefficiency in antigen uptake and presentation since 
their in vivo role is more immunomodulatory through cytokine secretion; experimental 
evidence has shown that pDCs can process TAAs for stimulation of CTLs (Villadangos 
and Young, 2008). In 2013, Tel et al. showed that natural pDCs can be isolated from 
melanoma patients by leukapheresis and cell sorting, loaded with gp100 peptides and 
reinjected a day later (Tel et al., 2013). Compared to matched historical controls, pDCs 
were shown to significantly increase overall patient survival, with an increase in TAA-
specific T cells in a number of the patients. While the efficacy of the therapy is difficult to 
confidently state in a small trial, the data presented are promising. pDCs are an example, 
however, of the importance of an appropriate route of injection. Circulating pDCs access 
the LN directly from the circulation through the HEVs as previously described, a unique 
route of migration among DC subsets. This precludes subcutaneous or intradermal 
injection strategies. Direct intranodal injection is possible (Tel et al., 2013), although 
migration to downstream LNs is not consistently seen in patients.  
Myeloid DCs, or cDCs as described earlier, are another in vivo DC subtype with a potential 
use in DC therapies. Like pDCs, cDCs have a specialised function and mainly migrate to 
the marginal zone of the LNs for surveillance of blood-borne bacterial and fungal antigens 
(Piccioli et al., 2009). In contrast to pDCs which have poor antigen uptake and 
presentation capability, cDCs are much more capable at endocytosis than most DC subsets 
(Schreibelt et al., 2010). This makes them a desirable DC subset to use therapeutically, on 
the rationale that improved antigen presentation may improve the resulting T cell response. 
cDCs can be further subtyped by expression of the surface markers CD1c and CD141, as 
described previously. CD1c+ cDCs are present in the blood at significantly higher numbers 
than CD141+ cDCs and have been used successfully in cancer clinical trials. Early phase I 
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clinical trials have supported the feasibility of isolating enough cDCs for therapeutic use, 
and that these cells are well-tolerated by patients (Prue et al., 2015). Schreibelt et al. 
showed that CD1c+ cDCs were capable of inducing de novo antigen-specific T cell 
responses even when as low as 3x106 cells were injected intranodally after overnight 
culture (Schreibelt et al., 2016). The cells were immunogenic and expressed markers CD83 
and CD86 highly, but CD80 and CCR7 more variably. T cells induced by the vaccine led 
to prolonged progression-free survival for up to a year longer in patients with detectable T 
cell responses to the DC vaccine compared to those without.  
Given the variety of tumour types, cell sources, maturation and antigen loading techniques, 
and injection routes which have been described here, assessing the efficacy and the future 
of DC vaccination as an immunotherapy is difficult.  
1.5 Improving dendritic cell therapies 
It is clear that increased understanding of DC biology has been crucial in the progression 
through these DC therapy generations. Integrating this understanding into clinical trials has 
improved the breadth of antigen loading techniques for applicability to more cancer types, 
and correlation of DC phenotype to the desired T cell response through selection of 
appropriate DC sources and maturation cocktails (Garg, Coulie, et al., 2017). Despite more 
than 20 years of improvements, DC clinical trials still show subclinical tumour responses 
and variable induction of T cell responses in patients. While DC phenotype has 
significantly improved, poor in vivo migration of cells to the LNs after injection remains a 
concern and is not yet sufficiently addressed in clinical trials. The threshold cell migration 
to the LN for activation of an anti-tumour response has been shown to be small (Lim et al., 
2007), however variable patient responses suggest even this number may not be being 
reached. Several strategies have been described which directly address improving cell 
migration post-injection, such as the route of injection, but novel strategies are clearly 
required to improve this. 
1.5.1 Alternative injection strategies 
After injection DCs must interact with T cells to exert their immunogenic function, which 
requires migration from the site of the injection into the LN. Appropriate injection 
strategies are a potential way of maximising LN migration from the injection site. It has 
been seen in numerous clinical trials that after commonly-used subcutaneous or 
intradermal injection, only a small percentage of the injected cells reach the LNs which is 
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crucial for their function. This was reportedly as low as 5% of the total injected cells 
(Verdijk et al., 2009), a very commonly quoted figure in the DC literature. DC maturation 
state is a key factor in the ability of the cells to migrate, so incorporation of maturation 
cocktails into second generation DC protocols did improve migration (de Vries, 
Krooshoop, et al., 2003).  
The rationale for subcutaneous and intradermal injection strategies is in the direct access of 
the injected DCs to the lymphatic vasculature (Lappin et al., 1999). As it reflects an 
endogenous migration by positioning mature DCs within the tissue and allowing natural 
migration, it was expected that these routes would provide the best route of injection to 
induce a T cell response. In comparison, as described previously, most DC subsets are not 
equipped to migrate from the blood into the LNs which precludes intravenous injection. It 
has been shown that intravenous injection leads to splenic T cell response as cells reach the 
spleen through the circulation (Mullins et al., 2003). This study showed that, although 
inducing a T cell response which controlled melanoma lung metastases, intravenous 
injection failed to control a subcutaneously growing melanoma. Fong et al. showed a 
similar inability of intravenously-injected DCs to induce IFNγ-producing T cells in 
melanoma patients compared to intradermally-injected DCs (Fong et al., 2001). While a 
splenic T cell response may be desirable in specific cancer types, the intradermal route was 
shown by Mullins et al. to also produce a splenic response in addition a response in the 
skin-draining lymph nodes.  
Directly introducing DCs to the LN by intranodal injection is a potential strategy to ensure 
contact with T cells, but this methodology has shown a surprising comparable efficacy to 
intradermal injection despite the inefficiency of intradermally-injected cells to reach the 
LN (Lesterhuis et al., 2011). Although intranodal DCs can immediately access T cells 
within the LN, there is some requirement for intranodal migration, as described previously, 
with no guarantee that injected DCs are capable of this. Additionally the surgery is 
technically complex and risks damaging the LN architecture, which severely compromises 
the potential immune response, and makes multiple injection strategies difficult (Tel et al., 
2013). Intradermally-injected DCs can also theoretically migrate to a number of LNs 
within the lymphatic branch, depending on the number and site of injections, but migration 
of intranodally-injected DCs through the efferent lymphatics has not been seen consistently 
(Quillien et al., 2005; Tel et al., 2013).  
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Taking these strategies into account, there is no clear superior injection strategy for 
maximising both appropriate DC migration and T cell communication. Each of these 
injection strategies have disadvantages and there is a clear need to develop new 
methodologies to improve migration. Given the current breadth of literature on DCs used 
clinically it was seen that DCs may be inherently incapable of migration upon injection by 
a lack of expression of the chemokine receptor CCR7.  
1.5.2 DC chemokine receptor expression 
In a number of trials discussed in this Chapter, DC surface marker expression was 
characterised prior to injection of cells. As discussed previously, the expression of CCR7 
on mature DCs is crucial for migration into the lymphatics from either tissues or the 
bloodstream, however many of the cells used in these trials fail to express CCR7. In very 
early first generation DC trials, CCR7 expression was not quantified (Mukherji et al., 
1995; Hsu et al., 1996; Nestle et al., 1998). In the absence of cell maturation cocktails, 
however, expression would be unlikely (de Vries et al., 2003). After the introduction of 
cytokine stimulation in the second generation of DC trials, assessment of CCR7 expression 
was more common (Zobywalski et al., 2007; Hobo et al., 2013) but is heterogenous in a 
mixed culture of mature and not-fully-mature DCs. This reflects in vitro evidence where 
CCR7 expression is not uniform in MoDC cultures using GM-CSF and IL-4. Taking these 
data into account, it possible that DCs prepared for clinical trials are not sufficiently 
equipped for migration to the LNs by heterogenous expression of CCR7. 
In 2014, a study by Le Brocq et al. showed that it was possible to stain and sort cells 
expressing CCR7 using a novel chemokine-fluorophore conjugate in the place of an 
antibody (Le Brocq et al., 2014). Given chemokine receptor structure, as described 
previously, specific, high-quality antibodies against chemokine receptors are difficult to 
produce. The study showed a reliable staining of CCR7-expressing cells which could be 
used to sort cells expressing the receptor to a high purity using magnetic beads; providing a 
methodology for isolation of these cells in a clinical setting. Expression of CCR7 is crucial 
for LN migration, so isolation of these cells would in theory isolate the DCs most capable 
of in vivo migration from a mixed culture. 
1.6 Project aims 
DCs have a significant potential for clinical use given their ability to stimulate the adaptive 
immune system against defined antigens. In a cancer context, targeting TAAs using DC 
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therapies can induce a robust, anti-tumour T cell response in patients. Although more than 
20 years of improvement has been made to manufacturing, maturing and delivering DCs in 
this context, clinical responses are variable and do not yet meet expectation of efficacy. 
One potential issue in therapeutic efficacy is in the inability of the cells to reach the LNs 
following injection due to lack of expression of the chemokine receptor CCR7, which is 
not always upregulated following ex vivo culture. Using the methodology developed by Le 
Brocq et al., it may be possible to isolate only CCR7-expressing cells from culture, which 
may provide DCs with an improve LN homing capacity and therefore therapeutic efficacy. 
The aims of this project are to understand: 
1. Does sorting DCs by expression of CCR7 improve their phenotype, migration and 
function? 
2. Does sorting DCs by expression of CCR7 confer therapeutic efficacy in a mouse 
model of cancer? 
In Chapter 3, sorting murine bone marrow dendritic cells (BMDCs) by CCR7 expression 
using CCL19 will be validated, and the cells characterised for surface marker phenotype, 
secretory profile, migratory capacity and immunogenic function. In Chapters 4 and 5, 
CCR7-sorted DCs will be challenged in the context of the subcutaneous and metastatic 
B16F10 melanoma models to assess their potential therapeutic benefit. Finally, in Chapter 
6, human MoDCs will be generated and sorted for CCR7 expression using a good 
manufacturing practice (GMP)-grade clinical cell sorter to assess the potential for clinical 
translation of the methodology. 
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2 Materials and methods  
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2.1 Cell culture 
2.1.1 Maintenance of cell lines 
The cell lines used and maintained in this thesis are described below. All cell culture and 
use were carried out under aseptic conditions i.e. within a tissue culture hood with a 
laminar High-Efficiency Particulate Arrestance (HEPA) filtration system and pre-sterilised 
equipment and reagents. 70% industrial methylated spirits (IMS) was used to sterilise 
equipment and hood surfaces before use. Centrifugation was performed at 300xg for 5min 
in a Biofuge primo centrifuge (Thermo Scientific) unless otherwise stated. All cultures 
were kept in an incubator at 37ºC / 5% CO2 / 95% humidity. 
The B16F10 murine melanoma cell line was maintained in Dulbecco’s minimal essential 
medium (DMEM) (Sigma Aldrich, UK) supplemented with 10% foetal calf serum (FCS) 
(v/v), and 2mM L-glutamine, penicillin (100 U/ml) and streptomycin (100μg/ml; all 
Sigma-Aldrich) (complete DMEM).  
2.1.2 Reconstitution of frozen cell lines 
Cell lines were reconstituted from liquid nitrogen stocks prior to culture. Recovery of cells 
was performed by thawing vials in a 37°C water bath. Cells were washed once in 20ml of 
medium (pre-warmed to 37°C) followed by centrifugation. The supernatant was decanted, 
and the pellet of cells resuspended in 25ml of fresh culture medium for transfer into a 
75cm3 tissue culture flask. 
2.1.3 Cell counting 
Viable cells were counted using a Neubauer haemocytometer (Hawksley, UK) with dead 
cells assessed using 0.4% Trypan Blue (Sigma-Aldrich) staining. 5μl of trypan blue was 
added to an equal volume of cell suspension and briefly incubated at room temperature 
before loading into the chamber of the haemocytometer. The number of cells in each of the 
4 x 4 grids was counted and an average cell number/grid was determined. Dead cells were 
identified by uptake of the Trypan Blue stain. Final cell number was obtained by 
multiplication of the average cell number with the dilution factor with Trypan Blue (x2) 
and a factor of 104 to give the number of cells/ml of cell suspension. 
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2.1.4 Passage of cell cultures 
Cell lines used were routinely passaged upon reaching 80-90% confluence, which was 
assessed by inspection of cell cultures using a light microscope (Zeiss). To passage cells, 
medium was aspirated, and cells were washed with 5-10ml Phosphate-buffered saline 
(PBS) (Invitrogen). Adherent cells were detached from plastic flasks by enzymatic 
detachment with 0.5% trypsin (w/v) (Invitrogen) (1ml for 25cm3 and 3ml for 75cm3). Cells 
were incubated for up to 5min at 37°C and assessed for detachment using a light 
microscope. Trypsin was quenched by the addition of complete medium to a final volume 
of 10ml, and cells were resuspended by manual agitation with a pipette. The suspension 
was centrifuged and the supernatant decanted; cells were resuspended in an appropriate 
volume of fresh medium and split into a new tissue culture flask with a dilution factor 
between 1:20 and 1:40.  
2.1.5 Freezing and storage of cell lines 
Early passage cells from all cell lines were frozen down for future use. Cell suspensions 
were first washed once in PBS, centrifuged and resuspended at a density of up to 1x107 
cells/ml in FCS with 10% dimethylsulphoxide (DMSO) (v/v) (Sigma-Aldrich) for freezing. 
1ml of cell suspension was added to 2ml cryo-vials, which were cooled overnight at -80°C 
before transfer to vapour phase liquid nitrogen storage tanks.  
2.2 Molecular methods 
2.2.1 Cell lysate preparation 
Cell lysates were prepared using the NP40 Cell Lysis Buffer (ThermoFisher Scientific). 
Cells were pelleted and washed twice with ice-cold PBS to remove the tissue culture 
medium. The cells were resuspended in cell lysis buffer at 5mg/ml as per the 
manufacturer’s instructions. After 15min on ice with occasional vortexing, the lysate was 
transferred to the microcentrifuge tube provided and centrifuged at 14000rpm for 10min at 
4ºC. The lysate was transferred to a clean microcentrifuge tube for storage. Total protein 
concentration was determined by Pierce bicinchoninic acid (BCA) protein assay 
(ThermoFisher Scientific) as per the manufacturer’s instructions. 
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2.2.2 RNA isolation 
All techniques involving RNA were performed taking care to minimise environmental 
contamination by RNases. RNase-free or autoclaved plastic and glassware were used, as 
well as sterile filter tips and RNase-free water (Ambion). Work surfaces and equipment 
were decontaminated with RNAzap RNase decontamination solution (Ambion) before use.  
RNA was extracted from cells using the RNeasy Mini Kit (Qiagen). Cells were pelleted, 
washed once in PBS and resuspended in an appropriate volume of RLT Buffer with β-
mercaptoethanol for the expected cell number (350μl for 1-5x106 cells; 600μl for >5x106 
cells). The suspension was homogenized using a QIAshredder spin column before 
proceeding with the extraction as per the manufacturer’s instructions. This included the on-
column DNase digestion using the RNase-free DNase Kit (Qiagen) and the additional 
column drying step. The final elution volume was spun through the column twice to ensure 
optimal RNA concentration. The RNA concentration of each sample was determined by 
nanodrop (Nanodrop 1000, Thermo Scientific). RNA was stored for future use at -80ºC to 
maintain RNA integrity. 
2.2.3 cDNA synthesis 
RNA was converted to complementary DNA (cDNA) using a two-step Reverse 
Transcription (RT) process. The High Capacity RNA to cDNA Kit (Applied Biosystems) 
was used for all cDNA synthesis as per the manufacturer’s instructions. Briefly, the 
reaction mix was prepared in 0.2ml PCR tubes as follows: 
* Substituted with nuclease-free water in control reactions. 
 
The contents of each tube were mixed by pulse centrifugation. The RT process was carried 
out in a thermal cycler set to run at 37ºC for 60min to allow annealing of the RT enzyme to 
the template RNA, then 95ºC for 5min to initiate the reverse transcription of the RNA into 
cDNA. Product cDNA was stored at -20ºC until required. 
Ingredient Volume (μl) 
Template RNA ≤ 9 
2x RT Buffer 10 
20x RT Enzyme Mix* 1 
Double-distilled Nuclease-free Water Up to 20 
Materials and methods 53 
 
2.3 Luminex 
Cell lysates were collected for Luminex analysis as described in 2.2.1. The Bio-Plex Pro™ 
Mouse Chemokine Assay (Bio-Rad) was used according to the manufacturer’s 
instructions. All of the reagents and standards were included in the assay kit and were 
prepared as instructed. Briefly, all cell lysate samples were diluted in standard diluent to a 
final protein concentration of 200-900µg/ml for the assay. 50µl of magnetic beads were 
added to each well, followed by 50µl of the sample or the prepared standards and placed 
on an orbital shaker at 850rpm for 30min at room temperature. The plate was washed three 
times with 100µl of wash buffer, and then incubated following addition of 25µl of the 
detection antibody as previously. The plate was washed as previously, and 50µl of the anti-
biotin detector antibody added to each well. After incubation on the orbital shaker at 
850rpm for 10min at room temperature, the plates were washed three times again and 
125µl of the assay buffer was added to each well. The plate was then immediately read 
using a Luminex 200 Bio-Rad analyser. The Luminex data were analysed as recommended 
by the manufacturer. Briefly, each microparticle bead region was designated as 
recommended, and doublet gates were set to between 8000 and 16500 to exclude 
aggregated beads detected by the lasers in the flow cell. The mean fluorescence intensity 
(MFI) was recorded for each sample, and the protein concentration of the samples 
determined using the standard curve acquired for each analyte. 
Table 2.1 - Chemokines and cytokines detected by the Bio-Plex Pro™ Mouse Chemokine 
Assay. 
 
 
2.4 Quantitative polymerase chain reaction (QPCR) 
2.4.1 Primer design 
For QPCR, two sets of primers need to be designed for each gene of interest, known as 
‘inner’ and ‘outer’ primers. Outer primers are used in the generation of standards for each 
gene by PCR; inner primers are designed to amplify a smaller region between the outer 
CCL1 CCL24 CXCL1 IFNγ 
CCL11 CCL25 CXCL10 IL-10 
CCL12 CCL27 CXCL12 IL-16 
CCL17 CCL3 CXCL13 IL-1β 
CCL19 CCL4 CXCL16 IL-2 
CCL2 CCL5 CXCL2 IL-4 
CCL20 CCL7  CXCL5  IL-6 
CCL22 CX3CL1 GM-CSF TNFα 
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primers and are used for gene quantification. To design accurate and efficient primers, the 
Ensembl software (www.ensemble.org) and Primer3 software (http://frodo.wi.mit.edu/) 
were used, with the following specifications: 
 
Additionally, primer sequences with more than two G or C bases within the last five bases 
at the 3’ of each primer (creating a GC clamp), or with stretches of four or more G or C 
bases in a row were avoided to generate primers with low spontaneity to form primer 
dimers or hair-pin loops. The primer sequences were checked using the Basic Local 
Alignment Search Tool (BLAST) (https://www.ncbi.nlm.nih.gov/tools/primer-blast/) to 
ensure specificity for the gene of interest and no off-target binding potential. All primers 
were synthesised by Integrated DNA Technologies (IDT).  
Table 2.2 - QPCR primer sequences 
*The CMV promotor and eGFP outer primers constitute a Forward and Reverse pair for plasmid 
cloning purposes. 
 
2.4.2 Polymerase chain reaction (PCR) 
PCR was performed using the Q5 High-Fidelity DNA Polymerase (Qiagen). The master 
mix for this PCR reaction was prepared as follows in RNase-free PCR tubes: 
Specification Optimal Value Range 
Primer length (bp) - 18 - 23 
GC content 50% 40 - 65% 
Melting temperature (Tm) 60ºC 59.5º - 61ºC 
Max. self-complementarity 2 - 
Max. 3’ self-complementarity 1 - 
Amplicon size (bp):  Inner primers 150 <150 
 Outer primers 750 700 - 800 
Primer Name Primer Sequences 
Blasticidin resistance 
(Inner) 
Forward 
Reverse 
5’- AGAACAGGGGCATCTTGAGC -3’ 
5’- AGAGGGCAGCAATTCACGAA -3’ 
*CMV promoter (Outer) Forward 5’- TGGCACCAAAATCAACGGGACT -3’ 
*eGFP (Outer) Reverse 5’- CGTCGCCGTCCAGCTCGACCAG -3’ 
GAPDH (Outer) Forward 5’- TGAACGGGAAGCTCACTGGC -3’ 
 Reverse 5’- TCCACCACCCTGTTGCTGTAG -3’ 
GAPDH (Inner) Forward 
Reverse 
5’- GTTGCTGTTGAAGTCGCAGGAG -3’ 
5’- ATGTGTCCGTCGTGGATCTGAC -3’ 
Kanamycin/Neomycin 
resistance (Inner) 
Forward 
Reverse 
5’- GAGGCTATTCGGCTATGACTGG -3’ 
5’- ACCGGACAGGTCGGTCTTGAC -3’ 
mRuby2 (Inner) Forward 
Reverse 
5’- TGGGAAAGAGTTACGAGATACGA -3’ 
5’- AACGAGACAGCCATCCTCAA -3’ 
OVA (Inner) Forward 
Reverse 
5’- CCAATCTGTCTGGCATCTCC -3’ 
5’- TGCTGACCCTACCACCTCTC -3’ 
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* Substituted with nuclease-free water in control reactions. 
 
Reactions were run in a 7900T thermal cycler (Applied Biosystems) with the following 
programme: 
 
 
2.4.3 Gel electrophoresis 
PCR products were run on an agarose gel to determine the size of the product against a 
ladder of known DNA sizes. A 1% agarose gel was used unless otherwise specified. The 
gel was made by adding 0.5g of agarose (Sigma-Aldrich) to 50ml of tris acetate 
ethylenediaminetetraacetic acid (TAE) buffer, which was heated in the microwave until the 
agarose was fully dissolved. Ethidium bromide was added to the partially-cooled agarose 
solution. The solution was poured into a gel cassette to cool, with combs inserted into the 
gel to create wells in which to load samples. Upon cooling, the gel was place in an 
electrophoresis tank, which was filled up with TAE buffer until the surface of the gel was 
covered. Samples were loaded by pipette with a DNA ladder to allow determination of 
sample size. For samples ≤10kb in length, a type IV hyperladder (BioLegend) was used.  
Samples were run for 60min at 100 volts, or until the loading dye had diffused to the end 
of the gel. The gel was then imaged by UV illumination using an Alpha 2200 Digital UV-
Visphoto (Alpha Innotech, Santa Clara, California). To prepare specific PCR products to 
be QPCR standards, the band representing the product was carefully cut out with a scalpel 
blade and halved. From this, the product was extracted using the QiaQuick Gel Extraction 
Ingredient Volume (μl/reaction) 
5x Q5 Reaction Buffer 5 
Q5 High-Fidelity DNA Polymerase 0.25 
dNTPs (10mM) 0.5 
Primer Mix (10μM for each primer) 2.5 
DMSO 0.75 
BSA 1.25 
Template cDNA* 1-2 
Double-distilled Nuclease-free Water Up to 25 
Step Temperature (ºC) Time  
Initial denaturation 98 3 minutes  
Denaturation 98 10 seconds  
Annealing 60 20 seconds Repeated for 40 cycles 
Elongation 72 40 seconds  
Final elongation 72 10 minutes  
Hold 4 Indefinitely  
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kit (Qiagen) as per the manufacturer’s instructions. The DNA obtained was stored at -20ºC 
in the elution buffer provided in the kit. 
2.4.4 QPCR assay 
SYBR Green, a cyanide dye which binds double stranded DNA (dsDNA), is used to 
quantify gene expression in each sample in QPCR. The QPCR master mix was prepared as 
follows using SYBR Green Fast Mix (VWR-International):  
 
 
QPCR assays were performed with samples in quadruplicate, so volumes above were 
adjusted according to experimental requirements. Using a multichannel pipette, 9μl of the 
master mix was added to each well of a 384-well thin-walled PCR plate. To these, 1μl of 
the desired cDNA or standard DNA was added and mixed thoroughly. A ‘no template 
control’ (NTC) was also run for each primer pair with double-distilled nuclease-free water 
used in place of the DNA. Once the samples had been loaded, the plate was carefully 
sealed using an optical plastic film (Applied Biosystems), briefly centrifuged at 500g at 
4ºC and run on a 7900HT thermal cycler (Applied Biosystems). The QPCR programme is 
described below: 
*Steps 4-5 were added to produce a dissociation curve for the primers to confirm specificity. 
 
2.4.5 Analysis of QPCR data 
Cycle threshold (CT) was used as a metric of gene expression: describing the cycle of the 
QPCR at which replication of the gene by the enzymes in the master mix becomes 
significantly detectable above background by the machine reader. With this information, 
genes with low CT values are highly expressed, and vice-versa. For each gene, the R2 value 
was considered: this uses the values from the standard curve constructed by dilutions of the 
Ingredient Volume (μl) 
SYBR Green Fast Mix 5 
Double-distilled nuclease-free water 4 
1:1 Primer mix 0.15 
Step Temperature (ºC) Time (s)  
1 95 20  
2 95 3 Repeated for 40 cycles 3 60 30 
4 95 15  
5 60 60  
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gene standard DNA to compare CT value consistency between replicates. The closer the R2 
value is to 1, the more accurately the gene expression in the experimental samples can be 
quantified using the standard curve. NTC control samples were also used to check for 
pipetting errors and are expected to have a very high or undetectable CT value. After these 
checks, the data were exported to Microsoft Excel and the expression of target genes 
normalised to the GAPDH housekeeping gene.  
2.5 In vivo procedures 
2.5.1 Animal welfare 
Animals were housed in the Biological Services Central Research Facility at the University 
of Glasgow and the Beatson Institute and maintained in specific pathogen-free conditions 
with unrestricted access to food and water. All experiments were approved by the 
University of Glasgow Ethical Review Committee and performed under the auspices of a 
United Kingdom Home Office License. 
2.5.2 Mice 
C57BL/6 mice were bred and maintained in-house but were also purchased from Charles 
River laboratories as required. 8 to 12-week old mice were used in this project. These mice 
were allowed a week to acclimatise to the environment before being put on procedure if 
arriving from an external supplier. 8 to 12-week old mice of either sex were used for 
generation of BMDCs, unless cells were being used for injections, in which case female 
mice were used as a source of BMDCs. 8 to 9-week old female mice were used as 
recipients for injections under procedure. Specifically-modified mouse strains used in this 
project are described in Table 2.3. Briefly, OT mice were used as a source of ovalbumin 
(OVA)-specific T cells used in the validation of B16-ova transfectants and in T cell 
stimulation assays. 
 Table 2.3 - List of mouse strains used in procedures. 
 
Genotype Modification 
OT-I Transgenic TCR recognising MHC class I restricted OVA peptide 
WT C57BL/6 – no modification 
WT albino C57BL/6 – albino 
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2.5.2.1 Schedule 1 
Mice were culled by exposure to rising concentration of CO2, a recognised Schedule 1 
procedure. The cull was confirmed by either cervical dislocation or by perfusion with a 
fixative such as 1% paraformaldehyde (PFA) in PBS (v/v) by injection into the circulation. 
2.5.3 Dissection techniques 
Mice were culled as described in 2.5.2.1, and the body pinned out on a cork board for 
dissection. Mice were sprayed with ethanol and the viscera exposed by pinching the skin 
on the abdomen and making an incision up the midline to the neck using a pair of surgical 
scissors. At the top and bottom of the incision, further incisions were made along the 
midline of fore- and hindlimbs, respectively. The skin was then pulled back to fully expose 
the viscera and pinned as appropriate. The contents of the abdomen were exposed by 
making an incision up the midline to the diaphragm. The contents of the thorax were then 
exposed by excision of the diaphragm along the line of the ribcage, and then along either 
side of the ribcage towards the neck. The ribcage was then folded back to fully exposure 
the lungs and heart. 
2.5.3.1 Bone marrow isolation 
To extract the bone marrow, hindlimb skin was first cut above the ankle using surgical 
scissors and manually pulled back from the limb. The muscle and tendons were then cut 
away to expose the bone. The femur was cut as close to the hip joint as possible, and the 
paw removed from the tibia. In an air flow hood, both the tibia and femur were cut at the 
knee to expose the marrow. The bone marrow was then flushed from the cavity by flow-
through of non-supplemented Roswell Park Memorial Institute medium (RPMI) 
(ThermoFisher Scientific) using a 20ml syringe and a 23G needle and collected in a 10cm2 
culture dish. Cells were then homogenised by passing through a 70um filter using the 
insert of a 1ml syringe and were then centrifuged at 300xg for 5min to pellet the cells. 
Supernatant was decanted, and the cells resuspended at 107 cells/ml for culture as 
described in 2.6.1. 
2.5.3.2 Lymph node isolation 
LNs were routinely isolated in this project for collection of T cells for culture and during 
tumour development, and collection of DCs in competitive migration experiments. The 
specific LNs taken and their location within the mouse are summarised in Figure 2.1.  
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Figure 2.1 - Schematic diagram of mouse LN locations and their experimental use. 
Inflammatory exudate from peripheral tissues and developing tumours drain into lymph nodes, 
such as those shown here, and except the mesenteric lymph nodes are reflected across the 
midline. The LNs in inset images are denoted by red arrows, with the axillary in the red box. LNs 
used in each experiment are identified by colour: T cell isolation/generation only (light green), 
competitive DC migration (dark green), and solid tumour (light blue) and metastatic tumour (dark 
blue) models. 
 
Dissection of the individual lymph nodes are described below, and unless otherwise stated 
were removed using sharp watchmakers’ tweezers: 
• Cervical – The skin is cut up the midline towards the mouth using scissors and 
peeled back to expose this cluster of lymph nodes. 
• Mediastinal (mLN) – This cluster of lymph nodes is partially visible at rest but 
become enlarged during inflammation in the lungs and lies along the trachea before 
the bifurcation to the lungs. 
• Inguinal (iLN) – The inguinal lymph node (also known as the subiliac lymph node) 
is located within the mammary fat pad in the lower abdomen. 
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• Lumbar – Located along the midline and descending aorta, the lumbar LNs are a 
pair of LNs visible before the bifurcation of the aorta to the hindlimbs. 
• Popliteal (pLN) – The popliteal lymph node is located in the popliteal fossa 
underneath the knee and is dissected by first pinning out the hindlimb at 90° to the 
body and peeling back the skin. The musculature is stripped away using tweezers 
until the lymph node is visible. 
• Mesenteric – These lymph nodes lie in a chain within the mesenteric region of the 
gut and are visible following incision of the peritoneum and mobilisation of the gut. 
• Brachial and Axillary – Both of these lymph nodes are located under the shoulder: 
the brachial lymph node lies directly below the upper forelimb if the mouse is 
pinned as described in Figure 2.1; the axillary LN is present sometimes as a 
cluster, in the musculature connecting the upper thorax to the skin when pinned.  
For all T cell cultures, all of the lymph nodes except the mediastinal were removed. After 
footpad injections, DCs were isolated from the popliteal, inguinal and axillary/brachial 
lymph nodes on the left of the animal which drained the injection site. Following injection 
into the footpad, as described in 2.5.4.1, the lymphatics in the hindlimb drain primarily into 
the popliteal LN, with some drainage seen into the inguinal, and axillary LNs via the 
efferent lymphatics (Harrell et al., 2008). In these experiments, the contralateral side LNs 
were dissected and retained as controls. In solid tumour experiments, the injection site-
draining LN (popliteal), and tumour-draining LNs (inguinal in the solid tumour model; 
mediastinal in the metastatic model) were taken to analyse induction of tumour-specific T 
cells. Lymph nodes were homogenised by passing through a 70um filter using the insert of 
a 1ml syringe, the homogenate pelleted by centrifugation and resuspended as appropriate.  
2.5.3.3 Spleen 
The spleen is located in the posterior abdominal cavity and is located by mobilisation of 
the viscera following incision of the peritoneum and removal with surgical scissors. A 
single cell suspension was obtained from the spleen following manual cutting into small 
sections with scissors and passing through a 70um filter as described previously. The cells 
were pelleted by centrifugation at 350xg and the supernatant removed. Red blood cells 
(RBCs) were removed using the RBC lysis buffer (BioLegend) diluted to 1x concentration 
in PBS. Briefly, each pellet was resuspended in 5ml of RBC lysis buffer on ice for 5min, 
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and the reaction stopped by addition of 25ml of PBS. After centrifugation at 350xg, the 
supernatant was removed, and the cells resuspended in the appropriate buffer or medium 
and counted. 
2.5.3.4 Lung lobe  
For this protocol, mice were perfused with 10ml PBS using a 25G needle inserted into the 
left ventricle of the heart. This allowed the lungs to be fully perfused with PBS before 
dissection with surgical scissors and was important to remove blood from the circulation 
for subsequent imaging and flow cytometry. A single cell suspension was obtained from 
the lungs following manual cutting into small sections with scissors and transferring the 
tissue into 15ml tubes. 2.5ml of digestion mix was added to each tube, which contained 
1.6mg/ml Dispase (Roche), 0.2mg/ml Collagenase P (Roche) and 0.1mg/ml DNase I 
(Invitrogen) in RPMI. The tissue was incubated at 37°C in a water bath for 40min, with 
manual agitation of the tube after 20min. Digested tissue was then passed through a 40um 
filter as described previously and washed with 10ml RPMI. After centrifugation at 350xg, 
the supernatant was removed, and the cells resuspended in the appropriate buffer or 
medium and counted. 
2.5.4 Procedures 
2.5.4.1 Footpad injections  
BMDCs were generated and sorted using 23-PEG bCCL19 as described in 2.6.1 and 2.6.2, 
respectively. In competitive migration experiments, albino mice were used. The cells were 
resuspended at 1x106 total cells in 25μl in PBS/0.1% bovine serum albumin (BSA) 
(Millipore) for injection. Footpad injections were performed in one of the two following 
ways: 
1. Mice were immobilised by the scruff by a member of staff, while the cells were 
carefully injected into the left footpad. 
2. Mice were first fully anaesthetised using 30% isoflurane in oxygen in a Perspex 
chamber, as tested by cessation of movement and hindlimb reflexes, before transfer 
of individual mice to anaesthetic ventilator masks and performing the injection into 
the left footpad. 
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In both cases, the left footpad and associated contralateral draining lymphatics were left as 
an internal control for each injection. 
To analyse the cells present in the footpad, mouse paws were removed and collected in 1ml 
of PBS in a 12-well plate. The skin was removed using surgical scissors and cut into small 
pieces. Both the skin and remaining paw were incubated with digestion mix which 
contained 2mg/ml Collagenase IV, 2mg/ml hyaluronidase and 0.1mg/ml DNase I (all 
Invitrogen) at 45°C for 20min in a shaking incubator. After incubation the tissue was 
removed and passed through a 100um filter as described previously and washed with 10ml 
PBS. Cells were washed twice by centrifugation, and then resuspended in the appropriate 
buffer or medium and counted. 
2.5.4.2 Tumour models 
B16F10 melanoma cells are a rapidly-metastasising subclone of the B16 murine melanoma 
cell line. In this project, the B16F10 line was transfected to express the ovalbumin cDNA 
and mRuby2 fluorescent reporter. Cells were grown to confluence in 75cm3 flasks and 
trypsinised as described previously and washed twice in PBS by centrifugation. The cells 
were resuspended at 5x106 cells/ml in PBS and kept at room temperature before injections 
to prevent aggregation of cells. 
Solid tumours 
For better visualisation and measurement of subcutaneously growing tumours, mice 
receiving subcutaneous tumour cell injections were shaved on the flank using an electric 
razor (Wella) the day before tumour cell injection. To induce solid tumour formation, 
5x105 B16F10 cells were injected subcutaneously into the lower back of the mouse. Under 
Home Office guidelines tumour-bearing mice were weighed daily, their tumour growth 
measured daily using digital Vernier callipers (Sealey Professional Tools) and were 
monitored daily for any signs of sickness. This procedure typically ran for between 3 and 4 
weeks before tumours reached maximal size and the mice were culled using an approved 
Schedule 1 procedure (see 2.5.2.1). 
Metastatic tumours 
Mice receiving the intravenous injections of tumour cells were first placed into a heated 
Perspex box to allow the blood vessels to dilate and become more visible. Individual mice 
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were contained in a Perspex holding tube with an adjustable head restraint to minimise 
movement and risk of harm to the mouse. A magnifying lamp was also used to help 
visualise the tail vein for the injection. B16F10 cells were injected in a 100μl volume, with 
each mouse receiving 5x105 cells total. Mice were kept for no longer than 14 days with 
developing tumours and were both weighed and monitored daily, as discussed previously. 
On day 14 post-injection, mice were sacrificed using an approved Schedule 1 procedure 
(see 2.5.2.1). 
2.6 Ex vivo procedures 
2.6.1 Generation of murine BMDCs 
Bone marrow cells were cultured in 10cm2 culture dishes at 107 cells/ml in RPMI 
supplemented with 10% FCS (v/v) and 2mM L-glutamine, penicillin (100 U/ml) and 
streptomycin (100μg/ml) (complete mRPMI). The medium was additionally supplemented 
with 20ng/ml recombinant murine GM-CSF (Peprotech) to support differentiation of the 
cells. On days 2 and 4 of the protocol, non-adherent cells in the medium were transferred 
to new culture dishes following manual agitation by pastette. New medium was added at 
these timepoints as necessary. On day 7, non-adherent cells were collected and 
resuspended at 8x106 cells/ml in complete mRPMI with 5mg/ml ovalbumin (Sigma-
Aldrich). Cells in suspension were counted by haemocytometer as previously described in 
2.1.3. The suspension was plated on Ultra Low-Adherence 24-well plates (Corning) and 
incubated for 4 hours under normal culture conditions. After 4 hours, the supernatant was 
removed from the wells using a pipette and collected in a 50ml falcon tube. TrypLE (Life 
Technologies) (diluted from 10x to 1x concentration in PBS) was then added for a further 
5-10min to detach the cells. After this the contents of the wells were manually agitated by 
pastette and collected with the non-adherent cells in the same 50ml falcon tube. The cells 
were washed by centrifugation and resuspended at 2x106 cells/ml in complete mRPMI. To 
stimulate the DCs to mature, 100ng/ml ultrapure LPS (Source Bioscience) and 50ng/ml 
murine recombinant TNF-α (Miltenyi Biotec) were added to the suspension, which was re-
plated in 6-well plates and incubated for 24 hours under normal culture conditions. The 
cells were then collected as previously described using TrypLE as it maintains cell-surface 
molecule expression due to its non-enzymatic nature.  
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2.6.2 Chemokine-based sorting 
Mature BMDCs were collected from culture and washed as described previously and 
resuspended at 107 cells/100μl in PBS with 0.5% (w/v) media-grade BSA and 2mM 
ethylenediaminetetraacetic acid (EDTA) (Ambion) (PEB buffer) for all sorting 
methodologies. Prior to staining, cells were blocked using FcR blocking reagent, as per 
manufacturer’s instructions (Miltenyi Biotec). Cells were incubated at 4ºC with either 
biotinylated CCL19 (bCCL19) with a polyethylene glycol (PEG) spacer residue set 
(400ng/ml; Almac Sciences, generated as described in Le Brocq et al., 2014) tetramerised 
with streptavidin-PE (SAPE)(50μg/ml; Life Technologies) for 30min, or bCCL19 
(400ng/ml) conjugated to anti-biotin PE (Miltenyi Biotec) as described previously (Le 
Brocq et al., 2014). 3-, 11-, and 23-PEG biotinylated CCL19 were used in this project, 
which describes the number of PEG residues in the chain separating the CCL19 molecule 
from the attached biotin residue. For cells being sorted by fluorescence activated cell 
sorting (FACS), an additional anti-CD45 antibody was added (1μl/107 cells), to further 
discriminate the cells cytometrically. After 30min cells were washed in PEB by 
centrifugation and resuspended in an appropriate volume of PEB. Cells were then sorted 
using either magnetic microbeads, the Aria II cell sorter (BD Biosciences) or the 
MACSQuant Tyto cell sorter, as described below. 
2.6.2.1 Chemokine-based sorting using microbeads 
For manual sorting, bCCL19-labelled BMDCs were resuspended at 107 cells/80μl in ice-
cold PEB and stained with anti-PE microbeads (20μl/107 cells) for 20min at 4°C. The cells 
were then washed in PEB by centrifugation and resuspended. MACS LS columns 
(Miltenyi Biotec) were used for manual cell sorting. These columns were mounted on a 
magnetic stand using the Miltenyi QuadroMACS magnet and rinsed once with PEB prior 
to adding the magnetically-labelled cells. To sort the cells, a 25G needle was attached to 
the end of the column, and the cells added to the top in 3ml of PEB. After the cell volume 
had run through completely by gravity, the column was washed 3 more times with 3ml of 
PEB. To collect the labelled cells, the LS column was removed from the magnetic stand 
and washed with 5ml of PEB by gravity without using the plunger to preserve cell 
viability. The positive and negative sort fractions were washed by centrifugation and 
resuspended in PEB for counting, analysis of purity by flow cytometry, and further 
experiments.  
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2.6.2.2 Chemokine-based sorting using Aria II 
Given the incorporation of a fluorescent conjugate into the sorting protocol for analysis of 
purity, the sorting method is amenable to translation to FACS. Two FACS sorters with 
unique sorting mechanisms were used during this project: the BD Aria II and Aria III (BD 
Biosciences) (which are functionally identical) and the MACSQuant Tyto (Miltenyi 
Biotec). 
To sort cells on the Aria II, the sorter was first set up to run at 20ºC with autoclaved PBS at 
a neutral pH (7.4), instead of the BD Sheath solutions to omit sheath preservatives such as 
2-phenoxyethanol, and the collection chamber pre-cooled to the same temperature to limit 
cellular metabolism without induction of cold shock apoptosis. If the cells were required to 
be sterile for further use, the aseptic cleaning process was also run. The sorter itself was 
fitted with an 85μm nozzle and was run at 45psi and a 52.3MHz frequency to produce a 
high frequency sort under minimal flow rate to maintain cell viability. Cells were filtered 
for sorting using 70μm filters (Greiner bio-one) and resuspended at 1x107 cells/ml in PEB. 
Forward scatter (FCS) and side scatter (SSC) gates were set using unstained cell controls, 
and the fluorescence gates set using single stained cell controls. For FACS, a dead cell 
discriminator was not used due to the fluidic sampling characteristics of the cells and 
potential intracellular activation as a result. The sorted cells were collected into sterile 
15ml falcon tubes containing 3ml of complete mRPMI supplemented to 50% FCS (v/v) to 
preserve the cells following the sort. The collected cells were washed by centrifugation and 
resuspended at an appropriate concentration for their future use. 
2.6.3 Cell labelling for in vivo tracking 
2.6.3.1 PKH67 dye 
PKH67 dye (Sigma-Aldrich) is a green fluorescent dye (ex: 490nm; em: 504nm) which 
intercalates into the lipid membrane of cells. Cells were labelled with this dye to allow in 
vivo tracking following injection, staining cells as per the manufacturer’s instructions. 
Briefly, the PKH dye solution was prepared by dilution of the PKH dye to a concentration 
of 4μM in 500μl of diluent solution. Cells were prepared for staining by single cell 
suspension by washing in serum free RPMI and were resuspended in 500μl of diluent 
solution. The PKH dye solution and cell suspension were mixed by direct addition of the 
cell suspension to the dye solution, to a final concentration of 2μM PKH dye. Cells were 
incubated at RT for 5min before the dye was quenched with hRPMI and washed by 
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centrifugation. This washing step was repeated once before enumeration and resuspending 
the cells in an appropriate volume of PBS/0.1% BSA for injection (2.5.4.1). Samples of 
cells were routinely assessed for successful staining by flow cytometry.  
2.6.3.2 CellTracker Red (CMTPX) 
CellTracker fluorescent dyes, such as CellTracker Red (CMTPX) (Life Technologies) 
enter cells by passive diffusion and are converted into cell impermeant molecules by 
endogenous enzymes. This leads to red cytosolic staining of target cells (ex: 577, em: 602). 
A working solution of dye was prepared by dilution of the stock CMTPX solution in to a 
concentration of 2μM in serum free RPMI. Cells were prepared for staining by single cell 
suspension by washing in serum free RPMI and directly resuspended in the CMTPX 
working solution. The cells were then incubated at 37ºC for 30min, after which the dye 
was quenched by the addition of hRPMI and washed by centrifugation. Cells were counted 
and resuspended in an appropriate volume of PBS/0.1% BSA for injection (2.5.4.1). 
Samples of cells were routinely assessed for successful staining by flow cytometry.  
2.6.4 Transwell migration assay 
A transwell migration assay was used to determine migratory capacity of cells sorted using 
bCCL19 and PEG-variants. BMDCs were first sorted as described in 2.6.2, retaining a 
small sample of unsorted, labelled cells as a control. Cells were first counted using a 
haemocytometer and resuspended at 1.5x106 cells in chemokine buffer for each condition: 
unsorted, positive and negative sorted fractions. To ensure that no serum components were 
inducing migration of cells, the chemokine buffer used was RMPI supplemented only with 
0.5% BSA (w/v). Dilutions of the CCL19 were also prepared in chemokine buffer at 0, 10, 
100 and 500ng/ml. 24-well transwell plates were obtained from Corning and prepared as 
follows: first, 600μl of chemotaxis buffer was added to each well and incubated at 37ºC for 
5min. This was then removed by pipette and replaced with chemokine solution in the 
relevant wells. Transwell inserts were then placed into the wells containing chemokine 
solution using tweezers, taking care to avoid the formation of bubbles which could hinder 
cell migration. 100μl of cell suspension, equivalent to 1.5x105 cells per well, was then 
added carefully onto the filter of the well insert using a pipette. The plate was placed in a 
tissue culture incubator under normal culture conditions for 3 hours to allow migration. 
After this, the medium in the top of the insert was removed by pipette and the insert moved 
into an empty well using tweezers. The medium in the bottom of each well was then 
collected in an Eppendorf tube. The wells were then washed with PBS by pipetting 2-3 
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times and the PBS collected and added to the respective Eppendorf tubes. Although trypsin 
is commonly used to detach cells, it was not used in this protocol due to the potential 
damage to chemokine receptors that can be caused by enzymatic digestion. Additionally, 
the filters were not removed from the inserts and washed as there was a concern about the 
fragility of BMDCs having gone through maturation, activation and sorting within 24 
hours. Cells were then prepared for counting by flow cytometry by spinning down in a 
microcentrifuge and resuspending in 200μl of FACS buffer. This protocol was repeated 
with cells allowed to rest for 4 hours in a tissue culture dish after labelling and sorting.  
2.6.5 T cell cultures 
Spleen cells were cultured in 12-well tissue culture plates at 2x106 cells/ml in complete 
mRPMI. To induce antigen-specific activation of naïve T cells, ovalbumin-presenting 
mature BMDCs, generated as described in 2.6.1, were added to the culture at a ratio of 
1:25 BMDCs to spleen cells. On days 3 and 5 of the culture, half of the medium in each 
well was removed and replaced with complete mRPMI containing 100U/ml and 50U/ml 
recombinant murine IL-2 (Miltenyi Biotec), respectively. 100U/ml IL-2 allows expansion 
of activated T cells from the initial mixed cell culture, and 50U/ml is a maintenance dose 
of IL-2 for cell survival. After 7 days in culture, the cells were then collected using TrypLE 
for use.  
2.7 Microscopy 
2.7.1 Preparation of frozen tissue sections for microscopy 
Immediately after dissection, tissues were immersed in 1% PFA overnight followed by 
immersion in 30% sucrose (Fischer) in PBS (w/v) overnight. After this, tissues were 
embedded in optimal cutting tissue (OCT) cryo embedding medium (Tissue Tek) within 
plastic tissue moulds by adding a small amount of OCT medium to the mould, placing the 
tissue down in the correct orientation using tweezers, and carefully covering in more OCT 
medium to ensure no bubbled formed. The tissue moulds were then chilled over dry ice 
until completely frozen and stored at -80ºC until required. Sections of these tissues were 
cut to 8μm thickness using an OTF5040 cryostat (Bright Instruments, UK), and mounted 
on polysine-coated SuperFrost slides (VWR, UK). These slides were stored at 4ºC until 
use. 
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2.7.2 Haematoxylin & Eosin (H&E) staining 
Tissues for haematoxylin and eosin (H&E) staining were first prepared for frozen sections. 
Samples were first warmed to room temperature from -80°C storage and then fixed using 
ice-cold acetone. The sections were allowed to air-dry for 30min at room temperature. The 
remaining protocol is the same for both types of section. The tissues were taken to water 
through 100%, 90% and 70% alcohol for 10 dips each, followed by washing in running 
water. Slides were immersed in Haematoxylin Z (CellPath, UK) for 7min, and then washed 
in running water until clear. Slides were dipped in 1% acid alcohol for 12 dips, washed in 
running water, blued in Scotts tap water substitute (STWS; CellPath, UK) for 2min, 
washed again, and then immersed in Putts Eosin (CellPath, UK) for 4min. After this, cells 
were washed in running water for 2min, before dehydration through alcohol to Xylene by: 
immersion in 70%, 90%, and 100% alcohol for 10 dips each, followed by immersion in 
fresh Xylene 3 times for 1min each. Sections were then mounted using Di-n-butyl 
Phthalate in Xylene (DPX; VWR, UK) and coverslipped. 
2.8 Flow cytometry 
2.8.1 Flow cytometry staining procedure 
Cells were prepared for flow cytometry by collection from culture or homogenisation from 
tissues, washed and resuspended at 1x106 cells in 200μl PEB in polystyrene FACS tubes 
(BD Biosciences). Non-specific binding of antibodies to cells, especially macrophages and 
dendritic cells, was blocked by incubating cells with FcR block (Miltenyi) at 5μl/sample 
for 20min at 4ºC. The samples were then washed in PEB and resuspended in 200μl for 
staining with antibodies at the concentrations listed in Table 2.4.  
For each fluorophore in a panel, a single stain was prepared using a drop of UltraComp 
beads (eBioscience) in place of cells. These single stained samples were used to set the 
compensation for the cytometers and limit fluorophore spillover between channels which 
could give false results. Fluorescence minus one (FMO) controls were also prepared using 
isotype control antibodies, described in 2.8.3. After staining for 30min at 4ºC, samples 
were washed with PEB and analysed using a MACSQuant (Miltenyi), LSR-II or LSR-
Fortessa (both BD Biosciences) flow cytometer. 
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2.8.2 Flow cytometry antibodies 
Table 2.4 - List of mouse antibodies used in flow cytometry. 
APC* (fluorophore) = allophycocyanin; BV = Brilliant Violet™; CD = cluster of differentiation; FITC = 
fluorescein; PE = phycoerythrin; PE-Cy = phycoerythrin-cyanine (conjugate).  
 
2.8.3 Analysis of flow cytometry data 
Data were analysed using MACSQuantify (version 2.6) software (Miltenyi) or FlowJo 
(version 10) software (FlowJo). Cells were identified first by forward scatter (FSC) and 
side scatter (SSC) profile, which quantifies the size and shape of the cells in the sample. 
These cells are further gated by selecting single cells using SSC-A and -H parameters: if 
the sample contains cell aggregates these will lie off the y=x line. Dead cells were then 
excluded using a dead cell discriminator dye. This gating hierarchy is common to all flow 
cytometry analysis performed in this thesis and is summarised in Figure 2.2, below. 
  
Target Fluorophore Clone Dilution 
(if not 1/200) 
Supplier 
CD11c PE X9-15  BioLegend 
CD8 FITC 5H10-1  BioLegend 
CD44 APC* IM7  BioLegend 
CD62L PE-Cy7 MEL-14  BioLegend 
CCR7 PE 4B12  BioLegend 
F4/80 FITC BM8  BioLegend 
MHC class I AF647 AF6-88.5  BioLegend 
CD40 PE-Cy5 3/23  BioLegend 
CD86 PE-Cy7 GL-1  BioLegend 
CD80 BV421 16-10A1  BioLegend 
MHC class II VioGreen M5/114.15.2  Miltenyi Biotec 
PD-1 PE 29F.1A12  BioLegend 
CD25 PE PC61  BioLegend 
Tetramer APC*  1/50 Caltag Medsystems 
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Figure 2.2 - Initial flow cytometry gating strategy. 
Cells in each sample are gated first by size and shape using FSC/SSC (A), then by single cells (B), 
and finally by live cells (C).  
 
To accurately analyse expression of surface markers and cytokines by antibody binding, it 
was important to use an FMO control. In each panel, an FMO control was made for every 
fluorophore, in which the fluorophore was replaced by an isotype control antibody bound 
to the same fluorophore. These FMOs acted as both negative controls for the fluorophore, 
allowing positive gates to be drawn for experimental samples and assessment of 
fluorophore spillover between channels. 
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3 Characterisation of CCL19-sorted murine 
dendritic cells 
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3.1 Introduction and aims 
Migration of DCs is crucial for their function and is almost exclusively controlled through 
chemokines and chemokine receptor expression. As briefly discussed in the Introduction, 
it is relevant to discuss the migration of the two main inflammatory DC subsets given their 
importance in DC therapy: steady-state, circulating DCs known as pDCs; and the typical 
inflammatory DCs (BMDCs in mice; MoDCs in humans). Ontogenically these subsets are 
quite different but are unified in their general function of uptake of both self and non-self 
antigens by endocytosis, and processing and presentation of these antigens to immune 
effector cells through MHC machinery. 
Plasmacytoid DCs are a subset of DCs which exist in the body in the steady-state as fully-
matured cells after development in, and egress from, the bone marrow. These cells can be 
identified by low expression of CD11b and CD11c, Siglec H and Ly6C in mice, and low or 
no expression of CD11c. pDCs highly express MHC class II and CD123 in humans 
(Rogers et al., 2013). Unlike their tissue-resident counterparts, pDCs circulate in the blood 
and are rarely found in the periphery with the exception of the intestine (Wendland et al., 
2007) and appear to only enter tissues transiently to sample self-antigens and promote 
tolerance as shown in the context of tissue grafts (Ochando et al., 2006), or in response to 
an inflammatory signal from the tissue. They can secrete large quantities of IFNα in 
response to viral pathogens (Hagberg et al., 2011). In both cases, pDCs can uniquely 
migrate back into the bloodstream after uptake of antigen and into the lymphatic organs 
through specialised venules called HEVs. pDCs express an unusual combination of 
canonically T cell-associated chemokine receptors (Seth et al., 2011) such as CXCR4, 
CXCR3 and CCR5. CXCL12, the ligand for the chemokine receptor CXCR4 is expressed 
constitutively by the lymphatics and was once thought to be the primary chemokine for 
steady state migration of pDCs into the LNs (Krug et al., 2002); with upregulation of the 
CXCR3 ligands CXCL9, CXCL10 and CXCL11 during viral infection potentially 
facilitating entry to the LNs during inflammation (Kohrgruber et al., 2004). Conflicting 
experimental evidence, however, suggests that these chemokine receptors do not induce 
pDC migration after activation (Penna, Sozzani and Adorini, 2001). In the steady state, 
these chemokine receptors may contribute more to the pDC surveillance of the periphery 
such as migration to the skin, or small intestine (Sozzani et al., 2010). Interestingly, recent 
studies using CCR7-/- mice have shown intrinsic defects in the homing of pDCs, 
particularly after activation (Seth et al., 2011) – highlighting this chemokine receptor as 
crucial for pDC migration, despite their expression of other chemokine receptors. 
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Inflammatory DCs are another subset of DCs, which are derived from myelomonocytic 
progenitors in the blood. These progenitors are released from the bone marrow as 
immature cells and migrate into tissues in response to inflammatory signals using the 
chemokine receptors CCR1, 2 and 5 (Fogg et al., 2006). The process of extravasation from 
the blood into the tissues, and the subsequent inflammatory context in the tissue 
encourages maturation of the cells into DCs or macrophages depending on development 
stage of the progenitor cell (Liu, Victora and Schwickert, 2009). The cells sample antigen 
from the tissue, including cell debris and apoptotic cells, which, in concert with local 
cytokine production from other immune and stromal cells, induce maturation of the DCs 
and upregulation of CCR7 and co-stimulatory molecules such as CD80 and CD86 
(Guermonprez et al., 2002). Antigen uptake alone is sufficient to induce this upregulation 
and induce migration, in common with other DC subsets described here (Marsland et al., 
2005), but intravasating cells receive additional signals depending on the inflammatory 
context which can strengthen the immunogenicity of the final mature cell phenotype.  
Migration of DCs to the lymph nodes using CCR7 is guided by expression of one of its 
ligands CCL21 by the lymphatic endothelium within the tissue (Saeki et al., 1999), and by 
the fibroblastic reticular cells in the lymph node proper (Luther et al., 2000). The highly-
charged C-terminal extension of CCL21 allows the chemokine to be immobilised in 
components of the ECM, and helps guide haptotactic migration of DCs into the afferent 
lymphatics (Weber et al., 2013). Once in the lymph node, mature DCs use CCL19 for fine 
migration control and have also been attributed as a source of CCL19. DCs present antigen 
primarily to T cells and provide 3 distinct signals for cell activation. Firstly, T cell 
recognition of the antigen-MHC complex provides Signal 1 (Bretscher & Cohn, 1970). 
Signal 1 in isolation is typically associated with T cell deletion or induction of a non-
cytotoxic phenotype. This signal can be provided by a number of APCs, not exclusively 
DCs. Signal 2 refers to co-stimulatory signals from the cell presenting the antigen, and 
conventionally describes the interaction of CD80 and CD86 with CD28 on T cells (Keir 
and Sharpe, 2005). CD80 is expressed by APCs solely in response to maturation signals as 
described previously, whereas CD86 is present at low levels and expression is increased 
after stimulation. The physical proximity required for Signal 1 allows other cell-cell 
contacts such as CD80/86-CD28, as such these signals are referred to as co-stimulatory. A 
third signal, Signal 3, is derived from paracrine factors secreted by the APC which can 
skew T cell differentiation into a particular phenotype. One of the most potent and well-
characterised ‘signal 3’ factors is IL-12, which specifically supports the production of 
CTLs and Th1 cells (Trinchieri, 2003). 
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In all DC subsets, expression of CCR7 is therefore crucial for cell function by allowing 
DCs to efficiently migrate to the lymph nodes following activation and induce the 
appropriate T cell response for their subset. Although DCs are utilised therapeutically, 
particularly in cancer therapy, the migratory capacity of the cells themselves are rarely 
taken in account and instead clinical trials use strategies such as intranodal injection (de 
Vries, Krooshoop, et al., 2003) or simply large doses of cells to ensure adequate nodal 
accumulation of the DCs and therefore a therapeutic response. DCs generated in ex vivo 
cultures invariably display heterogeneous expression of CCR7, which limits potential 
migration, but isolating the CCR7+ cells is technically challenging given the paucity of 
antibodies against chemokine receptors in general. A novel sorting methodology developed 
by Le Brocq et al. (2014) may present an alternative method, as it uses a biotinylated 
CCL19 in place of an antibody and shows reliable and better staining for the CCR7+ cells 
by flow cytometry. 
In this Chapter, DCs were sorted for expression of CCR7 using this CCL19-based sorting 
method and were characterised for their expression of co-stimulatory molecules on the cell 
surface, and their cytokine and chemokine expression profile. The migration of the cells 
was then assessed in vitro and in vivo, as well as an investigation into the kinetics of the 
receptor-ligand interaction. Finally, the ability of the sorted cells to induce functional T 
cell responses in vitro was explored using a co-culture system. 
3.2 Optimisation of chemokine sorting protocol 
3.2.1 Validation of chemokine staining 
The use of biotinylated CCL19 (bCCL19) to detect the presence of CCR7 on the surface of 
DCs has been well characterised (Le Brocq et al., 2014). Briefly, the bCCL19 is 
conjugated to phycoerythrin (PE) using streptavidin by first complexing streptavidin-PE 
(SAPE) into a tetramer, which is used as an antibody equivalent to stain cells expressing 
CCR7. This method was shown to identify the same population of cells as staining by a 
CCR7-specific antibody conjugated to PE. To ensure this protocol was reliably reproduced 
in this study, BMDCs were generated and stained with the bCCL19-SAPE conjugate. This 
is summarised in Figure 3.1, below. As shown, staining clearly identifies CCR7 
expression on BMDCs as previously described. 
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Figure 3.1 - Fluorescent discrimination of CCR7+ BMDCs using CCL19-SAPE conjugate. 
BMDCs were generated using GM-CSF culture and stained using CCL19-SAPE. Cells were gated 
as shown in Figure 2.2 prior to analysis. Following staining there is a clear CCR7-expressing 
population of cells, as shown in Pre-sort and effective separation of these cells by sorting, as 
shown in Positive (representative). 
 
3.2.2 Optimisation of chemokine sorting 
After confirmation of the staining protocol, next the sorting of cells using bCCL19 was 
validated. To reliably improve the protocol for a potential cell therapy, it was important to 
optimise the protocol for DC sorting. Le Brocq et al. (2014) used magnetic bead sorting to 
isolate DCs and T cells by CCR7 expression, and this was reproducible with respect to 
DCs in our hands (data not shown). To further improve sorting efficiency three 
modifications to the bCCL19 structure were also tested, which are described in Figure 3.2. 
The rationale for this modification was to accommodate the morphological change DCs 
undergo during maturation – an increase in the folded structure of the cell membrane 
known as spiculation, which increases the cell surface area to facilitate cell-cell contact 
(Xing et al., 2011). Manual separation of cells using a magnetic bead system requires 
binding of the chemokine-SAPE-bead conjugate successively, so extending the biotin 
moiety and adjoined SAPE from the bCCL19/CCR7 interaction would allow more space 
for the α-PE microbeads to bind stably to the tetramer. Although staining with the 
conjugate alone was consistent, these modifications were expected to increase consistency 
and yield of DC sorts. 
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Figure 3.2 - Schematic representation of PEGylated bCCL19-SAPE conjugation and sorting. 
bCCL19 is PEGylated to increase the distance between the peptide and the attached biotin moiety 
and conjugated to SAPE for 30min before adding to the cells. After 30min the cells are washed and 
incubated with anti-PE microbeads for sorting. 
 
Dendritic cells expressing CCR7 were isolated from a mixed population of cells using the 
bCCL19-SAPE conjugate with magnetic bead separation. The protocol was first tested by 
comparing bCCL19, where the biotin moiety was conjugated directly to the chemokine, 
with three PEG-chain variants where the distance between the biotin moiety and the 
chemokine was increased using 3-, 11-, or 23-PEG residue-long chains. Firstly, the CCR7+ 
population in the unsorted fraction was compared to the positive and negative post sort 
fraction for each of the four chemokine variants. 
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Figure 3.3 - Comparison of the CCR7-expressing population in the unsorted, positive and 
negative sorted fractions using bCCL19 variants. 
BMDCs were sorted by magnetic column separation using each of the bCCL19 variants (bCCL19 
(A), and 3-, 11-, and 23-PEG bCCL19; denoted as B-D, respectively) conjugated to SAPE to 
isolate the CCR7-expressing population. Tetramer-labelled, unsorted cells were retained as a 
control for initial populations and were compared to the negative and positive post sort fractions 
using flow cytometry. CCR7+ populations were gated first by size, single cells, and viability by 
DRAQ7. Data points represent individuals ± SEM. Statistical analysis was by one-way ANOVA with 
Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 0.01, *** P ≤ 0.001 (n = 4/group). 
 
All bCCL19 variants used were able to isolate CCR7-expressing cells to comparable 
levels, but statistical analysis of the individual variants highlights important individual 
differences. The only statistical difference in bCCL19 was between the negative and 
positive post sort populations, compared to any of the PEG-modified variants which all 
have additional significant differences between unsorted and positive sort populations 
(Figure 3.3). This suggests that bCCL19 can be used to sort BMDCs, however the positive 
population is not significantly enriched by the process (~66% in the presort to 81% in the 
positive). In comparison, PEG-modified bCCL19 was able to enrich the positive 
population for CCR7 expression from the starting population. 23-PEG bCCL19 was shown 
to be the most effective ligand for cell sorting based on the enrichment for CCR7-
expression in the positive sorted fraction (~56% to 84%) and the coincident reduction of 
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the CCR7-expressing population in the negative sorted fraction compared to the unsorted 
fraction (~56% reduced to 33%). In all cases, the negative cell fraction still contained 
CCR7+ cells, although this was decreased from 46.35% (±15.77%) using bCCL19 to 
42.17% (±6.626%), 39.5% (±8.21%), and 33.13% (±5.72% using 3-PEG, 11-PEG and 23-
PEG CCL19, respectively, possibly highlighting the superior ability of the PEGylated 
variants to bind DCs preventing them from being lost in the negative fraction following 
sorting. 
 
 
Figure 3.4 - Direct comparison of unsorted and positive sorted fractions using bCCL19 
variants. 
BMDCs were sorted by magnetic column separation using each of the bCCL19 variants (bCCL19 
and 3-, 11-, and 23-PEG bCCL19) conjugated to SAPE to isolate the CCR7-expressing population. 
Negative and positive post sort fractions were compared using flow cytometry, with anti-CCR7 
antibody-stained cells used as a control. Data points represent individuals ± SEM. Statistical 
analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 
0.01, *** P ≤ 0.001 (n = 4/group). 
 
Direct comparison of staining for CCR7 (Figure 3.4) showed only a small but non-
significant difference between the PEG-modified CCL19 variants in both pre-sort staining 
and isolation of CCR7+ cells. To allow comparison, one starting population was sorted 
using each of the four variants and should therefore have the same CCR7 expression. It can 
be seen, however, that bCCL19 may be overestimating the size of the CCR7+ population. 
Comparison of bCCL19 with a CCR7-specific antibody (Figure 3.4 – Ab) shows that it 
stained a significantly higher proportion of the cells (66.2% ±6% compared to 50.3 
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±2.1%). Although there was no statistical difference between the PEG-modified 
chemokine variants, the enrichment of the positive fraction described previously (presented 
in Figure 3.3) was an important consideration. Taking these data into account, 23-PEG 
bCCL19 was chosen for sorting BMDCs. 
3.2.3 Improving cell viability and yield 
While the CCL19 sorts routinely showed high purity of cells expressing CCR7 once the 
process was optimised for BMDCs, post-sort cell viability was the next key consideration. 
Magnetic column-sorting the cells requires all reagents and equipment to be at 4ºC, as 
shown in Figure 3.2,  and the protocol carried out swiftly in a tissue culture hood at room 
temperature (~22ºC) or in a cold room (~4ºC) depending on the level of sterility required. 
This temperature is crucial to prevent ligand-induced internalisation of CCR7 (Otero, 
Groettrup and Legler, 2006) and maintain accessibility of bCCL19 for subsequent 
microbead binding and therefore sorting. It was expected that DC viability following the 
magnetic sort would be reduced, given both the prolonged low temperature and mechanical 
stress from the magnetic column: if cell viability is low after the sort, this limits their 
potential viability in vivo. Although initial validation of bCCL19 was done using this 
separation, incorporation of a fluorophore conjugation step in the process allowed 
adaptation of the protocol for FACS as described in 2.6.2.2. This sorting strategy also puts 
the cells under physical stress but was compared as a potential alternative. Routine cell 
viability was assessed after each sort described in 3.2.2, and is summarised below. 
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Figure 3.5 - BMDC viability remains high in FACS-sorted cells compared to column sorting. 
BMDCs were taken from culture for chemokine sorting using each of the bCCL19 variants, or on 
the BD Aria II and were assessed for cell viability by flow cytometry using DRAQ7 compared to 
initial viability of cells in culture. Data points represent individuals ± SEM error bars. Statistical 
analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison Test: n.s. is not 
significant, *P ≤ 0.05, ***P ≤ 0.001 (n≥4/group). 
 
There was a significant loss of cell viability from the initial isolation of the cells from 
culture (black dots) through the bCCL19-SAPE and bead staining steps to the pre-sorted 
cells (blue dots) and after sorting (red dots) (Figure 3.5). The cells started at above 96.2% 
(±0.62%) viability immediately after harvest and decreased to 70-80% viability by the start 
of the sort for each of the bCCL19 variants, but did not lose viability between the pre- and 
post-sort steps. Although the viability did decrease overall, there appeared to be no loss of 
cell viability as a result of the column sorting itself despite the cells being under 
mechanical pressure during the process. In comparison, there was no difference in viability 
between cells from culture and either the pre- or post-sort cells using the Aria II. The 
viability of the cells remained at 90.18% (±1.49%) viability prior to the sort and decrease 
to 85.23% (±1.5%) after the sort, but this change is non-significant. This suggests that 
separation of CCR7+ cells by FACS maintained the highest cell viability and may be the 
best sorting method for use of the cells post-sort. Cell yield was also seen to be a consistent 
issue with column-sorted cell populations, so was again compared to the yield of 
fluorescently-sorted cells.  
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Figure 3.6 - BMDC post-sort yield is higher by FACS than column sorting. 
Cultured BMDCs were magnetically sorted using each of the bCCL19 variants or using the BD Aria 
II and the CCR7+ cell yield was calculated as a proportion of the total CCR7+ cells in the initial 
population. Total cells recovered from the column is included as a positive control, but not included 
in the statistical analysis. Data points represent individuals ± SEM. Statistical analysis was by one-
way ANOVA with Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 0.01 (n = 3-5/group). 
 
As shown in Figure 3.6, cell yield from the magnetic column sort was consistently only 
~40% of the total starting CCR7+ cells regardless of the bCCL19 variant used. When 
comparing the four, however, the bCCL19 variant yield was very variable (34.91% 
±12.49%) whereas the PEGylated variants showed a much lower variability in yield, 
suggesting that PEGylation of the chemokine improved the reliability of the sorting 
strategy. The remaining CCR7+ cells were present in the negative eluted fraction (as 
shown in Figure 3.3) or lost within the column itself. The total cell yield from the column 
was included here as a control, showing that up to 20% of the initial cell input can be lost 
just through the sorting process. The yield of the cells from the Aria II sort was 
significantly higher than any of the column-sorted groups, with almost double the number 
of returned cells (~40% for the column-sorted cells, and 84.7% ± 3.32% for the Aria II). 
Taking the viability and yield together, sorting cells by FACS was chosen for future use. 
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3.3 Sorted DCs migrate more efficiently to CCL19 
gradients in vitro and in vivo 
3.3.1 In vitro migration by Transwell Migration Assay 
It is well-characterised in chemokine receptor biology that ligand binding to the receptor 
causes rapid internalisation and subsequent resistance to ligand signalling until the receptor 
is recycled back to the surface. If chemokine-sorted cells are to be considered a viable 
therapeutic product, then the migration capacity of the cells following sorting needs to be 
assessed. BMDC migration before and after sorting was tested using a transwell migration 
assay, which quantifies active cell migration in response to a cytokine gradient set up in 
vitro. 
 
 
Figure 3.7 - CCR7-sorted DCs are capable of migration immediately after sorting. 
CCR7-sorted cell migration was challenged using a transwell migration assay. A – 0hr post-sort. B 
– 4hr post-sort. Three concentrations of chemokine were used based on previous work by Le 
Brocq et al., (2014) (n = 2). 
 
It can be seen at both timepoints that BMDCs in the positive sorted fraction migrated more 
effectively than the others, as presented in Figure 3.7. Chemokine concentrations used 
here reflect a concentration too low to induce migration (10ng/ml), a biologically relevant 
chemokine concentration (100ng/ml), and a concentration too high to induce migration 
(500ng/ml) (based on the study by Haessler et al., 2011). Chemokinesis has been shown to 
sharply decline with chemokine concentration above a functional maximum, during which 
the chemokine receptor is internalised and leads to cellular desensitisation and decline of 
cell migration. Up until this maximum, however, as the surface expression decreases, cell 
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sensitivity increases as the threshold signalling for migration is lowered (Petit, Chayen and 
Pease, 2008). Immediately after sorting, cells in the positive fraction migrated more 
strongly towards a 100ng/ml biological chemokine gradient compared to the other 
populations, with 53.3% (±14.5%) migrating through the transwell insert compared to the 
unsorted cells (26.9% ±4.5%) and the unsorted cells (18.4% ±5.4%). At the other 
concentrations there was little difference in migration capacity, if any. After 4 hours of 
rest, a similar trend in migration capacity was seen, however CCR7+ cells are also shown 
to migrate more than the other fractions at 500ng/ml CCL19. This data may be indicative 
of the bell-shaped curve of the chemokinesis response (Petit, Chayen and Pease, 2008). 
Immediately following sorting, the peak of the migration response appears to be between 
100ng/ml and 500ng/ml, whereas after allowing the cells to rest and recycle the receptor, 
this peak appeared to have shifted to a higher concentration as the migration responses to 
100ng/ml and 500ng/ml equalised.  
Taken together, these data suggested that there may be some degree of receptor recycling 
occurring within the sorted BMDCs, however, this recycling did not appear to hinder the 
immediate migration of the cells in vitro. This is therapeutically relevant because it would 
allow the sorted cells to be used immediately, reducing the requirement for a rest, or 
“wash-out” period and therefore maintaining the quality of the final cell therapy product. 
3.3.2 In vivo migration by footpad migration  
To continue assessing the migratory capacity of CCR7-sorted DCs, the ability of the cells 
to migrate in vivo was quantified. BMDCs were sorted using 23-PEG bCCL19 and labelled 
with a fluorescent dye (either PKH-67 or CellTracker Violet, as described in 2.6.3); a 
control population of unsorted cells was also labelled with the alternative dye. CCR7+ 
sorted cells were injected into one footpad, and unsorted cells containing the same number 
of CCR7+ cells were injected into the opposite footpad of the same animal. 48hr later, the 
footpads and pLN were removed for processing and flow cytometry to detect injected cells. 
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Figure 3.8 - CCR7-sorted BMDCs migrate more efficiently to the pLN following footpad 
injection but unsorted cells are retained at the injection site. 
BMDCs were sorted for CCR7-expression or left unsorted as a control, differentially labelled using 
fluorescent tracking dyes. 48hr after injection into the footpad, the pLN was removed for analysis of 
cell migration. A – Representative flow cytometry plots showing labelled cells in the (i) footpad and 
(ii) popliteal lymph node, with unsorted cells gated in blue and CCR7-sorted cells gated in red. B – 
Quantification of the cells present in each tissue. Data points represent individuals ± SEM error 
bars. Statistical analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison Test: n.s. 
is not significant, *P ≤ 0.05, ***P ≤ 0.001 (n = 3/group). 
 
As shown in Figure 3.8, CCR7-sorted BMDCs effectively migrate from the site of the 
injection to the draining lymph node in 48hr compared to the unsorted comparison 
population. In the footpad, there is a significant difference in unsorted cells remaining in 
the tissue compared to sorted cells, which are almost 5 times fewer in number (Figure 
3.8B). In contrast, in the footpad-draining pLN, there is almost double the number of 
CCR7+ cells in the sorted fraction. This highlights the importance of separating the 
migratory CCR7+ cells from the bulk population, as well as the removal of CCR7- DCs 
since they may contribute to retaining cells at the injection site. 
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3.4 Chemokine-sorted DCs represent a phenotypically 
distinct population of cells 
3.4.1 Surface phenotype 
Generation of murine BMDCs in vitro has been shown to yield a heterogeneous population 
of cells, comprising of both conventional DCs but also macrophages (Merad et al., 2013). 
This heterogeneity is evident in cultures using GM-CSF alone, a combination of GM-CSF 
and IL-4, or with Flt3-L. Recent work has begun to highlight the overlap in markers used 
to distinguish these two cell types, particularly with respect to the expression of CD11c on 
macrophages. To assess this complexity, bone marrow cultures with GM-CSF were stained 
for CCR7, the conventional DC marker CD11c, and the conventional macrophage marker 
F4/80.  
 
Figure 3.9 - Chemokine sorting effectively isolates a single cell population. 
A heterogeneous GM-CSF-induced cell population has four populations identifiable by differential 
F4/80 and CD11c expression. bCCL19-stained cells (red) display an F4/80- CD11c+ phenotype; in 
comparison, cells not stained by bCCL19 (blue) display either an F4/80+ phenotype or express 
neither F4/80 or CD11c. 
 
Staining with only CD11c and F4/80 identifies four cell populations in the culture. Cells 
were also stained for CD11b, the α-chain of the myeloid integrin Mac-1, which is 
expressed by monocytes and macrophages (Larson & Springer, 1990). CD11c 
discriminates DCs, as well as the final positive population following bCCL19-sorting 
(highlighted in red, Figure 3.9). This was expected since CCR7 is only expressed on 
mature DCs among mononuclear cells. F4/80 is a conventional macrophage marker, and 
F4/80+ cells here represent two populations further separated by expression of CD11c. In 
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vitro generation of mononuclear cells using only GM-CSF commonly produces this mixed 
population, which considering our interest in DCs in the culture is important to know to 
avoid assuming all CD11c+ cells in the culture are DCs. These two F4/80+ populations are 
thought to represent an M1 (CD11c+) and M2 (CD11c-) phenotype (Helft et al., 2015). 
The fourth population identified expresses neither F4/80 nor CD11c, and most likely 
represent undifferentiated cells in the myeloid lineage given the expression of CD11b (not 
shown). It is crucial to note that in mouse BM cultures derived using GM-CSF that only 
sorting by CCR7 expression results in a pure population of cells, with both alternative 
options (positive selection of cells expressing CD11c, and depletion of cells expressing 
F4/80) still resulting in a subtly heterogenous population. Crucially, the sorted CCR7+ 
population accounts for only ~60% of the total cell population (shown previously); 
highlighting the need for cell sorting to remove any immature cells from the product prior 
to injection which may result in development of unwanted T cell tolerance instead of 
proliferation (Hilkens et al., 2010).  
Since CCR7 is upregulated on DCs only after maturation, its expression can be used to 
reliably identify mature DCs in a mixed CD11c-expressing population comprising both 
immature and mature DCs. As shown in Figure 3.9, only one CD11c+ population is 
present, after exclusion of F4/80 expression. Subsequent care was taken to exclude F4/80-
expressing cells in future analyses to remove any influence of contaminating macrophages 
in the results. Cells were subsequently stained for markers of both DC activation status as 
well as receptors required for T cell costimulation to better characterise the cell phenotype. 
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Figure 3.10 - CD11c+CCR7+ and CD11c+CCR7- BMDCs are distinct by surface phenotype. 
A – Representative flow cytometry plots showing expression of activated DC markers in the CCR7- 
cells (blue) and CCR7+ cells (red). B – Quantification of expression shows these markers are 
significantly enriched in CCR7+ populations in comparison to CCR7- populations. Statistical 
analysis was by Students t test. * P ≤ 0.05 (n = 4).   
 
As expected, sorted BMDCs more highly express markers required for effective T cell 
stimulation in vivo (Figure 3.10). CD40, CD80 and CD86 are required by BMDCs for 
strong and effective T cell activation; without this interaction BMDCs are likely to induce 
anergy in antigen-specific T cells instead of activation (Crespo et al., 2013). CD80 and 
CD86 bind CD28 on T cells and induce activation in conjunction with TCR binding, as 
described previously. It is very important, therefore, for DCs to express these molecules for 
immune function, and CCR7+ DCs have been confirmed here to highly express them 
compared to the CD11c+ CCR7- DC population. CD40 functions similarly, interacting 
with CD154 on T cells and NK cells for induction of cytotoxicity (Grewal and Flavell, 
1998). This interaction between DCs and NK cells has also been shown to support the 
generation of anti-tumour CTLs in vivo (Adam et al., 2005). In addition to costimulatory 
molecules, CCR7+ DCs have an increased expression of MHC class I and class II 
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molecules, confirming the phenotype of this cell population as mature and 
immunostimulatory (de Vries et al., 2002). These data confirm the mature, sorted CCR7+ 
DCs are functionally capable of providing T cells with signals 1 and 2 for their activation. 
3.4.2 Chemokine and cytokine profile 
To further characterise the sorted and unsorted cells, the chemokine and cytokine secretion 
profile of the BMDCs was assessed by 33-plex Luminex analysis. BMDCs were generated 
and F4/80-CD11c+ cells were sorted using the BD Aria II. These cells were further sorted 
into CCR7+ and CCR7- cell fractions and lysed to collect proteins. Protein concentrations 
were determined using BCA assay prior to Luminex analysis to ensure an equivalent 
starting concentration (data not shown).  
The expression of 33 analytes was assessed, although most of the chemokines and 
cytokines were below the level of detection suggesting that they are not produced by either 
immature or mature BMDCs. Of these 33, 9 are differentially produced by the two groups: 
CCL3, CCL4, CCL5, CCL17, CCL22, CXCL2, CXCL16, IL-1β, and IL-16. These data are 
summarised in Figure 3.11. All chemokines and cytokines assessed are listed in Table 2.2. 
 
Figure 3.11 - Distinct chemokine and cytokine production by CCR7- and CCR7+ DCs. 
CD11c+CCR7- and CD11c+CCR7+ DCs were sorted using the BD Aria III and lysed to extract the 
proteins for Luminex analysis. 33 chemokines and cytokines were analysed, with production of 
these 9 detectable, and different between the two groups. A – analytes more highly expressed by 
CCR7- DCs; B – analytes more highly expressed by CCR7+ DCs. Data points represent 
individuals ± SEM error bars. Statistical analysis was by Students t test. * P ≤ 0.05, ** P ≤ 0.01 (n = 
3; 2 replicates each). 
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It is immediately apparent that CCR7- and CCR7+ DCs are phenotypically different by 
expression profile. As shown, CCR7- BMDCs produce at least 50-fold more CCL3 (80.59 
±25.1ng/mg protein), CCL4 (4.41 ±1.0ng/mg protein) and CXCL2 (3.76 ±1.48ng/mg 
protein), than CCR7+ DCs, with the latter two chemokines being undetectable in this 
group. Although there appeared to be a small decrease in CCL5 between the groups, this 
did not reach significance. CCR7- DCs, interestingly, produced more than double the 
amount of IL-16 than CCR7+ DCs (40.93 ±3.03ng/mg protein to 15.76 ±2.41ng/mg 
protein). In comparison, CCR7+ DCs expressed adaptive immune chemokines such as 
CCL22 and CCL17 more highly (284.0 ±33.73ng/mg protein to 187.8 ±36.76ng/mg 
protein, and 87.7 ±10.35ng/mg protein to undetectable, respectively) as well as more 
CXCL16 which was undetectable in the CCR7- DCs. The difference in IL-1β was only 
seen in 2 of the 3 samples tested so did not reach significance. 
CCR7+ DCs therefore express an array of potent immune-stimulatory factors compared to 
CCR7- DCs also present in the cultured population. Flow cytometry data for surface 
marker expression, and analysis of chemokine and cytokine secretion by these cells 
supports the hypothesis that CCR7+ DCs alone are a potentially viable population for the 
generation of a CTL response; this was next confirmed using an in vitro co-culture system.  
3.5 Sorted DCs induce an increased antigen-specific T 
cell response 
Finally, the interaction of sorted and unsorted DCs with antigen-specific T cells was 
quantified and assessed using the OT-I mouse model. It has been shown that CCR7-
expressing DCs highly express markers of T cell stimulation such as CD40, CD80 and 
CD86; exhibiting a more mature phenotype than CCR7- DCs. Additionally, CCR7+ DCs 
produced chemokines such as CCL17, CCL22, and CXCL16, suggesting these cells can 
potently attract T cells for activation. To quantify the ability of these cells to stimulate T 
cells, DCs were generated, fed ovalbumin and sorted as previously, with the addition of 
CD11c to separate immature (CCR7-) and mature (CCR7+) DCs. These cells were then 
cultured along with T cells recognising the MHC class I-ovalbumin epitope which were 
isolated from the lymph nodes of OT-I mice to assess changes in the T cell phenotype. 
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3.5.1 Conventional DCs (cDCs) 
GM-CSF-derived BMDCs were sorted into two populations based on CD11c expression 
and differential expression of CCR7. The CCR7+ and CCR7- DCs were incubated with 
ova-specific T cells for 7 days, after which their surface phenotype was assessed by flow 
cytometry. 
 
Figure 3.12 - CCR7+ and CCR7- DCs generated using GM-CSF induce distinct patterns of T 
cell maturity after co-culture. 
GM-CSF- BMDCs were sorted for expression of CD11c and into CCR7+ (red box) and CCR7- 
(pink box) cell populations and cultured with OT-I T cells. After 7 days T cells were phenotyped for 
expression of CD44, CD62L and PD-1. Data points represent mean ± SEM error bars. Statistical 
analysis was by one-way ANOVA. * P ≤ 0.05 (n = 3). 
 
After 7 days in culture with DCs, the T cells looked quite different in terms of surface 
marker expression. Using CD44 and CD62L to define cell maturity, T cells cultured with 
CD11c+ CCR7+ DCs expressed a more mature phenotype (defined by the CD44+ CD62L- 
phenotype). In comparison T cells cultured with CD11c+ CCR7- DCs were CD44- 
CD62L-, a less mature phenotype, with only a small percentage fully mature. This suggests 
that the phenotype associated with CCR7 expression on DCs is important for activation of 
antigen-specific T cells. PD-1 expression of these T cells was also assessed. PD-1 is a 
marker of functional exhaustion in T cells (Barber et al., 2006), so it was interesting to see 
CCR7 
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an increase in PD-1 expression in the most mature group of T cells exposed to either IL-2 
alone (white bars), or CCR7- DCs (pink bars), but that this was not observed in T cells 
exposed to CCR7+ DCs.  
3.5.2 Plasmacytoid DCs (pDCs) 
As previously described, the expression of CCR7 is also crucial for the migration and 
therefore the function of pDCs in vivo. Flt3-L-derived DCs, which here are defined as 
pDCs but are generally accepted to represent a more in vivo DC-like phenotype than GM-
CSF-derived DCs (Merad et al., 2013), were generated and sorted for CD11c expression 
and split into CCR7+ and CCR7- cell fractions. These fractions were then co-cultured with 
ova-specific T cells for 7 days as previously (3.5.1). 
 
 
Figure 3.13 - CCR7+ and CCR7- DCs generated using Flt3-L induce distinct patterns of T cell 
maturity after co-culture. 
Flt3-L-BMDCs were sorted for expression of CD11c and into CCR7+ (dark blue box) and CCR7- 
(light blue box) cell populations and cultured with OT-I T cells. After 7 days T cells were 
phenotyped for expression of CD44, CD62L and PD-1. Data points represent mean ± SEM error 
bars. Statistical analysis was by one-way ANOVA. * P ≤ 0.05 (n = 3). 
 
CCR7 
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Again, expression of CCR7 in pDCs seemed to correlate with the induction of a mature, 
response in antigen-specific T cells. CCR7+ DCs cultured with T cells lead to a mature T 
cell phenotype by expression of CD44 and CD62L compared to CCR7- DCs. Both IL-2 
alone and CCR7- DCs led to a primarily early ‘activated’ phenotype (CD44-CD62L-) 
which may be in the transition to a mature phenotype but requiring longer than 7 days to 
do so. Similarly to GM-CSF DCs, IL-2 and CCR7- pDCs induced the expression of PD-1 
more highly in the most mature T cell phenotype (CD44+CD62L+) suggesting exhaustion 
of these cells and a reduction in function or even senescence compared to T cells 
stimulated by CCR7+ pDCs. 
In the absence of in-depth assessment of cytokine production by the generated T cells, it 
would be difficult to define the induced response as cytotoxic or otherwise, but these data 
confirmed that sorting DCs for CCR7 expression produces a population of cells which can 
potently stimulate T cells in vitro. 
3.6 Discussion 
The cell-sorting protocol published by Le Brocq et al. (2014) was first optimised for 
BMDCs using PEGylated variants of bCCL19. Although the original bCCL19 protocol 
was sufficient for staining of CCR7+ cells, it was shown to be variable compared to any of 
the PEGylated CCL19 variants. The variant with the longest space between the chemokine 
and the biotin moiety, the 23-PEG bCCL19, was seen to be consistent in both staining and 
magnetic column-sorting BMDCs by comparing the purity of the positive sort fraction and 
the positive cells remaining in the negative fraction. The yield of the positive cells in all 
cases was seen to be lower than ideal, so the incorporation of the PE fluorophore into the 
CCL19 conjugate was utilised to adapt the sort for FACS using the BD Aria II and Aria III 
(Aria III data not shown). This strategy was shown to reliably sort the BMDCs to a high 
purity of CCR7 expression with a consistently high yield. This sorting strategy did not 
affect cell viability as drastically as expected compared to magnetic column sorting, which 
was attributed to the physical stress experienced by BMDCs during the preparation for 
column sorting, which includes several centrifugation steps and incubations, as well as a 
consistent, controlled temperature of 4ºC for success. For FACS, this requirement is 
minimised by omitting the magnetic bead incubation step. As described in 2.6.2.2, the 
settings of the Aria II itself can be adjusted to reduce shear stress experienced by the cells 
by controlling the flow rate and other parameters. In terms of cell viability, sorting the cells 
by FACS appears to have a smaller effect on cell viability than magnetic column sorting so 
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may be beneficial for cell survival and function after isolation. FACS was chosen as the 
sorting strategy for future experiments taking these data into account. 
Compared to CCR7- DCs, CCR7+ DCs were shown to have a more mature surface 
phenotype, with a higher expression of MHC class I and class II molecules required for 
antigen presentation to cells of the adaptive immune system. Recognition of presented 
antigen by TCRs provides only 1 of 3 ideal signals to the T cell for generation of a 
cytotoxic response; the other signals come from interaction with co-stimulatory molecules 
such as CD80 and CD86 (signal 2), and concurrent paracrine signalling through cytokines 
such as IL-12 (signal 3). CCR7+ DCs described here express co-stimulatory molecules 
very highly in comparison to the CCR7- DCs, and also secrete cytokines more skewed 
towards activation of the adaptive immune response. CCR7+ DCs express chemokines 
commonly associated with naïve T cell and memory T cell chemoattraction such as CCL22 
and CCL17, providing a potential mechanism for these cells to induce a cytotoxic T cell 
response and remodel an existing memory response in vivo (Adema et al., 1997; Sallusto et 
al., 1999). CXCL16 binds CXCR6 expressed by naïve, effector and NK T cells as well as a 
subset of memory CD4 T cells (Matloubian et al., 2000). In vitro evidence has shown that 
IL-1β can induce production of IL-12 by DCs in conjunction with ligation of CD40 (Wesa 
and Galy, 2001), suggesting a potential autocrine effect of CCR7+ DCs inducing their own 
IL-12 secretion for generation of a potent CTL response. CCR7- DCs, in contrast, secrete 
mainly chemoattractants for innate immune cells, as well as DCs, and it would be 
interesting to investigate if these chemokines contributed to the retaining of injected DCs 
in the footpad. CCR7- cells secrete more CCL3, CCL4 and CCL5 than CCR7+ DCs, for 
example. CCL3 and CCL5 bind CCR1, and all three bind CCR5, which are expressed on 
macrophages and TH1 cells (Weber et al., 2001). CXCL2 is primarily a neutrophil 
chemoattractant through binding of CXCR2 (Lim et al., 2015), but has also been shown to 
attract monocytes in humans (Geissmann, Jung and Littman, 2003). CCR7- DCs also 
secrete IL-16, which is a soluble ligand for CD4 and a chemoattractant for CD4-expressing 
T cells such as T cells, eosinophils and monocytes, but also DCs themselves (Kaser et al., 
1999). These data together suggest that CCR7- DCs attract primarily innate immune cells, 
with some contribution to a non-cytotoxic T cell subset and importantly, secrete IL-16 to 
control the migration of other DCs. This would highlight another reason for removal of 
these cells from a therapeutic regimen, as it would likely contribute to the poor migration 
of capable cells following injection.  
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Isolation of DCs expressing the chemokine receptor CCR7 is clinically relevant for two 
reasons. Firstly, CCR7 expression is crucial for efficient LN homing through CCL19 and 
CCL21 signalling (Hilkens et al., 2010), so sorting CCR7+ cells using this method yields a 
therapeutically viable cell population. Secondly, as the upregulation of CCR7 occurs in 
mature DCs, the sorting process described also reduces the number of immature DCs from 
the final population. As described in previous literature and supported by data presented in 
this Chapter, in addition to generating both mature and immature DCs, GM-CSF alone also 
generates a complex mixture of macrophage phenotypes which express F4/80, CD11c and 
MHC class II in mice (Helft et al., 2015). When considering sorting BMDCs to attain a 
pure cell population, both F4/80 and CD11c could be used, but would result in a mixture of 
cell types as summarised in Table 3.1.  
 
 
Table 3.1 - Cell populations remaining in GM-CSF bone marrow cultures after sorting 
strategies. 
After sorting GM-CSF-derived bone marrow cultures using F4/80 depletion or selection for CD11c 
or CCR7 expression three distinct cell populations remain, showing that these sorting methods are 
not necessarily equivalent. Y = population remains in culture following sort; N = population does not 
remain following sort. 
 
Both F4/80 and CD11c isolation strategies are currently available as GMP protocols, so it 
is important to consider both as potential alternatives to CCR7-sorting. Using F4/80 
depletion to remove macrophages, the remaining F4/80- cells could still contain a mixture 
of immature/mature DCs and macrophages as well as uncommitted progenitors. Similarly, 
using selection of CD11c+ cells would remove a bulk CD11c- macrophage population and 
uncommitted progenitors, but could still retain CD11c+ macrophages and a mixture of 
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immature and mature DCs. Uncommitted monocytic progenitor cells within the culture are 
multipotent and could potentially differentiate into either macrophages or DCs after 
injection and should be removed. Macrophages should also be removed, as they can both 
uptake antigen and process it under these culture conditions. Experimental evidence has 
shown that although they are less potent than DCs at doing so, macrophages can present 
and activate T cells both in vitro and in vivo (Helft et al., 2015). Immature DCs lack a 
number of costimulatory surface molecules required for activation of T cells (Förster et al., 
2008), so can instead lead to T cell anergy or tolerance towards presented antigens when 
introduced in vivo (Hilkens et al., 2010). The presented data support this: stimulation of T 
cells with CCR7- DCs leads to a large percentage of the immature CD44-CD62L- T cell 
phenotype which is no different to IL-2 stimulation alone. In addition to this, the mature 
CD44+CD62L+ T cell population also highly upregulates the exhaustion marker PD-1 in 
response to CCR7- DC stimulation. If these CCR7- cells are present within the initial cell 
injection, it is possible that further response to inflammatory signals from other injected 
cells or indeed at the injection site could promote upregulation of CCR7 and allow these 
cells to reach the lymph node. It is unknown at this time, however, if this upregulation 
might accompany a maturation of surface phenotype as seen in vitro. Voigtländer et al. 
showed that ‘tolerogenic’ DCs, which were only partially stimulated upon injection, 
became immunogenic following injection showing that DCs can undergo a second-wave of 
maturation in response to further stimulation (Voigtländer et al., 2006). This is an 
important therapeutic consideration, suggesting that the immature DCs have the potential 
to mature in vivo in response to endogenous signals but if these are insufficient to trigger a 
full mature phenotype then the DCs may develop as tolerogenic. Removal of these 
contaminating cell types are crucial for the production of a reproducible cell therapy. 
Although this wasn’t addressed in the footpad migration experiments presented above, it 
would be interesting to assess the phenotype of the cells remaining in the footpad at 48hr to 
see any reduction in the number of cells expressing an immature CCR7- DC phenotype. 
3.7 Chapter summary 
In this Chapter, it was shown that it is possible to sort mature BMDCs, generated through 
either GM-CSF or Flt3-L with a novel chemokine-based sorting method based on 
expression of CCR7 as described by Le Brocq et al (2014). Using biotinylated CCL19, as 
well as three PEGylated versions of CCL19, the sorting methodology has been optimised 
for BMDCs and adapted for magnetic column sorting of the cells and fluorescence-based 
approaches such as the BD Aria II with high cell viability and improved cell yield. CCR7+ 
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BMDCs represent a phenotypically mature cell population within the mixed cultures both 
in terms of surface phenotype and cytokine production suggesting that these cells are better 
equipped to attract T cells in vivo and potently activate them. Improved T cell stimulation 
was confirmed through co-culture with sorted or unsorted BMDCs using a model antigen. 
Additionally, it was shown that although utilising the CCL19-CCR7 ligand-receptor 
interaction for cell sorting may induce receptor internalisation, sorted cells still migrate 
more effectively to CCL19 gradients both in vitro and in vivo compared to a mixed cell 
population. Taking these data together suggest that improved migration of BMDCs to the 
lymph node after injection may induce a better antigen-specific T cell response which 
could be used for therapeutic benefit. In the next Chapter, the potential of CCR7-sorted 
BMDCs in a therapeutic context was assessed using an in vivo cancer model which 
expresses model antigen that can be targeted. 
 
97 
 
4 Assessing CCL19-sorted dendritic cells in the 
subcutaneous B16F10.ova model 
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4.1 Introduction and aims 
In the previous Chapter, the phenotype and function of CCR7-sorted DCs was compared to 
an unsorted DC population. It was shown that despite both populations expressing the 
classical DC marker CD11c, the CCR7-sorted population expressed markers associated 
with T cell co-stimulation more highly. The cells also expressed higher levels of T cell-
specific chemokines, and this correlated with the stimulation of T cell memory formation 
maturation in vitro. Additionally, CCR7-sorted DCs (sDCs) were shown to have an 
advantage in CCL19-directed migration compared to unsorted DCs (uDCs), both in a 
transwell assay of chemotaxis in vitro and to the lymph node (LN) in vivo. Taking these 
data together, we have provided evidence that sorted DCs could be more functionally 
valuable in models of antigen-specific T cell induction. 
Transplantable murine tumour models have been used extensively in the cancer field to 
understand tumour development and test novel therapeutics. As discussed in Appendix I, 
the B16 model is widely used for this purpose and is a particularly useful model with 
which to assess the therapeutic viability of CCR7-sorted DCs. Melanoma was the first 
clinical target of DC vaccines in 1995, as well as in many of the early clinical trials 
(Mukherji et al., 1995). The high incidence of de novo protein formation in melanomas 
make them attractive therapeutic targets but not all can be used as tumour-associated 
antigens in the context of treatment due to similarities remaining to self-antigens and thus a 
potential endogenous tolerance (Overwijk and Restifo, 2001). In this respect, the B16F10 
melanoma is a relevant model to use in cancer research. B16 cells have a deficiency in 
MHC class I machinery resulting in non- or low immunogenicity. MHC class I 
downregulation is a common immune escape mechanism (Seliger et al., 2001) but this 
machinery can be upregulated by stimulation with IFNγ (as shown Figure A.7). 
Melanomas are one of the few tumours with consistent tumour-associated antigen 
expression between patients (Butterfield et al., 2003) but animal models often fail to 
recapitulate this. B16 cells express some common melanoma-specific antigens such as 
tyrosinase and the MAGE family of antigens (Böhm et al., 1998), but not BRAF kinase for 
example (Melnikova et al., 2004) for potential immune targeting. To model a TAA in an 
experimental setting, the chicken egg protein, ovalbumin (OVA), was introduced to the 
cells by plasmid transfection. This allows expression of OVA by every B16F10 cell 
injected and mimics de novo protein expression by melanomas. In 1999 it was shown that 
adoptively transferred OVA-specific T cells could provide immune control in this tumour 
context despite poor MHC class I expression through initial recognition and subsequent 
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IFNγ signalling (Dobrzanski, Reome and Dutton, 1999). In vivo B16F10.ova tumours are 
quick-growing and generate a natural cytotoxic response following injection which fails to 
control tumour growth without intervention (Böhm et al., 1998). In Chapter 3, DCs were 
given the whole ovalbumin protein in vitro to present fragments of the molecule to T cells 
using MHC class I and MHC class II, allowing stimulation and proliferation of T cells 
recognising these epitopes. It was also shown that CCR7+ DCs could stimulate the 
formation of a functional antigen-specific T cell response with the formation of memory T 
cells. Early DC clinical trials have shown the immunogenicity of injected DCs, with the 
detection of tumour specific T cells in the blood detectable as early as 7 days after DC 
injection (Mukherji et al., 1995).   
In this Chapter, the induction of an antigen-specific T cell response by CCR7+ and 
unsorted BMDCs was quantified in the context of the B16F10.ova melanoma. Three cell 
dosing strategies were assessed: one single DC injection at the same time as the tumour 
induction; two DC injections prior to the tumour induction, representing a true vaccination 
strategy; and two DC injections, the second of which was given after tumour initiation. In 
these models, tumour growth was monitored, and the antigen-specific T cell response was 
quantified by flow cytometry at the tumour end-point. 
 
4.2 A single prior sDC injection is sufficient to control 
B16F10.ova subcutaneous growth. 
To examine how the increased migration of CCR7-sorted dendritic cells to the lymph node 
could be affecting the induction of a T cell response, the B16F10.ova model was used. In 
this model, development of ovalbumin-specific T cells can be quantified by flow 
cytometry, but their function can also be assessed in terms of cell phenotype and tumour 
growth control.  
In this first experiment, animals were injected with either sDCs or uDCs presenting the 
ovalbumin peptide into the footpad to generate an anti-ovalbumin T cell response. The 
footpad is a commonly used injection site in mice which is a combination of intradermal 
and subcutaneous injection (Kamala, 2008) and mimics the use of these routes in human 
therapy. PBS/0.1% BSA injections were used as controls. The following day, animals were 
injected with the B16F10.ova cells into the flank to induce subcutaneous melanoma. The 
timings of these injections were chosen to allow development of the immune response 
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concurrently with early tumour growth, as clinical trial data suggest that DC vaccination is 
less effective against fully-developed tumours (Constantino et al., 2016). 
Immunotherapeutic strategies are rarely used in late-stage tumours without combination 
surgery or chemotherapy, but this experimental modality was chosen to first assess the 
basic results of DC vaccination. The first DC injection strategy was as detailed in Figure 
4.1.  
 
 
Figure 4.1 - Experimental timeline of single prior DC injection in the B16F10.ova tumour 
model. 
Mice were first injected with either PBS/0.1% BSA, unsorted DCs (uDCs) or sorted DCs (sDCs) 
into the left hind footpad under isofluorane anaesthetic. The following day (d0), all mice were 
injected with B16F10.ova cells subcutaneously into the flank and allowed to grow to maximum 
tumour diameter. 
 
4.2.1 Tumour growth and survival 
B16F10.ova cells were injected subcutaneously into the flank and the mice were monitored 
daily and tumour growth was quantified using digital skin-fold callipers. The end-point of 
this experiment was the PBS control group reaching the maximum tumour diameter of 
12mm; on this day (d17), all mice in the experiment were culled and the relevant tissues 
processed as described previously. 
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Figure 4.2 - B16F10.ova tumour growth following a single DC injection. 
Mice receiving B16F10.ova tumours by subcutaneous injection into the flank were also injected 
with either PBS/0.1% BSA (black bars), unsorted DCs (uDCs – blue bars) or sorted DCs (sDCs – 
red bars), and the tumour growth monitored daily until the maximum tumour diameter had been 
reached. Statistical analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison Test: 
*P ≤ 0.05 for both PBS vs. sDCs and uDCs vs. sDCs (summary of 2 experiments with n = 5-
6/group). 
 
When mice were injected with uDCs there was no difference in tumour growth compared 
to the mice receiving only PBS/0.1% BSA into the footpad. In comparison, when mice 
were injected with sDCs there were significant differences in the tumour growth at 10, 12, 
14, 15 and 17 days post-injection compared to both uDC and PBS/BSA-receiving mice 
(Figure 4.2). Importantly, the tumour growth in the PBS control group is consistent with 
the rate of growth shown by other groups, making these data comparable to previous 
studies (Overwijk and Restifo, 2001). 
4.2.2 Antigen-specific T cell distribution 
To assess the effect of injected DCs on the generation of an antigen-specific immune 
response, T cells were isolated from the injection site-draining and tumour-draining lymph 
nodes, the pLN and iLN respectively, and the spleens from tumour-bearing mice. Antigen 
specificity was assessed using a fluorophore-conjugated tetramer of the MHC class I-
restricted OVA peptide SIINFEKL bound to MHC class I molecules (Caltag Medsystems). 
This tetramer binds TCRs specific for this epitope and allows identification of these cells 
by flow cytometry. 
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Figure 4.3 - sDC vaccination increases the magnitude of the antigen-specific T cell response 
in the lymphatic system. 
Mice receiving the B16F10.ova tumours by subcutaneous injection were assessed for the antigen-
specific T cell response to DC vaccination in the (A) popliteal LN (pLN); (B) inguinal LN (iLN); and 
(C) spleen by flow cytometry. Cell number was quantified by either percentage of live cells (i) or 
total cell number (ii) for each tissue. Data represent individuals ± SEM error bars. Statistical 
analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001 (n = 5-6/group). 
 
Induction of an antigen-specific T cell response in the injection site-draining lymph nodes 
was first assessed using the pLN, which drains the footpad (Figure 4.3A). Mice receiving 
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a single injection of sDCs had a 3-fold increase in T cell number compared to either PBS 
or uDC-receiving mice (6852 ±1051 to 2083 ±381.7 or 1997 ±324.2, respectively; Figure 
4.3Aii). These mice also had enlarged LNs compared to the control mice (data not shown). 
Although there was no difference in the response as a percentage of the cells in the LN, 
cell number clearly showed an increase in total cell number – which could be from an 
increased initial infiltration of DCs into the LN, or an increased capacity for T cell 
stimulation of these DCs as shown previously (Figure 3.13) or a combination of the two. 
In the iLN, the opposite was seen: mice receiving no DCs at all had the highest number of 
antigen-specific T cells (13907 ±2908) compared to the other two groups (6330 ±1671 or 
4954 ±1397 for uDC and sDC, respectively; Figure 4.3Bii). This 3-fold increase in cell 
number in one of the tumour-draining LNs suggests that this is an important site for the T 
cell response in untreated animals (Marzo et al., 1999), but is not directly accessed by DCs 
following footpad injection. In comparison, there was only a modest response in this LN 
by mice receiving either DC vaccination. In the spleen, the site of central T cell memory 
and a secondary site of cell proliferation, there was an increased response to the sDC 
vaccine in both percentage of the total cells (0.178% ±0.033%; Figure 4.3Ci) and the 
actual cell number (4052 ±742.5; Figure 4.3Cii). This could be migration of the DCs 
themselves into the spleen after injection, or as a secondary effect of the increased T cell 
production. There was no difference between the T cells in the spleen of mice receiving 
either PBS or uDCs. 
4.2.3 Antigen-specific T cell phenotype 
To understand the phenotype of the T cells present in the lymphatics, antigen-specific T 
cells from the pLN, iLN and spleen were further characterised by the expression of CD44 
and CD62L to determine the maturity and function of these cells. 
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Figure 4.4 - DC vaccination increases tumour antigen-specific T cell proliferation and 
maturity in the lymphatic system. 
Mice receiving B16F10.ova tumours by subcutaneous injection were assessed for the antigen-
specific T cell response to DC vaccination in the (A) popliteal LN (pLN); (B) inguinal LN (iLN); and 
(C) spleen by flow cytometry. Expression of CD44 and CD62L was used to phenotype the T cells, 
which were quantified by either percentage of live cells (i) or total cell number (ii) in each tissue. 
Data represent mean ± SEM error bars. Statistical analysis was by one-way ANOVA with 
Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (n = 5-6/group). 
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In the pLN (Figure 4.4A), there was a significant decrease in the naïve T cell 
(CD62L+CD44-) compartment as a percentage of the antigen-specific T cells after 
vaccination with either uDCs (44.9% ±2.37%) or sDCs (39.52% ±1.03%) compared to the 
PBS-receiving mice (53.27% ±3.99%). The primary phenotype in the DC-receiving mice 
was the mature, TCM phenotype characterised by expression of both CD62L and CD44, 
which was significantly increased compared to the PBS-receiving mice (49.30% ±1.83% 
and 52.86% ±1.95% compared to 28.82% ±6.10%). This may be indicative of DC-T cell 
interactions in the LN. Cell number also showed the magnitude of difference between 
sDCs and uDCs, with both the naïve and TCM cell numbers being between 3- and 4-fold 
higher than either control group (Figure 4.4Aii). In the iLN, there was a significant 
difference in the production of naïve T cells by the DC-receiving mice, but this was not 
supported by the actual cell number (Figure 4.4B). The PBS control group had a 
significantly increased TCM phenotype by both proportion and total cell number, suggesting 
that although antigen-specific T cells are generated in response to the tumour challenge, 
they may not contribute to tumour rejection. Finally, in the spleen there was an increase in 
the number of naïve cells produced by the spleen of DC-vaccinated mice by proportion 
(Figure 4.4Ci), but sDC-receiving mice had a significantly higher cell number compared 
to the other two groups. Interestingly, there was also a significant increase in the number of 
TCM cells compared to the other groups.  
 
4.3 Multiple prior injections of sDCs led to tumour 
control and increased survival duration. 
In this experiment, animals were injected with either sDCs or uDCs presenting the 
ovalbumin peptide, or PBS/0.1% BSA into the footpad as previously. After a week, 
injections were repeated to boost the primary immune response from the first injections. 
The following day, animals were injected with the B16F10.ova cells into the flank to 
induce the model of subcutaneous melanoma as previously. This injection strategy is 
summarised in Figure 4.5 below. 
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Figure 4.5 - Experimental timeline of multiple prior DC injections in the B16F10.ova tumour 
model. 
Mice were first injected with either PBS/0.1% BSA, unsorted DCs (uDCs) or sorted DCs (sDCs) 
into the left hind footpad under isofluorane anaesthetic. A week later (d-1), mice were injected 
again and then the following day (d0) all mice were injected with B16F10.ova cells subcutaneously 
into the flank, and tumours allowed to grow to maximum tumour diameter. 
 
4.3.1 Tumour growth and survival 
Mice were monitored daily and tumour growth was measured at their largest diameter 
using digital skin-fold callipers after injection of the B16F10.ova tumour cells. In this 
experiment, tumours reaching the maximum diameter of 12mm was the end-point, and 
animals were culled as they reached this point and relevant tissues taken for analysis. This 
is in contrast to 4.2.1, in which all experimental animals were culled at the same time.   
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Figure 4.6 - B16F10.ova tumour growth and survival after 2 prophylactic DC injections. 
Mice were injected with either PBS/0.1% BSA (black bars), unsorted DCs (uDCs – blue bars) or 
sorted DCs (sDCs – red bars), and week later these injections were repeated. The following day 
mice received B16F10.ova tumours by subcutaneous injection into the flank and the tumour growth 
monitored daily until the maximum tumour diameter had been reached. Decreased tumour growth 
(A) and increased individual survival (B) was seen in the sDC-receiving mice but not the control 
groups, uDC and PBS. Statistical analysis was by one-way ANOVA with Bonferroni’s Multiple 
Comparison Test: *P ≤ 0.05 for both PBS vs. sDCs and uDCs vs. sDCs (n = 5-6/group). 
 
Tumour survival was slightly longer in this experiment compared to in 4.2. This may have 
been as a result of culling individual animals at their maximum tumour burden instead of 
as a group as was done previously. This also reflects the slight variability in tumour 
development between individual animals. From day 18, there was a significant difference 
between the tumour growth in sDC-receiving mice and the control groups, with a 
difference of as much as 4mm in diameter (Figure 4.6A). Following this, the sDC-
receiving mice had significantly smaller tumour sizes compared to the controls and this 
had a significant effect on survival. Mice injected twice with sDCs prior to tumour 
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development survived for 27 days compared to uDC-receiving mice which survived for 22 
days or PBS/0.1% BSA-receiving mice which survived for 25 days (median survival; 
shown in Figure 4.6B), and had a 17-30% increase in mean survival duration compared to 
the control groups. There was also a small significant difference in the mean survival of the 
uDC and PBS groups, despite there being no difference in mean tumour growth.  
4.3.2 Antigen-specific T cell distribution 
The injection-site draining pLN, tumour-draining iLN, and spleen was removed from 
tumour-bearing mice and assessed for induction of tumour antigen-specific T cells by flow 
cytometry. 
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Figure 4.7 - Prior sDC vaccination increases the magnitude of the antigen-specific T cell 
response in the lymphatic system. 
Mice receiving the B16F10.ova tumours by subcutaneous injection were assessed for the antigen-
specific T cell response to DC vaccination in the (A) popliteal LN (pLN); (B) inguinal LN (iLN); and 
(C) spleen by flow cytometry. Cell number was quantified by either percentage of live cells (i) or 
total cell number (ii) for each tissue. Data represent individuals ± SEM error bars. Statistical 
analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison Test: *P ≤ 0.05 (n = 
6/group). 
 
As seen previously, sDC-receiving mice had a greater magnitude of T cell response in the 
injection-site draining pLN compared to either control group (Figure 4.7A). Although 
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there was no difference in cell number by percentage of live cells, there was a 2- to 3-fold 
increase in antigen-specific cells by total number (4887 ±309 compared to 2764 ±403 and 
2506 ±603 for PBS and uDC, respectively; Figure 4.7Aii). This agreed with data shown in 
Figure 4.3, and supports the hypothesis that increased migration of DCs to the draining LN 
can improve T cell stimulation. A similar pattern was seen in the tumour-draining iLN 
(Figure 4.7B), where sDC-receiving mice had a higher total number of antigen-specific T 
cells (10087 ±742.6) compared to the uDC (5182 ±1492) and PBS-receiving groups (5125 
±1014). This data could be indicative of T cell memory development as a result of the 
second DC injection. In the spleen, in comparison, there was no difference between any of 
the treatment groups (Figure 4.7C). The PBS control group had a similar response as in 
the single injection experiment, however the sDC-receiving group had fewer cells than 
previously (1820 ±392 to 4052 ±742). Although there appears to be a difference in cell 
number after uDC injections, this difference did not reach significance.  
4.3.3 Antigen-specific T cell phenotype 
To assess the function and maturity of the T cells produced in the lymphatic system in 
response to DC injection, T cells from the pLN, iLN and spleen were stained using CD44 
and CD62L for flow cytometry analysis.  
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Figure 4.8 - Prior DC vaccination increases tumour antigen-specific T cell proliferation and 
maturity in the lymphatic system. 
Mice receiving B16F10.ova tumours by subcutaneous injection were assessed for the antigen-
specific T cell response to DC vaccination in the (A) popliteal LN (pLN); (B) inguinal LN (iLN); and 
(C) spleen by flow cytometry. Expression of CD44 and CD62L was used to phenotype the T cells, 
which were quantified by either percentage of live cells (i) or total cell number (ii) in each tissue. 
Data represent mean ± SEM error bars. Statistical analysis was by one-way ANOVA with 
Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (n = 6/group). 
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In both the pLN and iLN there are more antigen-specific T cells after sDC injections, and 
the phenotype of these cells was primarily a TEFF CD62L-CD44+ phenotype (Figure 4.8A 
and B). The response was between 1.5- and 2-fold higher compared to the uDC- and PBS-
receiving groups, although in these groups the primary response was also skewed towards 
the TEFF phenotype which had previously not been seen. In the spleen, there was a 
significant decrease in the presence of activated antigen-specific T cells in the sDC group 
by percentage, but this did not reach significance by total number (Figure 4.8C). 
Similarly, although the proportion of TEFF cells in the spleen is highest in the sDC-
receiving mice, the uDC mice have more by total cell number (Figure 4.8Cii). This may 
suggest that more antigen presentation is occurring in the spleen in the uDC-receiving mice 
as a result of poor DC trafficking to the initial LNs. There is some evidence suggesting that 
immature DCs migrate preferentially to the spleen (Emmanouilidis et al., 2006) and could 
be contributing to this phenotype.  
 
4.4 A second sDC injection after tumour initiation does 
not control growth 
To better model the treatment of solid tumour growth with DC therapies as the strictest test 
of DC potential, tumours were allowed to develop first before the second DC injection. In 
this experiment, animals were injected with either sDCs or uDCs, or PBS/0.1% BSA into 
the footpad as previously. The following day, animals were injected with the B16F10.ova 
cells into the flank to induce the model of subcutaneous melanoma. A week into tumour 
development, as tumours were becoming palpable as observed previously, animals were 
injected with the same treatment a second time. This injection strategy is summarised in 
Figure 4.9 below. 
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Figure 4.9 - Experimental timeline of multiple DC injections in the B16F10.ova tumour 
model. 
Mice were first injected with either PBS/0.1% BSA, unsorted DCs (uDCs) or sorted DCs (sDCs) 
into the left hind footpad under isofluorane anaesthetic. The following day (d0), all mice were 
injected with B16F10.ova cells subcutaneously into the flank, and one week later (d7) were injected 
with PBS/0.1% BSA, uDCs or sDCs into the footpad again, and allowed to grow to maximum 
tumour diameter. 
 
4.4.1 Tumour growth and survival 
Tumour growth was measured using digital skin-fold callipers after B16F10.ova tumour 
injection. In this experimental setup, maximum tumour diameter was 12mm as previously, 
and individual mice were culled as they reached this end-point. The draining LNs and 
spleens were removed for flow cytometry analysis. 
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Figure 4.10 - B16F10.ova tumour growth and survival after multiple DC injections. 
Mice were injected with either PBS/0.1% BSA (black bars), unsorted DCs (uDCs – blue bars) or 
sorted DCs (sDCs – red bars), and the following day the mice received B16F10.ova tumours by 
subcutaneous injection into the flank. A week later the DC or control injections were repeated. 
Tumour growth was monitored daily until the maximum tumour diameter had been reached. No 
difference in tumour growth (A) and or individual survival (B) was seen in the sDC-receiving mice 
or the control groups, uDC and PBS (n = 5-6/group). 
 
Unlike previous experiments, injection of sDCs after establishment of the tumour growth 
does not lead to differences in tumour growth or to overall survival of the animals (Figure 
4.10). From the development of a palpable tumour mass around day 7 until the end of the 
study, the three experimental groups showed no difference in the rate of tumour growth 
(Figure 4.10A). In this experiment, uDC-receiving mice had the longest duration of 
survival post-injection of the B16F10.ova tumour (27.6 ±2 days) compared to either sDC-
receiving mice (25 ±0.9 days) or the PBS control mice (23.8 ±1.5 days) but this difference 
does not reach significance (Figure 4.10B). The median survival duration of the sDC 
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group (26 days) was also no different compared to the controls (PBS – 23 days; uDCs – 27 
days). 
4.4.2 Antigen-specific T cell distribution 
To assess the effect of injected DCs on the generation of an antigen-specific immune 
response, T cells were isolated from the injection site-draining and tumour-draining lymph 
nodes, the pLN and iLN respectively, and the spleens from tumour-bearing mice. 
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Figure 4.11 - sDC vaccination after tumour development increases the magnitude of the 
antigen-specific T cell response in the lymphatic system. 
Mice receiving the B16F10.ova tumours by subcutaneous injection were assessed for the antigen-
specific T cell response to DC vaccination in the (A) popliteal LN (pLN); (B) inguinal LN (iLN); and 
(C) spleen by flow cytometry. Cell number was quantified by either percentage of live cells (i) or 
total cell number (ii) for each tissue. Data represent individuals ± SEM error bars. Statistical 
analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 
0.01, ***P ≤ 0.001 (n = 6/group). 
 
In agreement with previous experiments, injection of sDCs effectively induced an antigen-
specific T cell response in the injection site-draining LN which was significantly higher 
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than either uDC-receiving mice or the PBS control (8541 ±2013 to 1675 ±464 and 2823 
±996 for PBS and uDC, respectively; Figure 4.11Aii). Up to a 3-fold difference in total 
cell number was seen in the sDC-receiving mice, consistent with previous data. In the iLN, 
however, the PBS-receiving mice had a significantly higher number of antigen-specific 
cells (13907 ±2908) than either of the DC-receiving groups (830 ±185 or 6150 ±770 for 
uDC and sDC, respectively; Figure 4.11B). This was much higher than previously seen in 
the PBS control groups and may be due differences in tumour cell preparation or cell 
viability before injection. Interestingly, the DC-receiving animals had fewer antigen-
specific T cells than seen before (Figure 4.3Bii; Figure 4.7Bii). The spleen, again, had a 
higher number of antigen-specific T cells following sDC injection (8075 ±1444; Figure 
4.11Cii). There was at least a 2-fold difference between the sDC-receiving and PBS 
control groups (3660 ±902), and up to a 3-fold difference between the sDC and uDC 
groups (1356 ±429).  
4.4.3 Antigen-specific T cell phenotype 
Antigen-specific T cells in the pLN, iLN and spleen were further phenotyped by flow 
cytometry using CD44 and CD62L as markers of cell maturity and in vivo function. 
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Figure 4.12 - sDC vaccination after tumour development increases tumour antigen-specific 
T cell proliferation and maturity in the lymphatic system. 
Mice receiving B16F10.ova tumours by subcutaneous injection were assessed for the antigen-
specific T cell response to DC vaccination in the (A) popliteal LN (pLN); (B) inguinal LN (iLN); and 
(C) spleen by flow cytometry. Expression of CD44 and CD62L was used to phenotype the T cells, 
which were quantified by either percentage of live cells (i) or total cell number (ii) in each tissue. 
Data represent mean ± SEM error bars. Statistical analysis was by one-way ANOVA with 
Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (n = 6/group). 
 
Antigen-specific T cells in the pLN in DC-receiving animals were mostly mature memory 
T cells, compared to the PBS controls which were primarily naïve by phenotype. In terms 
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of total cell number, the mice receiving 2 injections of sDCs had a significantly higher TCM 
number than the uDCs despite having no difference by proportion (Figure 4.12Ai). In the 
iLN the PBS control group has a very high antigen-specific T cell number compared to the 
DC-treated groups, which was unexpected but shows a similar trend to the single DC 
injection experiment (Figure 4.4Bii). The sDC-receiving mice showed a significant 
increase in TCM cells in comparison to the uDC group. In the spleen, sDC-receiving mice 
had significantly higher antigen-specific T cells of naïve, activated and TCM phenotypes 
compared to the uDC and PBS controls. This suggests that although tumour growth was 
not controlled in this experiment, there is a quantifiable immune response in response to 
the sDC injections. 
 
4.5 Discussion 
This Chapter presents data supporting the efficacy of CCR7-sorted DCs in the induction of 
a T cell response and in control of tumour growth in vivo. This confirms two important 
hypotheses described in the Introduction. Firstly, ensuring migration of injected antigen-
presenting DCs to the lymph nodes can improve an antigen-specific T cell response in 
vivo. This is consistent in all three of the DC injection strategies presented here, shown by 
a significant increase in T cell number in the injection site-draining lymph node. The 
phenotype of these cells is injection strategy-dependent, with a single injection of sorted 
DCs or with a second DC injection after tumour induction resulting in a production of both 
naïve, antigen-inexperienced T cells and mature memory T cells. Injection of multiple 
doses of DCs prior to antigen from the tumour as a traditional vaccination strategy, 
however, resulted in development of a more effector memory phenotype (Figure 4.8A). 
The same T cell response was not seen in the unsorted DC group despite the animals being 
given the same number of CCR7+ cells in the injection bolus. It is important to highlight 
the difference between T cell responses of the uDC and sDC groups is typically 2- to 3-
fold in magnitude in the pLN, even though the two groups were given the same total 
number of CCR7+ cells. Taking these data together with the cell phenotyping from 
Chapter 3, there is evidence that the CCR7- cells within the population are negatively 
affecting the ability of the CCR7+ DCs to induce a T cell response, whether this is by 
limiting cell migration to the lymph nodes or suppressing the T cell response itself. The 
second hypothesis was that this improved T cell response could be beneficial in the context 
of DC therapies. Treatment of late-stage solid tumours is clinically difficult as the tumour 
invades the stroma and subverts the systemic immune response, and rare in clinical trials 
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since most patients will have undergone a number of surgeries and treatments before being 
considered for DC therapy (Constantino et al., 2016). The data presented here highlights 
the potential benefits of CCR7-sorted DCs in a model system which is more extreme than 
would be seen in clinical use of these cells. In two of three injection strategies, CCR7+ 
DCs could control tumour growth and improve survival duration with no other 
interventions compared to the unsorted DC population. 
A single injection of sDCs at an early point in tumour development was shown to be 
effective in controlling tumour growth and extending survival duration of treated animals. 
Tumour growth was not controlled by an endogenous immune response in mice receiving 
only PBS/BSA, or by injection of an unsorted DC population containing an equivalent 
number of CCR7-expressing DCs. In the pLN, up to a 5-fold increase was seen in the 
number of T cells which recognise the antigen presented by the DCs in mice treated with 
sDCs compared to uDCs. The phenotype of pLN antigen-specific T cells was similar 
between these treatment groups, however, suggesting that there had been some infiltration 
of injected DCs. Since the uDC group does not control tumour growth as effectively, it is 
possible that although some DCs may reach the LN, the number of cells is too small to 
reach the T cell threshold required for control or rejection (Lim et al., 2007). Without an 
earlier timepoint this cannot be determined. The same was seen in the spleen, where the 
phenotype of T cells induced by DC vaccination was mostly naïve compared to PBS 
controls but no different between the DC-receiving groups. Actual cell number higher was 
3-fold higher in the mice receiving sDCs compared to the uDC group, suggesting that 
although the induced phenotype is similar between the two groups there is an increased 
magnitude of the response in the sDC-receiving group. Antigen-specific T cell presence in 
the spleen was unsurprising after sDC injection, but whether this was due to migration of 
the DCs themselves to the spleen for antigen presentation, or as a secondary effect of T cell 
production within the lymphatics is unknown.  
The dose of DCs given in these experiments is higher than in previous literature, and LNs 
have a limited capacity for cell infiltration (Mullins et al., 2003); it is possible, therefore, 
that increased migration of DCs into the draining lymph node causes spillover into the 
vasculature as LN capacity is reached. In the iLN, in contrast, tumour-bearing mice 
receiving only PBS had the highest induction of antigen-specific T cells of the three 
experimental groups. In the absence of a therapeutic intervention, the primary immune 
response occurs in the tumour-draining lymph nodes as tumour antigens are presented by 
endogenous APCs (Marzo et al., 1999). It is possible, however, that the presence of cells in 
Assessing CCL19-sorted dendritic cells in the subcutaneous B16F10.ova model 121 
 
the iLN does not necessarily correlate with cytotoxicity due to tumour-derived immune 
suppression mechanisms (Fransen, Arens and Melief, 2013). Generation of a natural 
immune response in the iLN appears to have no effect on the growth of the tumour, which 
suggests a suppressive mechanism may be involved. In DC-receiving mice the immune 
response is higher in the spleen and injection site-draining lymph nodes and is sufficient to 
slow tumour growth without involvement of the tumour-draining lymph nodes. Single 
therapeutic DC injections are rarely given, however, to better assess CCR7+ DCs in a 
therapeutically relevant model, multiple DC injections were given to B16 tumour animals. 
When multiple DC injections are given prior to the induction of tumour growth, CCR7+ 
DCs are again able to slow tumour growth compared to the control groups. This was 
thought to be due the formation of an antigen-specific memory, due to the high number of 
TEFF cells present in both the pLN and iLN of sDC-receiving mice. The generation of TCM 
cells seen after a single injection of DCs (Figure 4.4A) could be supporting the rapid 
expansion of antigen-specific effector cells in the lymph nodes after a second injection of 
the same DCs (Fearon, Manders and Wagner, 2001). Multiple uDC injections promoted a 
different pattern of T cell expansion, with the primary TEFF response occurring in the 
spleen. This was interesting as it reproduces the development of a T cell response seen in 
IV but not subcutaneous injection of DCs. Route of immunisation has a well-characterised 
effect on the biodistribution of DCs (Eggert et al., 1999): after IV injection, DCs 
accumulate within the spleen by being unable to access the lymphatics from the 
bloodstream. In comparison, DCs injected subcutaneously preferentially migrate to the 
LNs, if they express CCR7 (Mullins et al., 2003). This data may be indicative, therefore, of 
an increased migration of uDCs into the spleen and cause an increased effector response 
within that tissue.  
It is possible that this injection strategy could result in complete tumour prevention using a 
smaller tumour cell number. Previous studies use varying numbers of tumour cells, 
between 2x105 and 1x106 cells (Kline et al., 2012; Neubert et al., 2014), but this may be 
too high to allow effective rejection in this model. Multiple DC injections prior to tumour 
growth may not seem therapeutically viable, however this traditional vaccination strategy 
could be viable in preventing small metastases after tumour resection or reducing 
recurrence after complete cure. The latter strategy has been attempted clinically in AML, a 
cancer in which relapse is common after complete remission and often fatal (Ravandi, 
2013). Instead of treating a solid tumour, intradermally-injected DCs were used to control 
the recurrence of AML in patients following complete remission through chemotherapy 
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(Anguille et al., 2017). Induction of AML-specific T cell responses in patients correlated 
with increased survival, and the study achieved a 43% clinical response rate. Similarly, 
recurrence of cancer in patients with resected metastatic colorectal cancer can be delayed 
using DC vaccination (Morse et al., 2013). This could be replicated using the B16F10.ova 
model if tumour resection was a possibility, or by a reduction in initial tumour number to 
prolong the duration of the tumour growth. Generation of a T cell response against a 
tumour antigen can therefore be a viable treatment strategy for prevention of relapse; this 
could be improved in a clinical context using CCR7 sorting as described here.   
When the second DC injection is given after induction of the tumour growth, the T cell 
response does not control tumour growth as seen previously with the other injection 
strategies. In sDC-receiving mice, there was a significant increase in T cells in the pLN 
compared to the PBS and uDC controls. Most of these cells were of the TCM phenotype, 
which were 3 times higher in sDC-receiving mice than either control. In the iLN, PBS 
control animals had the highest antigen-specific response by total number. Again, this is 
likely to be the natural immune response in the tumour-draining lymph node. There is a 
difference in magnitude of response compared to previous experiments, but this may be as 
a result of increased immunogenicity of the tumour cells through passage or a lower cell 
viability between experiments which could stimulate the immune response. In the spleen 
there was a significant difference in naïve, activated and TCM cell numbers after sDC 
injection compared to the controls which mirrors the single DC injection. Although there is 
a clear increase in T cell number in both the pLN and spleen of sDC-treated mice, there 
was no control of the tumour growth in this experiment.  
It may be that directing the immune response to a LN distal to the tumour has a detrimental 
effect to protection giving the aggressive growth of this particular tumour model, a concept 
first described by Brown et al. (Brown et al., 2001). The reduction in T cells in the tumour-
draining lymph node (Figure 4.3Bii and Figure 4.12Bii) after a single dose of DCs or a 
second injection after tumour establishment is apparent compared to the natural T cell 
response seen in the PBS controls (Figure 4.12). Another possibility is that the tumour 
cells downregulate expression of ovalbumin, which is supported by the experimental 
evidence of a significant anti-ovalbumin response being unable to control the tumour 
growth. A study in 2013 showed that multiple ‘boosts’ of T cell activation by DC vaccines 
were actually detrimental in both the B16F1 model and a transgenic prostate 
adenocarcinoma model if used therapeutically (Ricupito et al., 2013) One hypothesis for 
this is overstimulation of the T cells if the doses of DCs are too close together, given that 
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the tumour itself provides antigen to further prime the response to the first dose of cells. 
This study used DCs presenting a single antigenic peptide. This is an important 
consideration for the therapeutic use of DCs: particularly in the selection of the antigen 
used.  
In this Chapter, only a single antigen is used to allow accurate quantification of the induced 
T cell response, however may not allow for a strong enough response, or conversely a 
response which is too strong, for complete tumour rejection. Analysis of the tumours 
themselves for expression of ovalbumin would be able to show the extent of tumour 
sculpting by the immune response by quantifying the proportion of cells which retain 
expression of the antigen. Single-antigen DC preparations do have clinical relevance, 
exemplified by Sipuleucel-T against PAP (Kantoff et al., 2010). In clinical trials, and since 
approval for clinical use, these therapies can prolong patient survival by increasing tumour 
antigen-specific T cells, but do not lead to striking tumour regression compared to 
equivalent T cell immunotherapies (Rosenberg et al., 2011). Tumour cells expressing 
alternative antigens can also arise under this immune pressure. Some clinical evidence 
does exist to support multiple therapeutic vaccines with a single antigen leading to 
immunosuppression and decreased survival (Eggermont, 2009); so care must be taken in 
clinical trial design, particularly if CCR7-sorted DCs prove to be significantly more 
immunogenic than current DC vaccines. To induce a more complete tumour response, 
multiple tumour antigens derived from tumour cell lysates or mRNA can be used; which 
could be done in this model given the availability of tumour cells prior to treatment. Using 
the melanoma cell-derived mRNA, clinical evidence showed detectable T cell populations 
recognising different tumour antigens following DC therapy (Benteyn et al., 2012). 
Although this method is outwith the scope of this study, this is a potential consideration for 
future work. 
To fully characterise the response of the immune system to this DC vaccine, it would be 
beneficial to understand the response of other cell types to treatment. The CD8+ T cell 
response is invariably important in the anti-tumour response (Kirkwood et al., 2012), but is 
not the only potential immune response from DC therapy. CD4+ T cells support the 
development of CD8 responses through cytokine production, but are stimulated by 
presentation of antigen by MHC class II instead of class I (Ossendorp et al., 1998). The 
presence and activation of CD4+ T cells in tumour immunology is understood to be both 
supportive of the CD8 response as well as in the production of IFNγ and TNFα for tumour 
killing (Shklovskaya et al., 2016). Cytokine production by CD4+ T cells leads to 
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downstream activation of other cell types, including cytotoxic eosinophils which can be 
recruited to the tumour (Hung et al., 1998). Uptake of exogenous whole-protein antigen by 
DCs allows presentation of antigen by both the MHC class I and II, compared to direct 
peptide loading which is specific for one of the two (Delamarre, Holcombe and Mellman, 
2003). Understanding of the CD4 response, and its potential downstream effectors, may be 
a novel outcome for DC therapy for cancer. Interactions of DCs with B cells in the lymph 
nodes is also a potential anti-tumour mechanism. Canonically B cell function is in the 
production of antibodies, and there is some evidence to support the importance of this in 
the B16F10 model (Guy et al., 2016). Production of cytokines by B cells within the lymph 
nodes can tailor the T cell response towards an antigen, making them relevant in tumour 
biology. Both positive and negative outcomes of B cell function in tumour development 
have been reported. B cell depletion in experimental knockout models has been shown to 
augment the anti-tumour response (Qin et al., 1998), but depletion of B cells in adulthood 
conversely inhibits the anti-tumour response (DiLillo, Yanaba and Tedder, 2010). DCs are 
capable of activating B cells and transferring antigen to them (Wykes, Pombo and Jenkins, 
2018), so it would be interesting to understand if increasing migration of DCs to the lymph 
node has any effect on these processes. 
 
4.6 Chapter summary 
In the previous Chapter, it was shown that sorting DCs by CCR7 expression is viable and 
beneficial to both cell migration and phenotype. Induction of a more mature T cell 
response in vitro was also seen, and to expand on this in a therapeutic context, the 
B16F10.ova model of melanoma was used. Three injection strategies were used to 
understand the consequences of improved migration in this tumour model: one single 
injection at the same time as tumour induction, or two injections with the additional 
injection before tumour induction to mimic a traditional vaccination, or after tumour 
induction to replicate therapeutic use. In all cases, CCR7-sorted DCs led to a significantly 
increased antigen-specific T cell number in the injection-site draining lymph nodes 
compared to the unsorted DC, and PBS control groups, which is proposed to be as a result 
of improved migration of the DCs. This agrees with the common hypothesis that a deficit 
in cell migration limits the efficacy of DC therapy (de Vries, Krooshoop, et al., 2003; 
Sabado and Bhardwaj, 2015). There was no difference in cell number between the uDC 
and PBS controls, suggesting that removal of the CCR7- cells from the injection bolus is 
beneficial in addition to just improving cell migration. After a single injection or two 
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injections after tumour development, cells in the pLN were antigen-inexperienced naïve T 
cells and developing memory T cells, suggesting clonal proliferation of DC-stimulated T 
cells in the lymph nodes. There was also a splenic response higher than the control groups. 
After two injections prior to tumour development, the primary response was in effector T 
cells which is proposed to be a second wave of antigen response after initial memory 
development. In the iLN, the PBS control group showed the highest antigen response 
which was expected as it drains antigen from the tumour and is the primary site of the 
endogenous immune reaction. In the single and vaccination strategies, sDCs slowed 
tumour growth and increased survival compared to the controls, but this was not seen in 
the treatment injection strategy. This was potentially due to diversion of the primary 
immune response to a non tumour-draining LN, but this hypothesis requires further 
assessment. In summary, sorting DCs by CCR7 expression does improve migration to the 
lymph nodes and increase the antigen-specific T cell response in vitro, and that these 
properties can be beneficial in a therapeutic context. 
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5 Assessing CCL19-sorted dendritic cells in the 
metastatic B16F10.ova model 
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5.1 Introduction and aims 
In Chapter 4, CCR7-sorted DC function was assessed in the control of subcutaneous 
melanoma growth. After a single injection, or multiple injections, prior to the initiation of 
tumour growth, sDCs were able to control tumour growth and increase survival times 
compared to the injection of an unsorted DC population. sDC injection led to the 
production of mature, antigen-specific T cells within the injection site-draining lymph node 
and in the spleen whereas this response was minimal after unsorted cell injection. Although 
survival duration was increased by 20-30% in this model, animals did still reach maximal 
tumour size after sDC injection. This suggests that DCs alone are not sufficient to control 
the rapid growth of subcutaneous tumours in this model even with prophylactic injection 
strategies.  
In a clinical setting, the majority DC therapies are given after removal of the bulk tumour 
mass by surgery or chemotherapy (Francia et al., 2011). Secretion of immunosuppressive 
factors such as TGFβ, IL-10 and indoleamine 2,3-dioxygenase (IDO) by the tumour 
reduces DC and T cell cytotoxicity, so removal of tumour mass is beneficial to the 
development of a therapeutic response (Gulley, Madan and Schlom, 2011). Multiple 
clinical trials with patient cohorts subdivided by tumour stage, and therefore tumour size, 
show that patients with less advanced tumours respond better to DC therapies (Hanna et 
al., 2006; Kantoff et al., 2010). Even after traditional interventions, residual tumour cells 
from the primary tumour or from developing metastatic lesions may remain in the patient, 
which may lead to relapse. In addition to control of primary tumour growth, enhanced 
antigen-specific T cell numbers can also help control the development of metastatic lesions 
after removal of the primary tumour. 
Metastasis, which is the occurrence of secondary tumour lesions distal to the primary 
tumour, is a complicated process and still not fully understood. It is thought to account for 
up to 90% of cancer mortality, depending on the type of cancer (Chaffer and Weinberg, 
2011). As described in the Introduction, there are a number of steps involved in 
metastasis including invasion of local tissue, escape into the blood, adherence within the 
vasculature, extravasation and survival within this secondary site. The initial anti-tumour 
response in the primary tissue site is often an innate mechanism. Macrophages are 
important in the development of many tumours and can comprise a large proportion of the 
actual tumour mass (Pollard, 2004). Macrophage knockout or inhibition can delay the 
development of angiogenesis within the tumour and invasion of the tumours into the local 
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stroma (Wyckoff et al., 2004). Tumour-associated neutrophils are also becoming better 
characterised as promotors of tumour metastasis (Fridlender et al., 2009).  
Although cytokines secreted by the tumour, such as TGFβ as described previously, subvert 
the immunogenicity of macrophages and neutrophils (Courau et al., 2016), a strong anti-
tumour T cell response can revert these cells back to a cytotoxic state and help prevent 
metastasis development systemically in addition to being directly cytotoxic to the primary 
tumour themselves (Governa et al., 2017; Hoves et al., 2018). The circulating T cell 
response against the primary tumour helps control early metastatic growth in distal tissues, 
a phenomenon known as concomitant immunity which was first described in 1986 (Dye, 
1986). The adaptive immune response does not effectively control tumour cells in the 
blood, as more than 80% of tumour cells have been shown to survive and extravasate to 
secondary sites (Koop et al., 1995). As the tumour grows and develops immune escape 
mechanisms, the protection of concomitant immunity decreases with the dearth of 
activated tumour-specific T cells (Janssen et al., 2017). Even removal of the primary 
tumour can trigger activation of dormant metastases if T cell protection decreases from 
inactivity. Reactivation or replacement of these T cells is therefore a viable and potentially 
necessary strategy for the control of metastatic development at secondary sites 
The ability of DC vaccination to induce significant anti-tumour T cell responses makes 
them an attractive target as cancer immunotherapeutics. Their viability in a solid tumour 
context have been described in Chapter 4 but primary, and secondary, metastatic tumours 
may both benefit from DC therapy. Despite the efficacy of novel treatments for primary 
tumour growth, there is an absence of effective anti-metastatic treatments, even given the 
high mortality attributable to cancer metastasis (Weigelt, Peterse and Veer, 2005). In the 
4T1 orthotopic model of breast cancer in mice, DC vaccination with dasatinib support was 
able to reduce metastasis from the primary tumour through expansion of CD8+ T cells 
(Song et al., 2018). In the B16 and Lewis lung carcinoma (LLC) models, DC vaccines 
have also shown efficacy in reduction of metastasis (Markov et al., 2015). Current clinical 
trials in metastatic tumour contexts have shown some success, such as improved survival 
of metastatic uveal melanoma (Bol et al., 2014). Dendritic cell vaccines have also been 
shown to have a significant effect on survival of metastatic melanoma, with almost double 
the survival duration compared to alternative treatments (Dillman et al., 2018). DCs are, 
therefore, a clearly viable therapy for metastasis.  
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The B16F10.ova model can be used as a solid tumour model (Chapter 4) but is most 
commonly used as a metastatic model. Multiple repeated isolations of the parental B16F0 
and F1 clones within lung tumour lesions have selected the F10 clone for lung-metastatic 
properties. This clone was then modified to express ovalbumin as a tumour-associated 
antigen (Appendix I). As in Chapter 4, the induction of an antigen-specific T cell 
response following either sDC or uDC was quantified in the context of the B16F10.ova 
metastatic melanoma model. Given the limited duration of this model, two injection 
strategies were assessed: one single DC injection at the same time as the tumour induction; 
and two DC injections prior to the tumour induction. Tumour lesion growth within the 
lungs was quantified at the experimental end-point, and the antigen-specific T cell 
response was analysed by flow cytometry. 
 
5.2 A single prior sDC injection does not fully control 
metastases-like lesions in the lung 
To examine the control of small, metastasis-like tumour lesions, the B16F10.ova model 
was used. Metastasis in this model is mimicked by intravenous injection of the tumour 
cells, as an alternative to the subcutaneous injection model (Chapter 4). This approach is 
slightly more limited in analysis due to the difficulty in monitoring and quantifying tumour 
growth over time and the shorter experimental duration.  
In this experiment, uDCs or sDCs were injected into the footpad, using PBS/0.1% BSA as 
a control as previously. The following day, B16F10.ova cells were injected intravenously 
into the tail vein and the animals were monitored for 14 days (Figure 5.1).  
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Figure 5.1 - Experimental timeline of single prior DC injection in the B16F10.ova metastatic 
tumour model. 
Mice were first injected subcutaneously with either PBS/0.1% BSA, unsorted DCs (uDCs) or sorted 
DCs (sDCs) into the left hind footpad. The following day (d0), all mice were injected with 
B16F10.ova cells intravenously into the tail vein and culled at d14. 
 
5.2.1 Tumour burden 
After 14 days, animals were culled and the lungs perfused with PBS and removed. 
Metastatic lesions within the lungs were identified by their dark melanin colour, with large 
external lesions visible by eye and smaller external lesions visible using a dissecting 
microscope. The lesions are melanin-positive in this model (spontaneous amelanic clones 
and cultures were discarded) and can be quantified without the need for secondary 
detection measures. The tumour burden was quantified by counting the total number of 
lesions visible in the lungs. 
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Figure 5.2 - B16F10.ova external metastatic tumour burden following a single DC injection. 
14 days after DC injection and B16F10.ova tumour induction, lung metastases were quantified by 
microscopy. A) Melanic tumour lesions are visible (red arrow – examples). B) No significant 
difference was seen between either DC-receiving groups or the PBS controls (individual data 
points represent one animal, with mean ± SEM error bars). Statistical analysis was by one-way 
ANOVA with Bonferroni’s Multiple Comparison Test (n = 10/group for PBS and uDC; n = 5 for 
sDC). 
 
There was no significant difference in tumour burden observed between the experimental 
groups after 14 days. After sDC injection, there did appear to be a reduction in tumour 
burden, although this does not reach significance. The large variability in external tumour 
numbers in the PBS and uDC-receiving groups made statistical analysis difficult, so 
internal tumour burden was also quantified. This variability may result from the numbers 
of tumour cells engrafting in the lungs after injection and may not represent a rejection 
response in these animals. The largest lung lobe was prepared for histology and sections 
were cut using a cryotome. For each animal, three non-serial sections were stained using 
H&E staining and tumour lesions were counted by microscopy. 
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Figure 5.3 - B16F10.ova internal metastatic tumour burden following a single DC injection. 
14 days after DC injection and B16F10.ova tumour induction, lung metastases were quantified by 
microscopy after H&E staining. A) Melanic tumour lesions are visible (red boxes – examples). B) 
sDC-receiving mice had fewer internal tumours than the PBS controls, but not the uDC-receiving 
mice (data points represent average tumour number between 3 lung sections per animal, with 
mean ± SEM error bars; scale bar is 500μm). Statistical analysis was by one-way ANOVA with 
Bonferroni’s Multiple Comparison Test: **P ≤ 0.01 (n = 10/group for PBS and uDC; n = 5 for sDC). 
 
Lesions were quantified across the whole section for each animal and an average value of 
three sections per animal was taken (Figure 5.3). Tumour lesions within the tissue itself 
are distinguishable from the lung parenchyma (red boxes, Figure 5.3A). In agreement with 
the external tumour data there was a large variability between internal tumour numbers 
(Figure 5.3B), however internal burden did significantly decrease after sDC injection (3.4 
±0.87) compared to the control groups (8.3 ±1.0 and 6.8 ±0.77 for PBS and uDCs, 
respectively).  
5.2.2 Antigen-specific T cell distribution 
To assess the induction of an ovalbumin-specific T cell response, T cells were isolated 
from the injection site-draining pLN and from the spleen, as well as from the lungs, and 
analysed by flow cytometry. 
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Figure 5.4 - sDC vaccination increases the magnitude of the antigen-specific T cell response 
in the pLN and spleen. 
Mice receiving the B16F10.ova tumours by intravenous injection were assessed for the antigen-
specific T cell responses to DC vaccination in the (A) popliteal LN (pLN) and (B) spleen. Cell 
number was quantified by either percentage of live cells (i) or total cell number (ii) for each tissue. 
Individual data points represent one animal, with mean ± SEM error bars. Statistical analysis was 
by one-way ANOVA with Bonferroni’s Multiple Comparison Test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 
(n = 5-10/group). 
 
In agreement with previous data from solid tumour models, injection of sDCs resulted in 
an increased antigen-specific T cell response (Figure 5.4). In the pLN (Figure 5.4A), 
sDC-receiving mice had an increased total number of antigen-specific T cells (11280 
±4100), compared to either PBS (2266 ±751) or uDC (1365 ±322) control groups. The 
total cell number was more variable than previously seen, however. A similar result was 
seen in the spleen (Figure 5.4B), with sDC injection resulting in the highest T cell 
response in both percentage and total cell number. The response was between two and 
three times higher after injection of sDCs (5815 ±568) in comparison with either control 
groups (1391 ±465 or 2271 ±356 for PBS or uDCs, respectively). 
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Figure 5.5 - sDC vaccination does not increase the magnitude of the antigen-specific T cell 
response in the tumour-bearing lungs. 
Mice receiving the B16F10.ova tumours by intravenous injection were assessed for the antigen-
specific T cell responses to DC vaccination in the tumour-bearing lungs. Cell number was 
quantified by either percentage of live cells (A) or total cell number (B) for each tissue but show no 
difference between experimental groups. Individual data points represent one animal, with mean ± 
SEM error bars. Statistical analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison 
Test (n = 5-10/group). 
 
In the tumour-bearing tissue, however, sDC injection resulted in no difference in the 
antigen-specific T cell response compared to the control groups (Figure 5.5A). There 
appeared to a decrease in the detectable cells after uDC injection, however this did not 
reach significance in this experiment. In the sDC-receiving animals, there was an average 
of 11071 cells (±2948 cells) specific for the tumour antigen, compared to 8452 (±3104) in 
the PBS-receiving animals and 4788 (±2175) in the uDC-receiving animals (Figure 5.5B).  
Since the antigen-specific response is not significantly different between the sDC groups 
and the controls, although there is a decrease in the internal tumour burden (Figure 5.3), 
these data may be indicative of the importance of other immune cells in the protection 
against the metastatic lesions in this model. 
 
5.3 Multiple injections of sDCs do not lead to tumour 
control in the metastatic model 
Despite detectable antigen-specific T cells in the pLN and spleen in sDC-receiving mice, 
there was no difference in the T cell number in the lungs. Although there was no difference 
in external lung tumour burden, there was a significant decrease in the internal tumour 
burden after sDC injection when analysed histologically. To better understand the 
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involvement of T cells in the anti-tumour response in the lungs, an additional injection of 
either DCs or PBS was given before induction of tumour growth. In this experiment, the 
additional injection of either sDCs or uDCs or PBS/0.1% BSA into the footpad was given a 
week before the second set of injections and the tumour induction. This strategy is 
summarised in Figure 5.6 below. 
 
 
 
Figure 5.6 - Experimental timeline of multiple prior DC injections in the B16F10.ova 
metastatic tumour model. 
Mice were first injected subcutaneously with either PBS/0.1% BSA, unsorted DCs (uDCs) or sorted 
DCs (sDCs) into the left hind footpad under isofluorane anaesthetic. A week later (d-1), mice were 
injected again and then the following day (d0) all mice were injected with B16F10.ova cells 
subcutaneously into the flank and culled at d14. 
 
5.3.1 Tumour burden 
14 days after IV tumour injection, melanic lesions on the surface of the lungs were counted 
by light microscopy. 
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Figure 5.7 - Multiple sDC injections have no effect on the number of external metastatic 
lesions in the lungs. 
Melanin-producing tumour lesions in the lungs after 14 days were quantified by light microscopy 
but show no difference between the experimental groups. Individual data points represent one 
animal, with mean ± SEM error bars. Statistical analysis was by one-way ANOVA with Bonferroni’s 
Multiple Comparison Test (n = 8/group). 
 
As shown in Figure 5.7, there is no difference in the total lesion count across all lung lobes 
between the experimental groups, although the range of counts within each group again 
highlight the variability inherent in the model. In the PBS control there was an average of 
176 ±23.1 tumour lesions, whereas in the uDC and sDC-receiving animals the average was 
182 ±21.2 and 186.9 ±33.4, respectively.  
5.3.2 Antigen-specific T cell distribution 
T cell responses in the lymph nodes were again assessed using flow cytometry. In this 
experiment, both the injection site-draining pLN and tumour-draining mLN were taken, as 
well as the lungs and spleen. 
Assessing CCL19-sorted dendritic cells in the metastatic B16F10.ova model 137 
 
 
Figure 5.8 - Prior sDC vaccination increases the magnitude of the antigen-specific T cell 
response in the lymphatic system. 
Mice receiving the B16F10.ova tumours by intravenous injection were assessed for the antigen-
specific T cell responses to DC vaccination in the (A) popliteal LN (pLN); (B) mesenteric LN (mLN); 
and (C) spleen by flow cytometry. Cell number was quantified by either percentage of live cells (i) 
or total cell number (ii) for each tissue. Individual data points represent one animal, with mean ± 
SEM error bars. Statistical analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison 
Test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (n = 6-8/group). 
 
In agreement with all previous data, sDC injection resulted in the highest induction of T 
cell responses in the pLN and spleen as both a percentage of live cells and in total cell 
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number (Figure 5.8A and C, respectively). In the pLN (Figure 5.8Aii), sDC-receiving 
mice had twice as many antigen-specific T cells as the uDC-receiving mice (2328 ±383.5 
to 1454 ±275) and four times as many as the PBS control group (650 ±209.9). In the spleen 
there was a very similar trend (Figure 5.8Cii), as sDC-receiving mice had 4776 ±909 
ovalbumin-specific T cells compared to 1432 ±375.4 in the PBS controls and 2174 ±552.7 
cells in the uDC group. In the mLN, however, there was no difference between any of the 
groups (Figure 5.8B). Mice receiving unsorted DCs appeared to have the lowest T cell 
response (982 ±308.7) when compared to the PBS control (1893 ±549.8) or the sDC-
receiving mice (1305 ±427.5), but this difference is not significant.   
 
Figure 5.9 - Multiple sDC injections do not increase the magnitude of the antigen-specific T 
cell response in the tumour-bearing lungs. 
Mice receiving the B16F10.ova tumours by intravenous injection were assessed for the antigen-
specific T cell responses to DC vaccination in the tumour-bearing lungs. Cell number was 
quantified by either percentage of live cells (A) or total cell number (B) for each tissue but show no 
difference between experimental groups. Individual data points represent one animal, with mean ± 
SEM error bars. Statistical analysis was by one-way ANOVA with Bonferroni’s Multiple Comparison 
Test (n = 6-8/group). 
 
Figure 5.9 shows the number of tumour antigen-specific T cells detectable within the 
lungs of tumour-bearing mice. In agreement with the single injection strategy, there was no 
difference between DC-receiving mice and PBS controls in the prevalence of T cells 
within the lungs during development of metastases. In the sDC group, the average T cell 
response is 12002 ±3370 cells, compared to the uDC group which had 10494 ±3363 cells 
and the PBS control group which had 11809 ±2321 cells.  
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5.3.3 Antigen-specific T cell phenotype 
To further phenotype the antigen-specific T cells in each of these tissues (5.3.2), antigen-
specific T cells were also characterised for expression of CD44 and CD62L.  
 
Figure 5.10 - Prior sDC vaccination increases the tumour antigen-specific T cell maturity in 
the lymphatics. 
Mice receiving the B16F10.oca tumours by intravenous injection were assessed for the antigen-
specific T cell response in the (A) popliteal LN (pLN); (B) mesenteric LN (mLN); and (C) spleen by 
flow cytometry. Expression of CD44 and CD62L was used to phenotype the T cells, which were 
quantified by either percentage of live cells (i) or total cell number (ii) in each tissue. Data 
represent mean ± SEM error bars. Statistical analysis was by one-way ANOVA with Bonferroni’s 
Multiple Comparison Test: *P ≤ 0.05, **P ≤ 0.01, ***P ≤ 0.001 (n = 6-8/group). 
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Antigen-specific T cell phenotype in the lymph nodes and spleen is shown in Figure 5.10. 
The primary phenotype of the cells in the injection site-draining pLN is effector T cells, in 
agreement with prior DC vaccination in the solid tumour model (Figure 4.8A). The sDC-
receiving mice had an average of 1623 ±355.8 T cells with a CD62L- CD44+ effector 
phenotype (Figure 5.10Aii). The PBS-receiving mice had only 514 ±167.2 cells, and the 
uDC-receiving mice had 1129 ±221.3 cells in comparison. There was no difference 
between any of the other T cell phenotypes in this LN (Figure 5.10B). In the spleen, a 
similar trend was seen to the pLN (Figure 5.10C). The sDC group had almost four times 
more antigen-specific effector T cells compared to the PBS controls (2525 ±603.7 to 633 
±164.5) and three times the number in the uDC group (903 ±210.5). There was a slight 
increase in the number of activated T cells (CD62L- CD44-) but this does not reach 
significance. In the mLN, the LN which drains the lungs, there was a higher activated T 
cell response in the PBS controls than either of the DC-receiving groups (1997 ±657.6 to 
753 ±234.8 and 940 ±31.3 for uDC and sDC, respectively).  
  
5.4 Discussion 
Control of subcutaneous B16F10.ova tumour growth by sDC injection was shown in 
Chapter 4, so metastatic B16F10.ova tumour growth was assessed to better understand the 
role the increased T cell response may have in the development of experimental metastasis. 
After a single sDC injection there was a significant increase in tumour antigen-specific T 
cell number in both the pLN and spleen compared to controls as seen previously (Chapter 
4). Similarly, after multiple sDC injections prior to the initiation of metastatic tumour 
development, there was a significant increase in antigen-specific effector T cells in the 
pLN and spleen compared to the uDC and PBS controls. This supports the hypothesis that 
DC vaccination augments the endogenous T cell response suggested in Chapter 3, 
although the extent to which the endogenous response controls the tumour response is 
uncertain. In comparison to the solid tumour model, T cells in this model didn’t reach the 
final TCM phenotype (Figure 5.10). The smaller tumour cell number in the absence of a 
bulky primary tumour may provide less antigen for endogenous antigen presentation and T 
cell activation. In mice, the development of T cells to this final memory phenotype appears 
to be progressive through the three other stages described (naïve, activated, TEFF) so it is 
possible that the short duration allowed by this model may not allow the full development 
of the memory phenotype (Sallusto, Geginat and Lanzavecchia, 2004) unlike in Chapter 4 
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which was up to 2 weeks longer in duration. Other groups allow tumour development for 
longer, up to 21 days post-injection, although by this point there may be pulmonary 
complications (Overwijk and Restifo, 2001). These data further support the first aim of this 
project: that by ensuring initial migration of sDCs to the LNs the T cell response can be 
enhanced.  
Despite the induction of a quantifiable antigen-specific response in the pLNs and spleens 
of sDC-receiving mice, however, a single therapeutic injection or multiple prior injections 
of DCs was not sufficient to control tumour growth. In both injection strategies, there was 
no significant difference in the number of metastatic lesions on the surface of the lungs. 
This disagrees with a number of studies using the B16F10.ova melanoma model which see 
tumour number decrease (Mac Keon et al., 2015), although care needs to be taken when 
comparing methodologies and results. There was a difference in internal tumour burden 
though after a single injection (Figure 5.3), confirming that sDC injection can contribute 
to tumour control even if this is minimal when compared to other studies and may 
represent an insufficiency in this DC injection strategy. If this decrease in internal tumour 
burden was similarly seen after multiple DC injections, the lack of a difference in the 
antigen-specific T cell infiltration seen in the lungs (Figure 5.9) could be indicative of 
alternative mechanisms of tumour rejection, but this would require further experiments. A 
number of immune cell types including NK cells (Grundy, Zhang and Sentman, 2007) and 
neutrophils (Jablonska et al., 2010) have been proposed to help control metastatic growth 
in this model. DCs can activate NK cells in vivo (Zobywalski et al., 2007), so this could be 
a potential anti-tumour mechanism.  
Even after multiple sDC injections there was no change in the numbers of antigen-specific 
T cells within the lung-draining mLN or within the lungs themselves. In this model, 
although useful to be able to quantify the immune response in an injection-site draining 
lymph node, it may have been beneficial for tumour control to inject the DCs to a 
lymphatic branch which can directly access the lungs. When considering the peripheral and 
central compartments as distinct, it was shown in 2003 that injection of DCs into the 
periphery, such as subcutaneously, is insufficient to control tumours growing centrally 
without development of memory T cells within the spleen (Mullins et al., 2003). Although 
a T cell response was quantifiable within the spleens of the sDC-injected group in these 
experiments, this was not seen to be fully mature when the phenotype was determined by 
flow cytometry (Figure 5.10Ci). A mature T cell response was seen previously, however, 
in a model of longer duration (Figure 4.4 and 4.8) which may suggest that sDC injection 
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induces a T cell response but after only 14 days is insufficient to control tumour growth. It 
is significantly increased compared to uDC injection however, which further addresses the 
first aim of this project. The prior vaccination strategy was also shown in the solid tumour 
model to slow tumour growth (Figure 4.6), so it was unexpected that no comparable 
tumour control was seen in this model. This may be attributable to the injection strategy, so 
using an alternative method of DC injection in this model may clarify the potential benefit 
of sorting DCs by CCR7 expression. One common alternative is the intravenous injection 
of DCs. Studies using pre-vaccination with tumour mRNA-loaded, or tumour lysate-
loaded, DCs showed efficacy in reducing B16F10.ova melanoma lesions within the lungs, 
but used multiple intravenous injections instead of subcutaneous as used here (Matheoud et 
al., 2011; Markov et al., 2015). While intravenously-injected DCs will reach the spleen by 
circulation in the blood, expression of CCR7 is crucial for effective intrasplenic migration. 
Previous studies have shown that in the absence of CCR7, endogenous DCs in the spleen 
fail to migrate to the T cell zone to effectively present antigen and this significantly 
reduces antigen-specific T cell proliferation (Calabro et al., 2016). Although requiring a 
different injection strategy, there is some evidence that CCR7-sorted DCs may also be 
more effective than unsorted DCs in intrasplenic migration. 
Antigen selection for loading DC vaccines is another key consideration, particularly in 
melanoma. Each cancer patient has a cancer specific to themselves, with growing evidence 
showing variable TAAs between patients in addition to the individual growth and 
metastatic potential between patients. In melanoma, several well-defined TAAs exist, 
including the MAGE family of antigens which are melanocyte-specific and frequently used 
for tumour targeting; however, both primary and metastatic melanomas are associated with 
hundreds of neoantigens (Lennerz et al., 2005). While these may not represent tumour-
driving mutations, they can result in de novo protein formation that can act as TAAs. 
Appropriate antigen selection is required especially if the goal is prevention of metastasis. 
A clinical trial of metastatic melanoma therapy using DCs showed superior protection 
using patient-derived tumour cells as a source of antigen (Dillman et al., 2018). Tumour-
derived mRNA or tumour cells themselves provide a large pool of potential TAAs and 
circumvent the need for molecular characterisation of de novo produced proteins for 
peptide synthesis, with experimental evidence showing that even single amino acid 
changes in proteins can be targeted for tumour control (Castle et al., 2012). While 
MHC/peptide complexes have short half-lives, limiting the potential presentation of 
antigen to native T cells by peptide or even lysate-loaded DCs, mRNA-loading extends the 
duration of antigen availability. This occurs through synthesis of all possible antigenic 
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proteins by the DCs, including multiple epitopes of the same antigen, and provides an 
internal source of peptides for further presentation (Schaft, Dörrie and Nettelbeck, 2006). It 
is possible, therefore, that a stronger and more effective response could be elicited using 
these methods of antigen loading. 
There is a clear variability in development of B16F10.ova metastatic tumour formation in 
this model. Although it is possible that variability may arise for experimental 
considerations such as cell aggregation over time before injection, or small differences in 
individual IV injections, there are other reasons to pursue future experiments with 
alternative models (Timmons, Cohessy and Wong, 2016). As described previously, the 
B16F10.ova model is used as an “experimental” melanoma and is not without limitations. 
Intravenous injection into the tail vein itself is difficult in mice can introduce variability. 
Over 10 generations of in vivo selection in the lungs, the B16F10 clone was selected for 
metastasis to the lungs, at detriment to MHC class I expression and immunogenicity which 
makes them difficult to target experimentally (Ishiguro et al., 1996; Figure 7.6). An earlier 
or alternative clone, such as the parental B16F1 or bladder-metastasising B16-BL6, could 
be used instead. Outwith experimental considerations, there is disagreement over how 
representative the B16F10 model is of clinical metastatic melanoma. Rapid growth of 
tumours from cell lines is a poor equivalent to human cancer development, and these 
models fail to recapitulate the, often significant, existing tumour burden and treatment 
history in patients with late stage cancers participating in clinical trials (Francia et al., 
2011). Introduction of a large number of tumour cells into the bloodstream is highly unlike 
human metastasis, which is a more gradual (Eyles et al., 2010). Disseminated tumour cells 
can even become dormant in the secondary tumour site, and the B16 model fails to 
recapitulate this. Intravenous introduction of these cells also skips important steps in the 
acquisition of tumour metastatic capability: acquisition of an invasive phenotype, shedding 
from the primary tumour and escape into the vasculature (Chaffer and Weinberg, 2011). 
The B16F10 model more closely represents the formation of multiple primary tumours 
lesions than true metastasis, by definition.  
To overcome this, subcutaneous B16F10 tumours could be allowed to develop until the 
occurrence of spontaneous metastasis, but this would be much less predictable than the 
metastatic model which is still likely to introduce variability between animals. The 4T1 
model of breast cancer has been shown to reliably metastasise within a few months post-
injection, so could be a potential alternative to the B16F10 model (Song et al., 2018). 
Genetically engineered mouse models (GEMMs) can be used to supplement experimental 
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metastasis models. GEMMs develop metastases through comparable mechanisms to 
human tumours through alteration of specific genetic pathways, especially those which are 
relevant in human biology. Mice which are transgenic for the Polyomavirus middle T 
(PyMT) gene develop spontaneous hyperplasia in the mammary gland, which is very 
similar to atypical human hyperplasia (Maglione et al., 2001), and progress to metastasis 
(Siegel, Hardy and Muller, 2000). Tumour-associated genes such as Brca and Pten can be 
manipulated to reflect germline BRCA1/2 mutations in metastatic breast and ovarian 
cancer (Gourley et al., 2010), and abrogation of PTEN in metastatic prostate cancer 
(Margue et al., 2006). These ‘knockdown’ models, however, showed limited similarity to 
the high metastatic potential of the human equivalents. More recent models using tissue-
specific genetic alterations may be more viable. For metastatic melanoma in particular, one 
possibility is a melanocyte-specific expression of a mutated BRAF proto-oncogene 
combined with PTEN knockout (Dankort et al., 2009). BRAF modification alone did not 
lead to melanoma progression in this mouse model, but addition of PTEN silencing 
resulted in melanoma with metastatic lesions and is therefore an attractive spontaneous 
model for future study. Another advantage of these models is the slow tumour 
development in association with local stroma and vasculature, which further increases the 
similarities to human tumours.  
 
5.5 Chapter summary 
In Chapter 4, it was shown that CCR7-sorted DCs were capable of reducing the rate of 
subcutaneous melanoma tumour growth, improving survival duration and significantly 
increasing the anti-tumour T cell repertoire of vaccinated mice. To assess the potential of 
this anti-tumour response in the development of secondary tumour growth, the B16F10.ova 
model was used to induce metastatic lesions in the lungs by intravenous injection. Two 
injection strategies were used to compare the tumour burden following DC injection: one 
injection at the same time as tumour induction, and two injections prior to tumour 
induction as a true vaccination strategy. In both cases, CCR7-sorted DCs led to a 
significantly increased tumour antigen-specific T cell number in the injection site-draining 
lymph nodes and spleen compared to the unsorted DC control and PBS control groups, 
which agrees with data presented in Chapter 4 and supports the first aim of this project. 
Similarly, cell phenotype was shown to be mostly mature T effector cells although the 
short duration of this model may limit the full maturation of the T cells combined with the 
absence of a large antigen source from a solid tumour mass for T cell memory 
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establishment (Ricupito et al., 2013). In this model, however, there was there was no 
control of external metastatic lesion growth and only a small reduction in internal lesion 
growth between the sDC group and the controls after either single or multiple DC 
injections. There was no difference in the mediastinal T cell response either, suggesting 
that the subcutaneous DC injection strategy was insufficient to generate a beneficial anti-
tumour immune response in this context. In summary, despite a conserved increase in cell 
migration to the lymph nodes and increase in the anti-tumour T cell response, in the 
B16F10.ova model, CCR7-sorted DC injection does not result in the reduction in tumour 
burden compared to the unsorted DC controls.  
146 
 
6 Development of CCL19-sorted human dendritic 
cells for therapy 
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6.1 Introduction and aims 
Dendritic cells are becoming increasingly valuable therapies for cancer and other diseases, 
but poor in vivo migration of the cells could limit their efficacy. The data presented thus far 
support the use of CCL19-sorting as a methodology for isolating functional BMDCs from 
non-functional or immature DCs present following the conventional GM-CSF culture 
method. This protocol resulted in consistent, high-purity sorting of CCR7-expressing DCs 
using both manual and FACS-based sorting strategies to optimise cell yield and viability to 
enable their therapeutic use. Expression of CCR7 is a marker of maturity, and CCR7+ cells 
were shown to also express other markers of maturity such as T cell costimulatory 
molecules and antigen-presentation machinery. It was then shown that CCR7+ DCs can 
induce a more mature T cell response in vitro, and using this response translates to a 
decrease in tumour growth and increase in survival in a mouse subcutaneous melanoma 
model. Improvement in the anti-tumour response is thought to be a combination of 
improved DC migration to the lymph nodes and mature phenotype, as well as the removal 
of potential immunosuppressive cells from the injection bolus. Taking these data together, 
increasing DC migration to the lymph node using CCL19 sorting is a viable and potentially 
beneficial therapeutic strategy. 
Current GMP generation protocols for human monocyte-derived DC production use GM-
CSF and IL-4, especially in cancer vaccination. Given the low prevalence of mature 
endogenous DCs in the blood, CD14+ monocytes, which represent ~10% of PBMCs, are 
extracted from the donor by apheresis and used as a cellular source in the majority of 
clinical trials (Constantino et al., 2016). These cells are cultured over 7-10 days, depending 
on the lab and protocol, in GMP-compliant media supplemented with GM-CSF and IL-4 to 
make MoDCs (de Vries et al., 2002). CD34+ progenitors from the blood have also been 
used, and culture with GM-CSF or Flt3-L as well as other cytokines can generate a 
heterogenous mixture of antigen-presenting cells including MoDCs (Ratzinger et al., 
2004). Although most commonly this is done in culture flasks, it has been shown that the 
entire process is amenable to a closed-bag culture system (Zobywalski et al., 2007; Macke 
et al., 2010): this is the most GMP-applicable protocol, as it provides enclosure and 
scalability of the protocol. Isolation of natural DC subsets such as pDCs (Tel et al., 2013) 
and cDCs (Schreibelt et al., 2014) is a more recent development in DC therapy but is also 
possible at GMP level.  
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Maturation protocols also vary but are an extremely important consideration to fully 
activate cells required for migration, as discussed previously. The most common 
maturation cocktails used in clinical trials include TNFα, IFNγ, polyI:C, and PGE2 in 
varying combinations. PolyI:C, a TLR3 agonist (Okada et al., 2011), is normally paired 
with PGE2 because although PGE2 increases CCR7 expression on DCs it has been shown 
experimentally to reduce production of inflammatory cytokines such as IL-12p70 which 
may increase migration to the detriment of T cell stimulation (Lee et al., 2002; Scandella et 
al., 2002). These maturation cocktails are all suitable for GMP use. 
The aim of this Chapter is to develop the CCL19-sorting protocol for human translation in 
as a GMP process. bCCL19, including the PEGylated variants, are synthesised chemically 
to high quantity and purity; and are already amenable to GMP use (Le Brocq et al., 2014). 
As described, all secondary reagents including cytokines and media have been developed 
by the manufacturers to GMP-grade use. The MACSQuant Tyto is a FACS-based cell 
sorter being adapted for GMP compliance through single-use sterile cartridges as a closed-
system cell sorter. Translation of the CCL19-protocol to the Tyto was first done using 
BMDCs, before using human MoDCs derived from buffy coats. Sorted MoDCs were 
analysed for surface phenotype by flow cytometry, and their function was assessed through 
co-culture with matched donor T cells. The T cell response was then characterised by 
surface staining for flow cytometry, and assessment of cytokine production after antigen 
re-challenge. 
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6.2 Materials and methods 
6.2.1 Isolation of PBMCs from buffy coat 
Human buffy coats were obtained from the SNBTS under appropriate sample governance 
and were used as a source of white blood cells. To isolate these cells, the whole blood 
volume, typically 45-50ml, was first diluted to 200ml in PBS. 50ml Leukosep tubes 
(Greiner bio-one) were prepared by adding of 15ml of Histopaque (Sigma-Aldrich) and 
centrifuging the tubes at 1000xg for 1min. The diluted blood was then added to these 
prepared tubes and was centrifuged at 450xg for 40min to separate the blood layers over 
the Histopaque gradient. After this, 20ml of the top fraction was removed by pastette, and 
the remaining volume above the filter was pooled into new Falcon tubes. This collected 
fraction was washed in PBS and spun down at 350xg for 7min. After this, the supernatant 
was discarded and the cell pellets pooled as a single buffy coat PBMC sample. The pooled 
sample was washed in PBS and spun down again before use. 
6.2.1.1 CD14+ cell isolation 
PBMCs were separated into CD14+ and CD14- cell fractions using anti-CD14 microbeads 
(Miltenyi Biotec), using a protocol similar to 2.6.2.1. Briefly, PBMCs were resuspended at 
107 cells/80μl in cold PEB and stained with anti-CD14 microbeads (20μl/107 cells) for 
20min at 4ºC. Unlike the previous protocol, anti-CD14 do not require additional staining 
steps for sorting. After 20min the cells were washed in PEB by centrifugation, resuspended 
and run through a MACS LS column (Miltenyi Biotec) as described previously. The 
positive and negative fractions were collected and washed by centrifugation and 
resuspended in PEB for counting, purity analysis by flow cytometry and further 
experiments. Pre-sort, positive and negative sorted fractions were routinely assessed for 
purity of CD14 expression by flow cytometry. 
6.2.2 Generation of human dendritic cells (MoDCs) 
Human dendritic cells were generated from monocytes present in the purified CD14+ buffy 
coat PMBCs as described in 6.2.1, and are known as MoDCs. Monocytes were cultured in 
24-well plates at a concentration of 2x106 cells/ml in RPMI supplemented with 5% human 
AB serum (SNBTS), and 2mM L-glutamine, penicillin (100 U/ml) and streptomycin 
(100μg/ml) (hRPMI). The medium was additionally supplemented with 50ng/ml 
recombinant human GM-CSF (Miltenyi Biotec) and 15ng/ml recombinant IL-4 (Miltenyi 
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Biotec) to induce differentiation of the cells. On days 2 and 4, half of the medium in each 
well was replaced with fresh hRPMI containing GM-CSF and IL-4. On day 6, immature 
DCs were loaded with Epstein-Barr Virus (EBV) antigen using the EBV Consensus 
Peptivator (Miltenyi Biotec) at a concentration of 20μl peptide per 107 cells. On day 7, the 
dendritic cells were matured by the addition of 20μg/ml PolyI:C (Miltenyi Biotec) and 
1μg/ml PGE2 (Sigma-Aldrich) to the wells, but the media was not replaced at this time to 
avoid removing any EBV antigen. The cells were incubated with these cytokines under 
normal culture conditions for a further 48hr before collection of the cells for further use 
using TrypLE as described previously. 
6.2.3 Generation of short-term human T cell cultures 
Human T cells were cultured from the purified CD14- buffy coat PMBCs as described in 
6.2.1. The CD14- fraction was cultured in 24-well plates at a concentration of 2x106 
cells/ml in complete hRPMI supplemented with 1μl/ml concanavalin A (ConA) (Sigma-
Aldrich) to encourage T cell outgrowth over the other cells present in the CD14- fraction. 
On day 4, 1ml of medium containing 40U/ml human IL-2 (Miltenyi Biotec) was added to 
each well to give a final IL-2 concentration of 20U/ml. On day 8, cells were spun down at 
300xg for 5min and resuspended in hRPMI containing 20U/ml IL-2 at a concentration of 
2x106 cells/ml. These cells were plated overnight, after which they were collected by 
pipetting for further use. 
6.2.4 Chemokine sorting using MACSQuant Tyto 
6.2.4.1 Cartridge and sample preparation 
To maintain a completely closed-system cell sort, the Tyto uses unique a sorting cartridge, 
shown in Figure 6.1, below.  
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Figure 6.1 - Schematic diagram of the MACSQuant Tyto sorting cartridge. 
A visual description of the MACSQuant Tyto cartridge, showing the input/output chambers, the stir 
propeller in the input chamber and the external priming fixture. 
 
These cartridges are first prepared by loading the cartridge into a priming fixture inside a 
sterile tissue culture hood and introducing ~500μl of Tyto Running Buffer (Miltenyi 
Biotec) using a luer lock syringe to cover the stir propeller. After this, sterile air is 
introduced using a syringe to pressurise the chamber and prime the cartridge filter. Excess 
running buffer was then removed. MoDCs were stained with CCL19-SAPE as described in 
2.6.2 and CD45-VioBlue (Miltenyi Biotec). Cells were resuspended in running buffer at a 
concentration no higher than 5x106 cells/ml in a maximum volume of 10ml (the cartridge 
limit). The cells were introduced to the input chamber using a luer lock syringe which was 
attached to the input valve with the plunger removed. Cells were added to the syringe 
barrel after filtering with a 70μm pre-separation filter (Miltenyi Biotec) and ejected into 
the chamber by inserting the plunger of the syringe into the barrel.  
6.2.4.2 Sorting protocol 
The loaded cartridge was inserted into the Tyto by first scanning the cartridge barcode 
using the barcode scanner peripheral attachment, opening the instrument door, and locking 
the cartridge in place in slot in the instrument stage within. To set-up the cytometer for the 
CCL19 sort, the ‘trigger’ was set to PE fluorophore as this is the defines the target cell 
population. The cells were initially analysed to set trigger and gating parameters using cell 
size and expression of CD45 to identify the bulk cell population and exclude debris, and 
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discrimination of the target cell population using expression of CCR7 by CCL19-SAPE 
before initialising the sort.  
6.2.4.3 Cell retrieval 
Cells were retrieved from the cartridge by first removing it from the instrument stage in the 
Tyto, and then from the cartridge by pipette with gel-loading pipette tips. For chambers 
with larger volumes, such as the negative output chamber, cells were collected by attached 
a luer lock syringe to the valve and inverting the cartridge. The positive and negative 
fractions were washed by centrifugation and routinely enumerated and assessed for cell 
yield and purity using the MACSQuant. Cells in the positive and negative chambers were 
kept separate for further analysis by flow cytometry or culture with T cells.  
6.2.5 T cell stimulation assay 
T cells were generated as described in 6.2.3 and co-cultured with CCR7+ or CCR7- 
MoDCs from chemokine sorting. The cells were collected as appropriate and mixed at a 
ratio of 1:25 DCs:T cells in hRPMI supplemented with 20U/ml IL-2 and plated in round-
bottomed 96-well tissue culture plates. Cultures were maintained for 10 days and media 
was replenished as necessary by the replacement of half of the media with fresh hRPMI 
containing IL-2. Cells were recovered by manual agitation and collection using a pipette, 
and their phenotype analysed by flow cytometry.  
To assess the production of cytokines in response to EBV antigen re-challenge, T cells 
were recovered from the 10-day culture and resuspended at 5x106 cells/well in hRPMI in a 
12 well plate. 1μg/ml of the EBV Consensus Peptivator (Miltenyi Biotec) was added to 
each experimental well, using 2μl/ml of PMA and ionomycin per well for the positive 
control wells and nothing in negative control wells. Cells were incubated at 37ºC for 2 
hours before addition of 1μl/ml of Brefeldin A was added to each well. The cells were then 
incubated for a further 3 hours. After this, cells were recovered by manual agitation and 
collection using a pipette and prepared for flow cytometry. 
6.2.6 Flow cytometry 
6.2.6.1 Flow cytometry staining procedure 
Flow cytometry staining for surface markers was performed as described previously in 2.8.  
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To assess the production of intracellular cytokine, cells were first stained for surface 
marker expression as appropriate, before being fixed and permeabilised using 
cytofix/cytoperm solution (BD Biosciences). Briefly, 500μl of cytofix/cytoperm solution 
was added to each sample and these were incubated at 4ºC for 20min. After this, samples 
were washed in perm wash buffer (BD Biosciences), diluted from 10x concentration to 1x 
in distilled water, and centrifuged at 350xg for 5min. The cells were resuspended in 200μl 
perm wash buffer and intracellular antibodies were added at dilutions shown in Table 6.1. 
Samples were incubated at 4ºC for 20min before washing and resuspending in PEA buffer 
for analysis by flow cytometry. 
6.2.6.2 Flow cytometry antibodies 
Table 6.1 - List of human antibodies used in flow cytometry. 
APC* (fluorophore) = allophycocyanin; BV = Brilliant Violet™; FITC = fluorescein; PE = 
phycoerythrin; PE-Cy = phycoerythrin-cyanine (conjugate) 
 
 
  
Target Fluorophore Clone Dilution 
(if not 1/200) 
Supplier 
CD11c PE X9-15  BioLegend 
CD14 VioBlue M5E2  BioLegend 
CD25 BV421 BC96  BioLegend 
CD45Ra PE-Vio770 T6D11  Miltenyi Biotec 
CD45Ro PerCP-Vio700 UCHL1  Miltenyi Biotec 
CD8 VioGreen BW135/80  Miltenyi Biotec 
CD80 FITC 2D10  BioLegend 
CD83 PE HB15e  BioLegend 
CD86 APC* IT2.2  BioLegend 
IFNγ eF450 45.B3 1/50 eBioscience 
IL-2 APC* MQ1-17H12 1/50 BioLegend 
MHC class II FITC L243  BioLegend 
TNFα PE-Cy7 REA636 1/50 Miltenyi Biotec 
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6.3 Results 
6.3.1 Both BMDCs and MoDCs can be sorted using CCL19 on the 
MACSQuant Tyto 
6.3.1.1 BMDC sorting 
In this study, BMDCs were readily accessible and were first used to optimise the Tyto 
sorting protocol before more valuable human samples were used. Purity of the cell sort was 
first assessed by staining the cells with the CCL19-SAPE conjugate, sorting the cells, and 
assessing the expression of CCR7 in each of the sort fractions. 
 
 
Figure 6.2 - BMDCs can be effectively sorted for CCR7 expression using the MACSQuant 
Tyto. 
BMDCs were sorted using the MACSQuant Tyto and the CCR7 expression of each sort fraction 
was compared to the initial pre-sort (black) by flow cytometry. The negative fraction (blue) is split 
into pre- and post-optimised groups, compared to the total positive samples (red). Data points 
represent mean ± SEM error bars. Statistical analysis was by one-way ANOVA with Bonferroni’s 
Multiple Comparison Test: **P ≤ 0.01, ***P ≤ 0.001 (n = 9/group; negative groups are n = 4 and n = 
5/group). 
 
Figure 6.2 shows clearly the ability of the fluorophore to identify and be utilised of the 
sorting for both BMDCs and MoDCs. With BMDCs, this sorting protocol increased the 
purity of CCR7 expression from 39.16% (± 4.85%) in the pre-sort fraction, to 85.13% (± 
2.11%) with high consistency. The lack of a significant reduction in the negative fraction 
in the early optimisation (validation), however suggested that although the sorted cells 
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were ~90% CCR7+, the yield of these cells from the initial sorting population was low. 
After optimisation of the sorting parameters such as transit time and valve opening 
frequency there was a significant reduction in percentage of CCR7+ cells in the negative 
fraction, decreasing from 53.6% (± 0.76%) to 23.94% (± 5.37%). As previously with Aria 
II sorting, the cell yield and viability were next assessed.  
 
 
Figure 6.3 - High yield and viability of Tyto-sorted BMDCs using CCL19. 
After optimisation of the sorting protocol for the BMDC CCL19-SAPE strategy, there was a 
difference in (A) cell yield (n = 4-5/group) from the total CCR7+ cells in the pre-sort sample, 
whereas (B) cell viability always remained high and was not affected by the sorting protocol (n = 
4/group). Data points represent mean ± SEM error bars. Statistical analysis was by unpaired 
Student’s t test: n.s. = non-significant, ***P ≤ 0.001. 
 
Yield of the CCR7+ cells in the positive fraction was shown to be low in the initial cell 
sorts, as predicted by the lack of depletion of the negative fraction. The initial sorts were 
all less than 40% yield (12.8% ± 7.18%) but increase significantly to 63.51% (± 4.42%) 
after optimisation. This approached the cell yield from the Aria II as shown previously 
(3.2.3). Cell viability, in comparison, remained consistently high between the pre-sort and 
sorted cells. Taken together with viability assessment (3.2.3), FACS-based sorting had no 
immediate effect on the viability of BMDCs.  
6.3.1.2 MoDC sorting 
Once optimised, the protocol was extended to MoDCs to explore the feasibility of using 
the Tyto for GMP-like sorting with CCL19-SAPE. MoDCs were generated from buffy 
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coat-derived monocytes as described above and labelled with CCL19-SAPE for sorting 
using the update parameters from the BMDC optimisation. 
 
 
Figure 6.4 - MoDCs can be effectively sorted for CCR7 expression using the MACSQuant 
Tyto. 
MoDCs were sorted using the MACSQuant Tyto and the CCR7 expression of each sort fraction 
was compared to the initial pre-sort (black) by flow cytometry. The negative fraction (blue) is split 
into pre- and post-optimised groups, compared to the total positive samples (red). Data points 
represent mean ± SEM error bars. Statistical analysis was by one-way ANOVA with Bonferroni’s 
Multiple Comparison Test: **P ≤ 0.01, ***P ≤ 0.001 (n = 8/group). 
 
Using the optimised parameters from the BMDC sorts, MoDCs can be sorted for high 
purity of CCR7 expression using the Tyto (Figure 6.4). The pre-sort population were 
enriched from 54.37% (± 4.2%) to 83.42% (± 4.48%) expression of CCR7, reaching higher 
than 90% on three occasions. Additionally, as shown previously, there was a significant 
depletion of the negative fraction which drops to 29.47% (± 8.4%), with three of these 
samples lower than 10%.  
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Figure 6.5 - Yield of Tyto-sorted MoDCs is high and cells maintain viability during the 
protocol. 
Using an optimised sorting protocol, MoDCs could be sorted on the Tyto using CCL19 with (A) high 
cell yield from the pre-sort fraction and (B) cells remained highly viable after sorting. Data points 
represent mean ± SEM error bars. Statistical analysis was by unpaired Student’s t test: n.s. = non-
significant (n = 4/group). 
 
The optimised sorting protocol resulted in a high yield of CCR7+ cells from the pre-sort 
sample (Figure 6.5), which is 63.48% (± 4.67%). Although this was lower than seen with 
the Aria II (84.7%; Figure 3.6), it is comparable and higher than the column yield. There 
was no decrease in cell viability immediately after the sort (Figure 6.5B) by DRAQ7 
staining; which was again consistent with previous FACS-based sorting on the Aria II. 
These data together support the use of the MACSQuant Tyto for adaptation of the CCL19-
sorting protocol to a GMP-compliant protocol.  
6.3.2 CCL19-sorted MoDCs are phenotypically distinct 
Like BMDCs, inflammatory MoDC migration in vivo is tightly regulated as a function of 
cell maturity: MoDCs undergo a distinct shift in chemokine receptor expression and 
therefore migratory capacity after exposure to antigen and maturation signals such as 
cytokines. Surface phenotype of CCR7+ and CCR7- MoDCs was analysed after sorting 
using flow cytometry and compared. 
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Figure 6.6 - CCR7+ and CCR7- MoDCs are distinct by surface phenotype. 
Expression of activated DC markers were significantly enriched in CCR7+ populations (red bars) in 
comparison to CCR7- populations (blue bars). Statistical analysis was by Students t test. * P ≤ 0.05 
(n = 3). 
 
As expected, CCR7+ MoDCs expressed more highly several markers of cell maturity 
including MHC class II, CD83 and CD86 (Figure 6.6); which was consistent with the 
phenotype of CCR7+ BMDCs (Figure 3.10). This data was consistent with 
characterisation of therapeutic DCs previously described (de Vries et al., 2002), as 
expected. There was also a small but non-significant increase in expression of CD80 
(MFIs: 36 ± 5 to 389.63 ± 145.9) and CD25 (MFIs: 39.33 ± 3.28 to 494 ± 271). CD25 is 
the IL-2 receptor, and is expressed on DCs maturing in response to PGE2 (von Bergwelt-
Baildon et al., 2006). DCs lack the signalling pathways to functionally respond to IL-2 
stimulation like T cells do but CD25 expression has been suggested to enhance T cell 
activation alongside traditional immunogenic markers CD80, CD83 and CD86 (Velten et 
al., 2007). Although not particularly novel, it was important to again highlight the 
variability of the GM-CSF and IL-4 culture system and that CCR7-expressing cells within 
this system were phenotypically distinct in agreement with mouse in vitro data. 
6.3.3 CCL19-sorted MoDCs induce a distinct T cell phenotype 
after co-culture 
To confirm the function of MoDCs after sorting and compare CCR7- and CCR7+ MoDCs 
in T cell stimulation, sorted DCs were co-cultured with donor-matched buffy coat T cells. 
After 10 days of culture, T cells were collected and analysed by flow cytometry. 
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Figure 6.7 - CCR7+ MoDCs stimulate expansion of stem memory T cells but no other subset. 
(A) T cell subset gating strategy. (B) After 10 days of culture together, CCR7+ MoDCs (red bars) 
stimulated more expansion of stem cell memory T cells but did not affect other subsets compared 
to controls (IL-2 alone – black bars; CCR7- DCs – blue bars). T cells were classified by surface 
marker expression analysed by flow cytometry. Abbreviations: TCM – central memory T cell; TEFF – 
effector T cell; TEM – effector memory T cell; TSCM – stem cell memory T cell. Statistical analysis 
was by Students t test. * P ≤ 0.05 (n = 3). 
 
T cells in this experimental set-up showed little stimulation in response to CCR7+ DCs 
compared to the IL-2 alone control, or CCR7- DCs (Figure 6.7). T cell subsets were 
identified using the surface markers CD45Ra, CD45Ro and CD62L. The common 
leukocyte antigen in humans, CD45, has two isoforms which can be used to discriminate 
naïve (CD45Ra) and memory (CD45Ro) T cells (Faint et al., 2001). CD62L, also known 
as L-selectin, is involved in T cell migration, and shed during the acquisition of lytic, 
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effector function (Yang et al., 2011). Using these markers, T cell subsets were defined 
phenotypically as described in Figure 6.7A, with increasing differentiation as follows: 
Naïve, TSCM, TCM, TEM, and TEFF. CD45Ra-CD45Ro- cells were excluded from analysis 
despite expression of CD8, as these cells could be NK or NK T cells (Baker et al., 2001). 
Similarly, CD45Ra+CD45Ro+ cells were excluded as they may be a transitional 
phenotype not accommodated by these defined subsets (Golubovskaya and Wu, 2016). 
Taking this into consideration, it was seen that CCR7+ MoDCs only increased the 
proportion of TSCM cells in the culture (13.44% ± 1.29%) compared to CCR7- MoDCs and 
IL-2 alone (4.94% ± 0.66%, and 2.06% ± 0.22%). No difference in total T cells by cell 
number was observed, however (data not shown), suggesting that CCR7+ MoDCs are 
skewing the cell response towards a memory phenotype. There was also no difference in 
expression of CD28 or CD57 between the groups (data not shown). 
To better understand the induction of antigen specific cells, and not the maintenance or 
induction of T cells by MoDC cytokines alone, T cells were re-challenged with the EBV 
peptide and assessed for production of three important T cell cytokines: IL-2, IFNγ and 
TNFα. 
 
Figure 6.8 - CCR7+ MoDCs induce T cell memory phenotypes by cytokine production. 
After 10 days of culture, CCR7+ MoDCs (red bars) stimulated the development of antigen-specific 
T cells with memory phenotypes compared to CCR7- cells and IL-2 alone. T cells were assessed 
by intracellular flow cytometry after restimulation with peptide. Abbreviations: TCM – central memory 
T cell; TEFF – effector T cell; TEM – effector memory T cell (n = 1) (Kwak et al., 2013). 
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Although only one buffy coat donor responded to peptide restimulation detectable above 
the background response, it was still possible to distinguish different cell phenotypes using 
cytokine production (Figure 6.8). In agreement with earlier surface phenotyping, CCR7+ 
cells resulted in the stimulation of TCM cells which secrete IL-2, as well as TEM cells 
secreting all three cytokines. TSCM cytokine phenotype is less well-defined than the other T 
cell phenotypes, but may be represented here by the IL-2+ cells (Roberto et al., 2015). In 
contrast, CCR7- cells resulted primarily in the production of more terminal effector cells 
such as IFNγ+ TNFα+ cells and cells secreting IFNγ+ alone. This agreed with the surface 
phenotype shown in Figure 6.7. Overall this suggests that CCR7+ cells can activate robust 
antigen-specific memory cell proliferation which may lead to an increased downstream 
effector response, compared to CCR7- cells which activate only the effector response.  
6.4 Discussion 
In this Chapter, it was shown that sorting MoDCs by CCR7 expressing using bCCL19 is 
translatable to a GMP-grade protocol, and results in an inflammatory MoDC population 
capable of stimulating T cells in vitro and induction of a memory response. 
Using a GMP-grade protocol, it was possible to sort both BMDCs and MoDCs to high 
yield and cell purity for expression of CCR7 using bCCL19-sorting as described in 
Chapter 3. Although the MACSQuant Tyto was used for optimisation of this protocol, the 
adaptation of the protocol for flow-based cell sorting allows the methodology to be broadly 
applied to other clinical grade cell sorters. It is likely that additional instrument-specific 
modifications will be required to achieve a consistent high purity and cell viability as 
shown here with the Tyto system. With these modifications, the protocol presented here is 
immediately applicable to human delivery if required.  
Characterisation of the MoDC phenotype shows that, as seen in BMDCs, CCR7 is 
expressed on cells along with markers of cell maturity and immunogenicity such as CD80, 
CD83 and MHC class II. As described previously, enrichment of these cells is beneficial in 
the induction of a T cell response. In BMDCs, removal of immature, CCR7- cells from the 
bulk population enhanced T cell maturity after co-culture (Figure 3.13). In comparison the 
CCR7- cells alone produced only immature T cells by surface phenotype and potentially 
the induction of early cell anergy. Preliminary T cell phenotyping shown here show a 
similar trend in activation, with CCR7+ MoDCs inducing the production of more mature T 
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memory cells when compared to CCR7- cells and IL-2 alone. Interestingly, this response 
was seen in each of the three buffy coats used despite only one of these showing a 
significant antigen-specific response by cytokine production (Figure 6.8). This suggests 
that in addition to providing strong antigen presentation to cognate T cells, CCR7+ 
MoDCs may also produce other signals for expansion of the memory response in the 
absence of direct TCR recognition. Production of cytokines such as IL-15 and IL-2 can 
support expansion of memory T cells specifically both in vitro and in vivo (Klebanoff et 
al., 2004). Previous experimental evidence shows that activated MoDCs can secrete IL-15 
in culture (Gorvel, Korenfeld and Tung, 2017), making it possible to promote the 
expansion of memory T cells in a paracrine manner. It would be interesting to further 
analyse MoDCs for cytokine production as done with BMDCs in Chapter 3 to confirm 
this potential mechanism of T cell stimulation. 
Unlike with the OT-1 T cell model used in Chapter 3, the prevalence of EBV-responsive 
people within the human population had to be used to quantify an antigen-specific T cell 
response in human MoDC/T cell co-cultures. In mice, it is possible to engineer a culture 
system where almost 100% of T cells are reactive against one antigen, ovalbumin in the 
OT-1 model, and use this to quantify a bulk response to a stimulus such as ovalbumin-
presenting DCs. In humans, the small proportion of circulating EBV-specific T cells had to 
be used instead, as donor T cells recognise a multiplicity of antigens in comparison. It is 
expected that 90% of the world’s population will have been exposed to EBV by adulthood 
(Lennon, Crotty and Fenton, 2015); with lifelong, latent infection being maintained by low 
grade replication after exposure. Using EBV as a model antigen requires careful analysis to 
not over-interpret observations, so to confirm this finding the T cells were further 
phenotyped for cytokine secretion to quantify a true antigen-specific response by 
restimulation with the EBV peptide. As shown in Figure 6.8, one buffy coat donor was 
responsive to the EBV peptide, which was determined by cytokine production above the 
background of T cells maintained in IL-2 alone. Through analysis of three important T cell 
cytokines, IFNγ, TNFα and IL-2 it was possible to identify cell phenotypes within the 
antigen-responding population only (Seder, Darrah and Roederer, 2008).  
IFNγ is a potent cytotoxic cytokine, involved in the defence against pathogens and tumour 
cells alike (Shankaran et al., 2001). Coordinated secretion of IFNγ and TNFα has been 
shown to increase cytotoxicity (Bogdan et al., 1990); as well as upregulate MHC class I 
and II on both tumour cells and endogenous APCs (Restifo, Dudley and Rosenberg, 2012). 
IL-2 production is a determinant of T cell function after exposure to antigen: naïve CD8+ 
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T cells expressing IL-2 is closely associated with the formation of antigen memory, 
whereas failure to express IL-2 after activation tends the cell towards effector function 
(Malek and Castro, 2010). IL-2 as a cytokine is an extremely potent T cell growth factor, 
usually produced by CD4+ T cells, but to a lesser extent CD8+ T cells too. T cell 
polyfunctionality through production of these three cytokines has been shown to increase 
efficacy of these cells in an antiviral and antitumour context (Klebanoff, Gattinoni and 
Restifo, 2006; Precopio et al., 2007). In addition to the superior cytotoxicity of IFNγ and 
TNFα together compared to IFNγ alone, these T cells also produce more IFNγ per cell 
which further increases cytotoxicity (Precopio et al., 2007). Production of IL-2 by these 
cells also promotes the expansion of both effector and memory T cells, supporting further 
expansion of the antigen-specific T cell response in this context. Analysis of these 
phenotypes in future buffy coat samples will be vital to ensure reliability and allow 
accurate statistical analysis, but the initial data are encouraging. 
Although preliminary, this analysis supports the expansion of mature, memory T cells by 
CCR7+ human DCs and not by CCR7- cells. The TSCM phenotype shown by flow 
cytometry have been characterised in vivo as an early memory phenotype, which is highly 
proliferative and effective in the antitumour defence (Gattinoni et al., 2012). These cells 
can also give rise to TCM and TEM cells as differentiated progeny, expanding the 
multifunctional antigen-specific response (Flynn and Gorry, 2014). As described 
previously, characterisation of TSCM cells by cytokine production is difficult given the 
production of IFNγ, TNFα and IL-2 transiently in healthy human blood (Roberto et al., 
2015). In a number of studies, the generation of more TCM cells by vaccination strategies 
has shown superior protective immunity (Klebanoff, Gattinoni and Restifo, 2006). In a 
cancer context, transfer of TCM cells compared to TEM cells has the potential to induce not 
only an increased effector cell proliferation but to also support the formation of durable 
antigen memory with correction of the endogenous memory (Kaech, Wherry and Ahmed, 
2002). The generation of this response endogenously by vaccination could have the same 
beneficial effect, in particular the benefit of overcoming endogenous immune suppression 
as a result of persistent tumour antigen exposure. 
 
6.5 Chapter summary 
This Chapter presents data which supports the viability of bCCL19-sorting as a GMP-
grade clinical protocol, with immediate clinical applicability. In Chapter 3 it was shown 
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that it was possible to sort murine BMDCs for expression of CCR7 using a novel CCL19-
sorting strategy (Le Brocq et al., 2014). While originally a magnetic bead-based 
methodology, incorporation of a fluorophore conjugate into the chemokine tetramer 
allowed translation of the strategy to FACS using the BD Aria II. In this Chapter, data 
presented show that the strategy can be further modified to near-GMP compliance by 
sorting using the MACSQuant Tyto. After optimisation of the sorting parameters, MoDCs 
generated using GM-CSF and IL-4 were shown to be sorted by expression of CCR7 to 
greater than 90% purity and a high yield from the initial starting population. Preliminary 
flow cytometry analysis agreed with previous mouse in vitro and in vivo data that CCL19-
sorted cells had improved surface phenotype, however further phenotyping needs to be 
done to characterise the CCR7+ MoDC population. Finally, CCR7+ MoDCs were capable 
of inducing more memory T cells, both by direct antigen presentation but possibly also 
cytokines, which was assessed by flow cytometry of T cells after co-culture. Function of 
the T cells was also assessed following antigen restimulation with peptide antigen by 
intracellular cytokine production, confirming, importantly, that these T cells can produce 
cytotoxic and immune-enhancing cytokines such as IFNγ, TNFα and IL-2 which are 
beneficial in a cancer context. Taking these data together, CCL19-sorting of MoDCs is a 
viable clinical protocol which could have therapeutic benefit in a cancer context. 
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7.1 Introduction 
7.1.1 Dendritic cell therapies 
Dendritic cells are the most potent antigen-presenting cell in the immune system, which 
makes them an attractive cell type for utilising therapeutically. DC therapy is currently a 
safe and feasible immunotherapy in a number of clinical contexts including cancer. T cells 
can be used in cancer therapy for their antigen-specificity and cytotoxicity (Rosenberg et 
al., 2011); DCs can be used to induce this in vivo T cell response against a specific target 
antigen expressed by tumour cells. These antigens can be neoantigens, such as those from 
genetic changes and resulting in de novo protein formation, viral antigens in the case of 
oncogenic viruses, overexpression of tissue-specific antigens or even the re-expression of 
developmental proteins not normally subjected to immune control (Bol, Schreibelt, et al., 
2016). Although more than 20 years of clinical trial data show that the induction of an 
immune response is possible, DC therapy still fails to elicit consistent anti-tumour effects 
which lead to survival in cancer patients. In comparison to the clear effect of alternative 
immunotherapy approaches such as chimeric antigen receptor (CAR) T cells, the early 
potential of DC therapy has not yet been realised. However, significant progress has been 
made in the improvement of DC therapies since the first reported DC clinical trial in 1995 
(Mukherji et al., 1995). Three generations of DC therapies have explored a variety of 
alternative DC sources, methods of delivering of antigens to target the immune response to 
tumours, ‘maturation cocktails’ to influence DC phenotype and the resulting immune 
response, and injection strategies to influence cell migration in vivo.  Competent migration 
is integral for DC function, and crucially has been shown to be variable in clinical trials 
and is therefore only recently becoming adequately addressed in this context as will be 
described in the following sections.   
7.1.2 Source of DCs 
Early trials used heterogenous cell populations which included DCs, whether this was the 
whole mononuclear fraction from patient blood, or culturing DC progenitors. More recent 
trials have used naturally occurring DC subsets for their specific immune qualities. Each of 
these cell sources pose different challenges for therapeutic use and have different potential 
benefits. Culturing DC progenitor cells such as cytokine-mobilised CD34+ bone marrow 
progenitors or CD14+ monocytic progenitors is desirable because of the large cell number 
that can be derived from ex vivo differentiation (Nestle, 2000). Transcriptomic data, 
however, distinguishes these cells from ‘true’ in vivo DC populations such as circulating 
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pDCs and cDCs (Lundberg et al., 2013). The paucity of in vivo DCs makes them 
challenging to use therapeutically, but despite this small circulating cell number both pDCs 
and cDCs can be isolated in sufficient number for therapeutic use by  positive selection for 
BDCA4 (CD303) expression for pDCs (Tel et al., 2013) or BDCA1 (CD1c) for cDCs 
(Schreibelt et al., 2016) from patient leukapheresis. Different DC subsets have been 
trialled primarily to improve the anti-cancer immune response, although it is interesting to 
note that migration of all of these subsets is strongly dependent on expression of CCR7 
(Förster, Davalos-Misslitz and Rot, 2008).  
As described in the Introduction, upregulation of CCR7 is intrinsic to the process of DC 
activation. Immature DCs increase expression of CCR7 following uptake of antigen and 
exposure to local inflammatory stimuli and use this receptor to migrate to the lymph nodes 
via the lymphatics between 24hr and 48hr (Huang et al., 2001). This change is seen in ex 
vivo-generated DCs as well as cDCs, although heterogeneous CCR7 expression can limit 
potential migration (Sabado, Balan and Bhardwaj, 2017). pDC migration is slightly 
different, however. Expression of CCR7 on pDCs has been reported in the steady state, 
although lower than the other DC cell types, and contributes to lymph node migration 
without prior antigen exposure (Penna, Sozzani and Adorini, 2001; Seth et al., 2011). 
Natural and ex vivo generated pDCs do also upregulate CCR7 after cytokine and antigen 
exposure, accompanying upregulation of conventional markers of DC maturity such as 
CD80 and CD86 (Krug et al., 2002) (Figure 3.11). In comparison to the migration of other 
DCs, which is through tissue and lymphatics to the lymph node, pDCs utilise CCR7 and 
CD62L to enter the lymph nodes from the circulation through the high endothelial venules 
(Seth et al., 2011). Taking these studies into account, CCR7 can be used as both a marker 
of cell maturity and migratory capacity. Isolation of DC expressing CCR7 is therefore a 
potential benefit for DC therapy regardless of the source of DCs used in clinical trials.  
7.1.3 Maturation of DCs 
Most DC maturation cocktails focus on strengthening DC-T cell interactions in vivo, 
although there are some used specifically to enhance CCR7 expression. Human MoDC 
cultures can be supplemented with PGE2, which increases the expression of CCR7 through 
prostaglandin receptors leading to downstream cAMP signalling and metalloproteinase 
activity to further support migration (Scandella et al., 2002). Some early studies suggest 
that PGE2 skews the T cell response to DC stimulation to a more regulatory or TH2 
phenotype through suppression of IL-12p70 production, which limits its use as a cancer 
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therapeutic (Jongmans et al., 2005). IL-12p70 induces CTL development and its 
production by DC vaccination correlates with increased time to progression and survival 
(Carreno et al., 2013). The production of IL-12p70 has been shown to be largely 
recoverable with the addition of other maturation stimuli such as PolyI:C, a TLR3 agonist 
(Krause et al., 2009). There is evidence supporting the transient nature of CCR7 
upregulation, and the suppression of DC CCL19 secretion which attracts naïve T cells 
within the lymph node (Muthuswamy et al., 2010). Other studies show conflicting 
evidence of the ability of PGE2 to enhance T cell proliferation by DCs, and therefore 
immunogenic function.  
In addition to this, the timing of the maturation protocol during ex vivo manipulation is 
important to DC function. In clinical trials, DCs are most commonly matured for between 
24 and 48hr to ensure the mature phenotype prior to injection into recipients (Sabado, 
Balan and Bhardwaj, 2017). This has been shown, however, to have a potentially negative 
effect on DC function. After the initial maturation stimulus, including cytokine stimulation 
in vitro, there is a complex change over time in the ability of the DC to secrete cytokines 
which support T cell activation such as IL-2 (Dohnal et al., 2009). While these longer 
maturation times seen in clinical trials allow maximum cell maturity, and the desirable 
expression of CCR7 (de Vries, Krooshoop, et al., 2003), this can lead to ‘exhaustion’ of 
cytokine production and may be disadvantageous overall (Langenkamp et al., 2000). 
Upregulation of the CCR7 mRNA has been shown as early as 4hr post-stimulation, and the 
receptor detectable on the surface as early as 10hr post-stimulation (Sallusto, Palermo, et 
al., 1999; Jin et al., 2010) The combined use of shorter cytokine stimulation times and 
isolation of sufficiently matured cells by expression of CCR7 may therefore be beneficial 
to ensuring and improving DC T cell stimulation. This would also shorten the culture time 
and cost required for clinical preparation of DCs for therapy in addition to potentially 
improving efficacy. 
7.1.4 Routes of injection 
Finally, different injection strategies have be explored to ensure DC migration to the target 
tissues. Most of these focus on localising DCs within the lymph node for stimulation of T 
cells, but intra-tumoural injection has been attempted. The rationale for this strategy allows 
direct tumour sampling by the injected DCs, which can uptake and then present tumour-
targeting antigens to T cells either in situ or after migration to the draining lymph nodes. 
Injected DCs would have to then overcome the overwhelmingly immunosuppressive TME 
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for function (Galluzzi et al., 2012). In practice, this injection strategy is also technically 
challenging since not all tumours will be easily accessible for direct injection, and if they 
are accessible, tumour biopsy and ex vivo DC preparation may be a more feasible strategy. 
Other injection routes include subcutaneous, intradermal, intravenous, intralymphatic and 
intranodal.  
Subcutaneous, intradermal or intravenous injection comprise the three most frequently 
used injection strategies (Constantino et al., 2016). Subcutaneous and intradermal 
injections both facilitate the access of injected cells to the lymphatic system, allowing 
natural migration to the lymph nodes after injection (Lappin et al., 1999). This strategy, 
however, has been shown to limit the number of cells reaching the lymph nodes after 
injection, which has been reported as less than 5% in cell tracking studies (Verdijk et al., 
2009). Compared to intravenous injection strategies, DCs require receptors such as CCR7 
for active migration into the lymphatic vessels; as discussed previously, however, CCR7 is 
not expressed by all cells generated ex vivo. Increasing the injected cell number is not a 
feasible approach, as this can lead to cell death in situ and have an effect on the potential 
generation of the T cell response. Under significant cell influx, LN congestion also 
prevents the entry of more cells via the lymphatics to protect the LN architecture and the 
developing immune response (Förster et al., 2012). The use of multiple, smaller doses at 
different injection sites can potentially overcome these issues (Sabado, Balan and 
Bhardwaj, 2017), although crucially these cells still require expression of CCR7 for this 
migration. 
Intravenously injected cells, in comparison, are less limited in number than either 
subcutaneous or intradermal injection, but there is still debate over the migration pattern of 
IV-injected cells. Most types of DCs used clinically are less capable of LN entry from the 
blood due to their maturity and downregulation of tissue-homing chemokine receptors 
(Hauser and Legler, 2016), the exception being pDCs which are fully capable. This leads 
to sequestering in tissues such as the spleen or non-lymphoid tissues such as the lungs 
which negatively effects their function (Butterfield, 2013). Biodistribution of mature DCs 
can influence the immune response, so IV injection may be beneficial if the target is 
metastatic lesions which can be more effectively controlled by splenic memory T cells than 
by those resulting from e.g. subcutaneous injection (Mullins et al., 2003). Although natural 
circulatory flow can direct IV-injected DCs to the spleen, it was shown by Calabro et al. 
that expression of CCR7 is required for intra-splenic migration to the T cell zone for 
function (Calabro et al., 2016).  
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In each of these injection routes, CCR7 expression is important for direct migration. Direct 
injection of DCs into the lymph nodes themselves has been tried to overcome the need for 
in vivo migration, but this technique is technically challenging and may not be performed 
consistently between patients (Verdijk et al., 2009). Although it was expected to show 
superior clinical response as a result of the immediate access of injected DCs to T cells 
within the lymph node, intranodal injection has at best shown comparable efficacy to 
intradermal injection (Quillien et al., 2005; Lesterhuis et al., 2011). There are some 
studies, however, which show superior immune responses to intranodally-injected DCs 
compared to other routes (Bedrosian et al., 2003); although at least highlights the potential 
for inconsistency between clinical trial centres.  
Intradermal injection strategies facilitate the migration of DCs to multiple LNs via 
lymphatic drainage, while single intranodal injections have not been shown to facilitate 
this consistently. Potential hydraulic disruption of LN architecture can limit both the 
immune response and DC migration to adjacent LNs via the lymphatics. The technical 
complexity of intranodal injection also precludes multiple LN injections (Tel et al., 2013). 
Taking this into account however, a role for CCR7 expression can still be proposed – both 
to ensure subsequent migration of the cells to other LNs through the lymphatics, and to 
isolate the mature population from the immature population which is normally retained at 
the injection site after intradermal injection and does not reach the lymph node. 
7.1.5 Project aims 
Using the novel cell sorting methodology first described by Le Brocq et al. (2014), the aim 
of this thesis and the experiments within was to develop CCL19-based DC sorting as a 
potential improvement for therapeutic applications. The first aim was to show that CCL19 
sorting can isolate a mature, migratory DC subset expressing the chemokine receptor 
CCR7 from a bulk population. The sorted cells should display a more effective lymph node 
migration. This aim was addressed in Chapters 3 and 6. Mouse and human DCs were 
generated using appropriate, clinically-relevant protocols (human cells), and sorted for 
CCR7 expression using an optimised chemokine sorting method. These DCs were 
characterised by flow cytometry for markers of DC maturity, and the production of 
immune-activating chemokines and cytokines to predict in vivo function. Migration of the 
sorted DCs was also compared to unsorted DCs using transwell migration as well as in 
vivo LN chemotaxis assays. Finally, the antigen-presenting function of these cells was 
assessed in vitro by culturing them with T cells. The second aim was to show that this 
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sorting protocol alone can improve the generation of an antigen-specific response and as a 
result improve an anti-tumour response in a mouse model of melanoma. In Chapters 4 
and 5, the B16F10.ova model was used to determine the potential benefit of CCR7-sorted 
DCs in the induction of an antigen-specific T cell response in solid tumour growth or 
metastasis models respectively. To support the translation of this protocol to clinical use 
and other potential cell therapies, work in Chapter 6 also adapted the sorting protocol for 
future GMP compliance. 
 
7.2 CCL19-sorted DCs have improved in vitro migration 
and function 
Discovery of novel DC subsets or improved culture conditions has improved in vivo DC 
function and potential efficacy as a cancer immunotherapy, but this efficacy is still limited 
if DCs do not migrate sufficiently to lymph nodes after injection. As previously discussed, 
multiple methods have been tested to improve migration to the lymph nodes, where DCs 
can contact and activate T cells, whether by using an alternative DC subset (Lundberg et 
al., 2013), adapting the culture methods to increase expression of surface molecules 
involved in migration such as CCR7 (Krause et al., 2009), or simply by different routes of 
injection such as directly into the lymphatics or lymph nodes themselves (Lesterhuis et al., 
2011). The advantages and disadvantages of these methods have also been discussed.  
To allow the data generated during the project to have the widest relevance, the most 
commonly-used DC generation protocols for mice and humans were chosen. In mouse 
models, bone marrow progenitors were expanded in ex vivo culture with GM-CSF alone, 
and stimulated using TNFα and LPS (Mac Keon et al., 2015). This culture produced a 
heterogeneous population of myeloid cells including uncommitted progenitors, 
macrophages and BMDCs (Helft et al., 2015), which can then be separated by expression 
of common DC markers such as CD11c but are most commonly used as a bulk population. 
These cells were characterised and used for experiments in Chapter 3. In humans, the 
majority of DC clinical trials use DCs manipulated ex vivo, with most of these developed 
from CD14+ progenitors using GM-CSF and IL-4 (Constantino et al., 2016). The cells in 
this study were matured using PolyI:C and PGE2. These cells were characterised and used 
for experiments discussed in Chapter 6. Although many novel protocols exist for 
improving DC function, these are not easily compared and difficult to standardise within 
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the current literature. In addition to this, in vitro functionality does not necessarily translate 
to in vivo functionality if DCs do not sufficiently migrate to the lymph nodes.  
In both Chapters 3 and 6, DC generation protocols resulted in at least one population of 
mature, activated DCs as determined by expression of CCR7, as well as MHC class II, 
CD86, and CD80 (in mouse) and CD86 (in humans) (de Vries et al., 2002). As shown in 
Chapter 3, DCs can be sorted for expression of CCR7 using both magnetic and flow 
cytometry-based bCCL19-sorting methods. CCR7+ cells were capable of immediate 
response to ligand after sorting and show greater migratory capacity to the lymph nodes 
draining the injection site. Using an unsorted DC population as a control, it was also shown 
that 10 times more unsorted cells were retained at the injection site than following CCR7+ 
DC introduction, and only half as many DCs reached the lymph node despite an equivalent 
cell number being injected. This is clinically relevant for two reasons. Firstly, expression 
of CCR7 on DCs is indicative of cell migratory capacity, given that only CCR7+ DCs are 
responsive to its ligand CCL19 both in vitro and in vivo. This is in agreement with findings 
by Le Brocq et al. in the original literature for this methodology (Le Brocq et al., 2014). 
Separation of these cells from a bulk population isolated the most capable cells for 
immediate migration to the lymph nodes. Secondly, the presence of CCR7- cells in the 
injected population which were retained at the injection site highlights the need to remove 
these cells from the bulk population. In mice, these cells are macrophages with some 
immature DCs (Figure 3.10), which were shown to actively produce innate-attracting 
chemokines as well as IL-16 (Figure 3.12). Not only did these cells not move to the LNs 
within their lifespan, limiting their therapeutic function, they may in fact have had a 
detrimental effect on migration of capable CCR7+ cells by competing for chemotactic 
signals. This was seen following footpad injection, where after injection of CCR7+ DCs 
alone there were very few cells still in the footpad at 48hr, but when unsorted cells were 
injected containing the same number of CCR7+ DCs more than 10 times the number of 
cells were found in the footpad (Figure 3.9).  
Retention of cells at the injection site was not thought to be simply due to an excess of 
cells as other studies have injected up to 5-fold more cells into the footpad with no 
apparent consequences to the viability of the injected cells in situ or in their migration to 
lymph nodes (Martin-Fontecha et al., 2003). In humans, CCR7- cells are primarily 
immature DCs which may not undergo subsequent maturation in vivo after injection due to 
tumour suppressing factors. Data presented here show that CCR7- cells produced innate 
immune-attracting chemokines, which could chemotactically confine DCs to the injection 
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site and therefore provide some mechanistic insights for retention other than physical 
constraint and poor cell survival in both mouse models and human clinical conditions 
(Verdijk et al., 2009). This may provide additional rationale for removal of the CCR7- cell 
population. 
Expression of CCR7 is also a marker of functionally mature DCs, and it was shown that 
only the CCR7+ DC population was capable of inducing a mature T cell response in vitro 
but not the CCR7- population. Using expression of CD44 and CD62L, it was shown that T 
cells stimulated by CCR7+ DCs were mature effector T cells and memory T cells, which 
showed almost no expression of the exhaustion marker PD-1 (Figure 3.13). In comparison, 
although the CCR7- cell population could stimulate T cells, these cells were primarily 
activated naïve T cells. The few mature T cells present in the CCR7- DC culture also 
expressed PD-1 as highly as the T cells stimulated with IL-2 alone, suggesting the 
activation of these cells without the development of memory observed in the CCR7+ cell 
culture. These data are consistent between DCs generated by both GM-CSF, and Flt3-L 
suggesting that in vitro expression of CCR7 on the cells, regardless of ontogeny, leads to 
the development of a more clinically relevant T cell phenotype. 
The benefit of DC therapy in comparison to other immunotherapies is the potential for both 
priming naïve T cell development as well as restimulating chronically activated and 
functionally inactive memory T cells (Klebanoff, Gattinoni and Restifo, 2012). Newly 
formed naïve and memory T cells generate CTLs, which are directly anti-tumourigenic 
(Palucka and Banchereau, 2013). These cell types were both produced in vitro only in 
response to CCR7-expressing DCs, suggesting that these cells might produce this desirable 
immune phenotype in vivo. Reactivation of endogenous memory T cell function is not 
assessable in the murine system, however, since freshly isolated T cells have not yet 
encountered the model antigen in this system so as a result have no existing memory of the 
antigen. In a human system, this can be assessed using EBV as a model antigen. Exposure 
to EBV is expected in up to 90% of the population, and as is associated with a prolonged 
latent infection and development of an immune memory against the antigen (Lennon, 
Crotty and Fenton, 2015). In Chapter 6, MoDCs presenting the EBV peptide were co-
cultured with T cells from 3 individual buffy coat donors to replicate the murine culture 
system. Although only one donor was reactive to the EBV antigen, expansion of a central 
memory T cell secreting IL-2 and an effector memory T cell secreting IFNγ, TNFα and IL-
2 was noted in response to the CCR7+ DCs alone (Figure 6.8). The generation of T cells 
expressing these three cytokines may confer superior cytotoxicity in an antitumour context, 
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as suggested by previous studies (Klebanoff, Gattinoni and Restifo, 2006). Taking care to 
not over-extrapolate the data, there is some evidence that CCR7+ DCs can therefore lead to 
expansion of therapeutically desirable T cell phenotypes, although it is clear that more 
replicates would be required for confirmation. 
Taking these in vitro data together, it has been shown that isolating CCR7-expressing DCs 
from a mixed culture was beneficial to both DC migration and functional activation of T 
cells. In confirmation of previous literature, CCR7+ DCs migrated more effectively to 
CCL19 in vitro as well as to the popliteal LN following footpad injection than cells lacking 
expression of the receptor. The CCR7- cells in the injection bolus were shown by flow 
cytometry to comprise immature progenitors, macrophages and immature DCs, and using 
Luminex analysis were shown to produce large amounts of innate immune cell-attracting 
chemokines which could cause an unwanted inflammatory effect or and led to retention of 
cells at the injection site. In addition to this, in vitro data suggest that these cells do interact 
with T cells. This has also been reported from in vivo studies (Helft et al., 2015). 
Combined immune stimulation data from mouse and human studies highlighted the 
production of CTLs and memory T cells to de novo antigens, as well as the reactivation of 
memory T cells in a recall response by CCR7+ DCs but not CCR7- cells. Both of these 
qualities are described as the ‘ideal’ T cell response to immunotherapy (Palucka and 
Banchereau, 2013). In a cancer context, CTL generation is required for efficient rejection 
of the primary or secondary tumours (Durgeau et al., 2018). Memory T cells both support 
CTL function and provide a prolonged antigen-specific response to control occult 
metastases which may develop later in life (Klebanoff et al., 2005). These data, therefore, 
show that CCL19-sorted DCs would have several benefits in a tumour context. 
 
7.3 CCL19-sorted DCs can improve the anti-tumour T cell 
response in the B16F10.ova model 
7.3.1 Solid tumour model 
The B16F10.ova model was used in this project to assess the effect of improving 
therapeutic DC migration on the anti-tumour immune response using single or multiple 
injection strategies in both solid and metastatic tumour development. The solid tumour 
model, in which tumour cells were subcutaneously introduced into the flank, is a widely 
used model for the study of novel therapies; although it doesn’t mimic the slow growth 
seen in many types of cancer (Mac Keon et al., 2015). In control animals, there is a 
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detectable tumour antigen (anti-ova) response primarily in the tumour-draining lymph 
nodes (Figure 4.3A, 4.7A, 4.11A). Similarly to human tumour data, tumour-specific T 
cells exist in the tumours, lymph nodes and circulation but do not sufficiently control 
tumour growth. This may be due to the immunosuppressive pressures of the TME in the 
human context - whether this is inhibiting their cytotoxicity or triggering cellular 
exhaustion (Thommen and Schumacher, 2018). After injection with CCL19-sorted DCs 
but not unsorted DCs, a significant increase in the development of antigen-specific T cells 
in both the injection-site draining lymph nodes and the spleen was seen suggesting a robust 
T cell stimulation by the sorted cells. Between 2 and 3-fold more T cells were seen in these 
tissues compared to the either the control or unsorted DC-receiving animals. This T cell 
expansion was also consistent regardless of the injection strategy: a single DC injection, or 
a second prior to or after tumour initiation. In the human setting this replicates quite well 
the development of a de novo response to a novel antigen (Butterfield, 2013). Early proof-
of-principle studies have shown that DCs can elicit de novo antigen-specific responses to a 
number of melanoma-associated antigens such as gp100 and MAGE-3, even in late-stage 
patients (Schuler-Thurner et al., 2000; Banchereau et al., 2001). This is supported by 
numerous later studies showing inducible responses to neoantigens presented by DCs 
(Carreno et al., 2015).  
After injection of unsorted DCs into the footpad there was no difference in immune 
response compared to the untreated controls, despite both the sDC and uDC-receiving mice 
having the same total number of CCR7-expressing cells in the injection bolus. It was 
shown in Chapter 3 that these cells can reach the LNs, but may fail to reach the threshold 
required for T cell activation (Kaech, Wherry and Ahmed, 2002). Taking these data 
together again confirms the first aim of the project that CCL19-sorting of DCs can improve 
their migration to the lymph nodes and induction of a T cell response in vitro. Despite 
injection of the same number of CCR7-expressing cells, the number of DCs reaching the 
injection site-draining LNs was not the same following injection of sorted or unsorted 
cells. In each of the injection strategies, injection of CCL19-sorted cells strongly supported 
the development of new naïve and memory T cells in the injection site-draining lymph 
nodes and spleen. Consistent with in vitro data presented in Chapter 3, these T cells were 
both naïve antigen-specific T cells and central memory T cells as determined using 
CD44/CD62L discrimination. Additionally, a second injection of DCs prior to induction of 
the tumour growth resulted in a largely effector T cell response, suggesting the expansion 
of an initial memory population (Palucka and Banchereau, 2013).  
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In both the single injection, and double pre-tumour injection ‘booster’ strategy, it was seen 
that injection of CCR7+ cells slowed the tumour growth rate and increased survival of the 
animals. Tumours did still reach the maximum tumour size. One mechanism of tumour 
escape from the immune system is downregulation of antigen presentation machinery or 
antigen shedding under immune pressure (Schreiber, Old and Smyth, 2011). It would be 
interesting to assess the antigen presentation of the tumour cells at the tumour end-point to 
see if any differences were seen in the mice receiving CCL19-sorted DCs compared to the 
control groups. Use of multiple TAAs, through tumour mRNA or lysate loading, has been 
shown to provide a more comprehensive anti-tumour T cell response (Garg, Vara Perez, et 
al., 2017) and prevent, for example, the survival of tumour cells which have lost surface 
expression of ovalbumin being used for tumour targeting (Neller, López and Schmidt, 
2008). This strategy has been shown to be feasible and effective in a number of clinical 
trials for cancers such as melanoma (Redman et al., 2008). When the second injection was 
given after the tumour development, however, no benefit in slowing tumour progression 
was seen (Figure 4.10) despite the strong induction of the same T cell distribution and 
phenotype seen previously. This is striking since almost all clinical trials using DCs utilise 
multiple injections to sustain the T cell response to reach clinical efficacy (Santos and 
Butterfield, 2018). Introduction of 1 or 2 injections of CCL19-sorted DCs prior to tumour 
development are both efficacious, but data here suggest that further DC injections after 
tumour development are not, despite an equivalent induction of T cell response in the 
injection-site draining lymph nodes and a higher number of antigen-specific T cells in the 
spleen.  
The second injection of DCs was closer to the first than is commonly seen in clinical trials, 
which are more likely to be 2 weeks or even months apart (Constantino et al., 2016). 
Injections in proximity to the same lymph node have also been shown experimentally to be 
detrimental to prevention of tumour growth in the B16 model (Ricupito et al., 2013) when 
the transplantation of the tumour itself can be considered an adjuvant to the generation of 
an anti-tumour immune response. Given that there is a quantifiable T cell response in the 
lymph nodes and the spleen, it could be possible that diverting the T cell response to an LN 
uninvolved in the tumour response allows early development of the early tumour, after 
which it is less susceptible to CTL control. This hypothesis is supported by early data from 
studies using this model (Brown et al., 2001). Stimulation of Treg generation by CD8+ T 
cells is another important possible mechanism for this unexpected detrimental effect of 
repeated T cell stimulation (Spranger et al., 2013). In summary the solid tumour model did 
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provide insights into the potential superiority of CCL19-sorted DCs which is applicable to 
a number of clinical tumour contexts.  
7.3.2 Metastatic tumour model 
In comparison to the subcutaneous model, there was no significant effect on the 
development of experimental metastasis after single or multiple DC injections. Treatment 
of metastasis is a major focus of novel cancer therapies as it represents up to 90% of cancer 
mortality depending on the type of cancer (Chaffer and Weinberg, 2011). In this project, 
the B16F10.ova model was used to induce ‘experimental’ metastatic lesions by intravenous 
injection. DC injection was given once or twice prior to induction of tumour formation, 
and the effect on metastatic development was assessed. In contrast to the solid tumour 
model, neither DC injection strategy had any significant effect on the number of lesions in 
the lungs of recipient mice compared to the controls. After a single injection of DCs, there 
were significantly fewer internal tumours within the lungs which may suggest a non-T cell-
mediated immune control of these tumours when taken together with the T cell data. These 
data were surprising given the wealth of clinical trial data showing efficacy in delaying 
metastasis as measured by overall survival particularly in melanoma (Bol et al., 2014; 
Alvarez-Dominguez et al., 2017; Dillman et al., 2018).  
Similarly to the solid tumour model, however, antigen-specific T cells were quantifiable in 
the injection-site draining lymph nodes and in the spleen; although this was not observed in 
the tumour-bearing lungs themselves. This is partially agrees with clinical trial data for 
metastases, in which patients receiving DCs had a measurable induction of antigen-specific 
T cells (Lim et al., 2007). T cell phenotyping was only done in the two-injection 
experiment, but the phenotype agreed with previous data from the same strategy in the 
solid tumour model. The injection-site draining lymph node and spleen both showed 
primarily an effector T cell response, but a very small number of memory T cells (Figure 
5.10A). The shorter experimental duration may be the cause of this, as murine T cells 
develop sequentially through these stages of maturity (Sallusto, Geginat and Lanzavecchia, 
2004) 
In addition to the considerations discussed in the previous section such as antigen selection 
and tumour-derived immune suppression, route of injection potentially contributes to the 
subclinical response observed in this model. For direct analysis of the draining lymph node 
T cell population, the popliteal LN-draining footpad injection strategy was again 
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performed. As part of the peripheral lymphatics, migration of DCs to the popliteal LN may 
not allow T cells access  to the central compartment which drains the lungs (Mullins et al., 
2003). Intravenous injection of DCs is commonly used in this model and has been shown 
to induce protective T cell immunity against metastatic B16F10 challenge (Matheoud et 
al., 2011; Markov et al., 2015), so appropriate alternative injection strategies would be 
worth pursuing to confirm the potential for clinical efficacy. Most DCs arrive in the spleen 
following IV-injection by the circulation without the need for active chemotaxis, but 
previous studies support a role for CCR7 in correct positioning within the spleen for T cell 
stimulation (Calabro et al., 2016). As discussed previously, CCL19-sorted DCs may still 
be superior in this case, but this would need to be addressed in future experiments.  
7.3.3 B16F10.ova as a model of human cancer development 
Human tumours develop through three immune phases, distinguishable by the 
characteristics of the tumour cells themselves and by their interaction with the host 
immune system: these are the elimination, equilibrium and escape phases. These stages 
were described in more detail in the Introduction but are relevant here to understand the 
role of T cells and the relevance of the DC therapy in this project. In the elimination phase, 
T cells and other immune cells can effectively control tumour growth through endogenous 
cytotoxicity mechanisms. This phase is difficult to observe in humans, but is supported by 
prevalence of tumour-specific T cells at clinical presentation as well as experimental 
mouse models in which cancer development can be induced (Vesely et al., 2011). Immune 
pressure alone can prevent this small initial lesion from developing further, but failure in 
control at this phase leads to further growth into tumour equilibrium. In this phase, 
proposed to be the longest stage due to slow proliferation, tumour cells continue to be 
subjected to immune pressure but undergo the process of editing and acquisition of the 
hallmarks of cancer as proposed by Hanahan and Weinberg (Hanahan and Weinberg, 
2011). The adaptive immune system is primarily responsible for restricting tumour growth 
during this phase as shown by experimental suppression of CD8 and CD4 T cells in a 
model of chemical carcinogenesis (Koebel et al., 2007).  
Under constant immune selection pressure, an evolution occurs in the presentation of 
antigen by tumour cells, presentation of antigen through MHC class I molecules is 
downregulated, or cells with less immunogenic antigens are selected for (Dunn et al., 
2002). Through the acquisition of further mutations and development of an 
immunosuppressive TME, tumours progress to the escape phase (Schreiber, Old and 
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Smyth, 2011). As a result, tumour growth becomes uncontrolled and leads to the 
presentation of detectable tumour masses and often, clinical presentation and diagnosis. By 
production of TGF-β or IDO, for example, or the upregulation of PD-1 expression, the 
tumours can directly suppress the function of T cells, even those introduced therapeutically 
(Vesely et al., 2011). The control of the T cell response is crucial to each of these phases 
and understanding of these mechanisms in both the murine model and human setting is 
important. Experimental murine models of tumour development are useful but not 
completely indicative of tumour development in the human clinical setting. The 
B16F10.ova model used in this project is a murine melanoma transduced to express the 
‘neoantigen’ ovalbumin. T cells generated in vivo in response to this tumour developing 
have not been subjected to the same thymic selection pressures which a human T cell 
might have been in the same context (Mac Keon et al., 2015). The tumour model also does 
not mimic the slow tumour growth seen in many types of cancer, with an extremely quick 
growth to the maximum size between 15 and 20 days post-transplant (Overwijk and 
Restifo, 2001). In the three-stage model of tumour development, the B16F10.ova model 
therefore reflects the initial elimination phase and progresses rapidly to the uncontrolled 
growth escape phase.  
To assess the T cell response in the absence of tumour-intrinsic suppressive mechanisms, 
DC injections were given prior to tumour development in both the solid (Chapter 4) and 
metastatic (Chapter 5) B16F10.ova model. It is likely, therefore, that T cells produced by 
CCL19-sorted DCs used here augment the natural anti-tumour response. This is apparent 
from the differences in solid tumour growth at the earliest detectable stage, where mice 
receiving CCL19-sorted cells showed significantly smaller subcutaneous tumours than 
either control group. Since no further DC injections were given in these dosing strategies, 
T cells induced by the DC injections have a similar function to those in the elimination 
phase when the tumour immunosuppressive mechanisms have not yet developed. Clinical 
use of DCs in patients at high risk of metastatic tumour occurrence has been shown to be 
up to 3 times more effective in the induction of an immune response compared to those 
with active metastatic disease (Bol, Aarntzen, et al., 2016). In vitro, or immediately after 
injection, B16 cells do not express common immune suppressive mechanisms such as IDO 
or PD-L1 but these do increase with increasing CD8+ T cell infiltration into the tumour 
mass (Spranger et al., 2013). This is indicative of the tumour escape phase, as described 
previously. Given the rapid progression of the tumour to this stage it is technically 
challenging to assess DC function in this context, although it would be more clinically 
viable. It has been shown by meta-analyses of clinical data that increasing tumour volume 
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negatively correlates with the success of immunotherapeutic approaches (Gulley, Madan 
and Schlom, 2011).  
The increased magnitude of the T cell response, both in the production of antigen-specific 
T cells and the development of antigen memory, was shown in these experiments to 
prolong animal survival in the solid tumour model, although it did not prevent tumour 
growth. Without a timepoint earlier in the tumour development, such as 1 or 2 weeks post-
transplant, it is difficult to suggest a reason for this other than T cell insufficiency against 
the rapidly growing tumour. Since it can be seen that sorted DC-receiving mice still have 
significantly more antigen-specific T cells at the maximum tumour growth (Figure 4.3, 
4.7, 4.11), the hypothesis is that at this point the tumour milieu is actively suppressing T 
cell function (Fransen, Arens and Melief, 2013). This is consistent with the significant 
number of antigen-specific T cells present in the tumour-draining lymph node in the 
control mice which have no apparent effect on the progression of tumour growth . To 
clarify this, profiling the tumour for expression of IDO or PD-L1 (Spranger et al., 2013), 
or other more general immune suppressors such as TGF-β or vascular endothelial growth 
factor (VEGF) known to be important in the B16 melanoma model (Courau et al., 2016), 
may help clarify the mechanism of suppression to allow therapeutic manipulation. Future 
tumour models could explore the immune response earlier in the tumour development to 
assess the effect of CCL19-sorted DC therapy at earlier stages in the tumour progression, 
and correlate this with progression of the tumour between the elimination, equilibrium and 
escape phases.  
Taking this into consideration, these in vivo data may not fully recapitulate the human 
cancer context and it would be important to fully characterize the response to CCL19-
sorted DCs in a more clinically relevant model. Other mouse models of tumour 
development may lead to mechanistic insights into the development of an immune 
response following DC injection, and how the suppressive tumour milieu interacts with 
this immune response. As described in Chapter 5, a number of alternative models exist 
which could better replicate the human cancer context. The ideal model would consist of a 
primary tumour which can be treated with the DC therapy at this stage but could continue 
on to develop metastatic lesions which could also be used to assess DC function. Our 
current in vivo data support the development of a supplemented primary immune response, 
which could be relevant in a human context using tumour neoantigens or whole tumour 
lysates to target antigens more poorly expressed by the primary tumour or expressed by 
occult metastatic lesions (Dillman, 2017).  
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7.3.4 Combination therapies using CCL19-sorted DCs are a 
potential future strategy to increase therapeutic efficacy 
Although DC function and migration to lymph nodes is crucial to the improvement of DCs 
as a cell therapy for cancer, in many of these contexts the subversion of the immune 
system by the tumour still limits the therapeutic T cell response induced. The combination 
of DC vaccination with chemotherapy may seem counterintuitive given the leuko-depletive 
effect of many chemotherapeutic agents but has been shown to improve survival in a 
number of clinical trials. Cytotoxic regimens using chemotherapy such as the alkylating 
agent, dacarbazine or an antimetabolite such as methotrexate can have beneficial effects in 
this context, releasing tumour antigens from dying tumour cells and increasing their 
expression of danger signals and deletion of immune suppressing immune cells such as 
Tregs within the TME (Butterfield, 2013; Bracci et al., 2014). Use of these regimens in 
combination with DC therapy is becoming more common, defined as a 
chemoimmunotherapy (Anguille et al., 2014). As a standard-of-care treatment, many 
patients enter into DC clinical trials having previously undergone chemotherapy, and those 
undergoing next generation trials are already being treated with the combination of 
therapies (Garg, Vara Perez, et al., 2017). A similar chemotherapeutic approach could be 
used in future animal models to assess the benefit of CCL19-sorted DCs in this more 
clinically-relevant context.   
T cell suppressive mechanisms are highly involved in late stage cancer and further limit the 
efficacy of adoptively transferred T cells and DC therapies alike. Future advances in the 
immunotherapeutic approach may, therefore, require blocking these pathways to ensure 
consistent T cell activation. CTLA-4 was one of the original targets chosen for this use in 
metastatic melanoma using the monoclonal antibody Ipilimumab (Hodi et al., 2010). 
CTLA-4 is expressed by T cells, is structurally similar to CD28 and binds the same 
ligands; CTLA-4, however, acts as an agonist to CD28 and prevents its signaling during 
TCR engagement, and suppresses T cell activation (Teft, Kirchhof and Madrenas, 2006). 
Increased expression of CTLA-4 occurs on T cells following frequent TCR stimulation, 
and functionally limits T cell proliferation (Melero et al., 2007). Conversely this is 
desirable in cancer, reactivating the exhausted tumour-specific T cell response and 
allowing recovery of cytotoxicity (O’Day, Hamid and Urba, 2007). Prolonging the T cell 
response by combination therapy of CCL19-sorted DCs with anti-CTLA-4 antibodies is 
therefore a viable treatment strategy and ensures that the threshold of T cell responses is 
consistently reached. Interestingly, in early use of anti-CTLA-4 antibodies in poorly 
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immunogenic tumour contexts, prior vaccination strategies, including using DCs, were 
required for maximum efficacy (Chambers et al., 2001). This regimen has been tested in 
several small clinical trials, showing that the combination of anti-CTLA-4 antibodies and 
DCs lead to CR in 20% of the treated patients and PR in 18% compared to matched control 
patients, with anti-tumour T cells detectable in the peripheral blood (Ribas et al., 2009; 
Wilgenhof et al., 2016). Another mechanism for T cell suppression discussed in the 
previous section is expression of PD-L1 by tumour cells, which interacts with PD-1 on T 
cells to inactivate them (Zarour, 2016). Blockage of PD-1 on T cells (Brahmer et al., 
2012), or PD-L1 on the tumour cells (Brahmer et al., 2012) using specific monoclonal 
antibodies are similarly viable strategies to CTLA-4 blockade. A number of clinical trials 
using either anti-PD-1 or anti-PD-L1 antibodies in combination with DC therapies are 
currently recruiting (Bol, Schreibelt, et al., 2016). As PD-1 has been shown to be 
expressed by B16F10 tumour cells, blocking this T cell checkpoint may be of benefit in 
this model in both the control and CCL19-sorted DC-receiving animals which have a 
robust but non-functional T cell repertoire. The combination of both anti-CTLA-4 and anti-
PD-1 antibodies has been used successfully in the B16 model and resulted in expansion of 
antigen-specific T cells and depletion of immune suppressive cells, suggesting that 
incorporation of DCs might further improve this (Curran et al., 2010).  
7.3.5 Summary of dendritic cell therapy 
Evidence presented in this project shows the benefit of sorting CCR7+ DCs for cancer 
therapy, given the decrease in tumour burden and increased survival in these in vivo 
models. This highlights the CCL19-sorting protocol as potentially beneficial in these 
regimens and confirms the hypothesis that focusing on cell migratory capacity alone can 
improve therapeutic outcome. Although it is clear many studies focus on strengthening the 
phenotype of the DC to improve the generation of an anti-tumour T cell response using 
novel strategies (Constantino et al., 2016), such as the source of DCs, maturation cocktails, 
and route of injection, limited cell migration will always limit therapeutic efficacy if DCs 
cannot reach T cells to activate them. Data presented in Chapters 3-5 show that CCL19-
sorted DCs are more capable of migrating and stimulating anti-tumour T cells, which can 
slow tumour growth and improve survival in the subcutaneous B16F10.ova model. In 
Chapter 6 it was shown that this protocol is adaptable to GMP DC production as required 
for use in clinical trial vaccinations, using GMP-compliant reagents for development of the 
DCs ex vivo and the MACSQuant Tyto (Miltenyi Biotec) - a closed-system clinical-grade 
cell sorter. With the ability to purchase chemically-synthesised CCL19 and other 
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chemokines at GMP-grade, these preliminary data support the benefits of CCR7-sorting 
human MoDCs and growing efficacy data on the superiority of CCR7-sorted BMDCs in a 
melanoma model, this project offers the direct applicability of the CCR7-sorting 
methodology to future clinical trials using DC vaccines.  
 
 
Figure 7.1 - Modifying current clinical protocols for dendritic cell production to include 
CCR7-sorting. 
The CCR7-sorting methodology described here can be easily adapted into current clinical trial 
methodologies using patient-derived monocytes (grey) to separate CCR7+ DCs (purple) from 
CCR7- DCs (pink) (*: general steps which are variable between studies). 
 
7.4 Improved DC migration is relevant in non-cancer 
clinical contexts 
7.4.1 Antiviral therapies 
There are a number of alternative contexts in which DC vaccination may be of benefit in 
addition to cancer; DC therapies can induce strong and durable antigen-specific responses 
in patients with chronic infections such as Human immunodeficiency virus (HIV). HIV is 
most commonly treated with combined antiretroviral drug therapy (cART), which 
suppresses viral replication and allows reconstitution of the depleted CD4+ compartment 
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specifically targeted by the virus (Vrisekoop et al., 2015). Although able to lower viral 
titres to undetectable and non-transmittable levels, cART cannot induce an HIV-specific 
immune response and therefore cannot completely ‘cure’ the infection requiring patients to 
be on cART indefinitely(van den Ham et al., 2018). This is reported to be due to 
incomplete distribution of cART through the body, which leads to continued replication in 
restricted anatomical sites such as the gut and LNs (Lorenzo-Redondo et al., 2016).  
Alternative, or complimentary, strategies focus on this aspect of treatment; with DC 
therapy a potential option. In particular, the ability of DCs to cross-present antigens to 
CD8+ T cells without requirement for CD4+ cooperation (Fonteneau et al., 2003) makes 
them especially attractive as a therapy because CD4+ T cells are depleted in untreated HIV 
patients or those beginning cART. In completed clinical trials, DC vaccines show a modest 
success but broad conclusions again are limited by the variety of DC preparations and 
maturation cocktails, cell number, antigen selection, and injection strategy (Miller and 
Bhardwaj, 2014). Importantly, migration of cells post-injection has been highlighted as a 
potential concern – resulting, in part, in the need for different injection strategies (García 
and Routy, 2011) or indeed, methods to improve cell migration to the lymph nodes such as 
sorting for CCR7 expression. One of the first of these studies in 2004 showed that 3 
intradermal injections of HIV-mRNA loaded MoDCs was able to elicit HIV-specific CD4+ 
and CD8+ T cells in patients, with half of those experiencing these responses for at least 1 
year (Lu et al., 2004). Interestingly, the investigators measured draining lymph node size 
which could be used a surrogate measurement of DC migration following injection, but for 
obvious medical reasons were unable to quantify this migration. DC phenotype was 
assessed for quality control purposes but did not include analysis of CCR7 expression – 
although other markers of maturity such as CD80, CD83 and CD86 were upregulated to 
greater than 70% expression in the injected bolus.  
A more recent study using ASG-004, an MoDC product with electroporated HIV-specific 
mRNA encoding HIV-1 Gag, Nef, Rev and Vpr genes, has also shown the ability to induce 
functional anti-HIV immune responses in patients with chronic HIV infection in a small 
trial (Gay et al., 2017). In this study, it was shown that conversion of the existing central 
CTL immunity to an effector CTL immunity may be influential in viral control, but in 
neither this study nor previous studies using ASG-004 (Routy et al., 2010) was the 
migration of DCs to the lymph node assessed. Development of a measurable anti-HIV 
immune response is typically seen, although control of viraemia is not consistent between 
trials (García and Routy, 2011).  In the absence of migratory information of anti-HIV DC 
therapies, it would be interesting to explore if the quality of cell migration is limiting 
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therapeutic efficacy as is the leading hypothesis in cancer vaccination, and if improving 
this leads to efficacy as shown here.  
In chronic Hepatitis C infection, a strong antiviral T cell response has been shown to be 
able to clear the virus again making DC vaccination a viable therapeutic option (Zhou et 
al., 2012). Current treatment includes interferon and ribavirin but this is only effective in 
about half of patients (Poynard et al., 2002), and with a third of patients eventually 
progressing to cirrhosis and then liver failure, hepatitis C is a major public health risk. DC 
vaccines have been shown to induce strong anti-hepatitis C T cell responses in a mouse 
hepatitis C antigen-expressing tumour, resulting in control of tumour growth and validating 
the efficacy of the generated T cell response (Encke et al., 2005). This study uses peptide-
pulsed, subcutaneously-injected DCs for therapy, but did not assess migration of the DCs. 
It also showed a prophylactic benefit to the tumour challenge, as shown with the 
prophylactic injection strategy presented in 4.3, which opens up an interesting avenue for 
the use of DCs prophylactically in addition to use as a treatment option to support 
conventional vaccines. In human hepatitis C infection, DC clinical trials have shown 
detectable antigen-specific T cell induction but no viral clearance, suggesting insufficiency 
of T cell induction to be the primary reason for the lack of efficacy (Zabaleta et al., 2015), 
and not immune suppression as seen in cancer. This study also highlighted the differences 
between patient-derived and healthy control-derived DCs in function, which may require 
identification of an alternative source of cells for therapy depending on the disease context 
of the individual.  
7.4.2 Antifungal therapies 
Finally, DCs have been used as anti-fungal therapies in the context of stem cell 
transplantation. Aspergillosis, infection by fungi of the Aspergillus genus particularly A. 
fumigatus, occurs insidiously in approximately 10% of haematopoietic stem cell transplant 
(HSCT) recipients as side effect of immune suppressive regimens (Marr, 2008). The 
highest risk period for Aspergillosis is 60-90 days post-transplant even with prophylactic 
anti-fungal drug treatment. Despite occurring in up to 10% of HSCT recipients, 
Aspergillosis symptoms are difficult to diagnose and the infection still has a high mortality 
rate (Miceli et al., 2017). Uptake of fungal spores and components induce a potent anti-
tumour function in DCs, shown experimentally as an increase in IL-12 production and a 
subsequent induction of Th1-mediated anti-fungal immunity in vivo (Bozza et al., 2002). 
In T-cell depleted mice, anti-fungal DC vaccination induced accelerated reconstitution of 
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aspergillus-specific T cell responses compared to the slow recovery of the response in the 
untreated group (Bozza et al., 2003) which prevent infection upon subsequent challenge. 
Cell migration in this study showed limited migration to the lungs, and lymphoid tissue 
including thoracic lymph nodes and thymus. During T cell reconstitution, it may be of 
benefit to guide more DCs to the thymus and lymph nodes for direct T cell education than 
to the periphery; for which CCR7-sorting could be useful. This response can also be 
replicated in a human in vitro context, supporting the translation of this strategy to the 
clinic (Grazziutti et al., 2001). Induction of IL-12 production by DCs using mRNA has 
been shown to enhance defence against intracellular pathogens such as Leishmania as both 
a prophylactic and therapeutic treatment (Ahuja et al., 1999; Roy and Klein, 2012). Both 
MoDCs and pDCs (Matsuse et al., 2017) have been shown to contribute the anti-fungal 
response, particularly in the lungs, but crucially require LN migration to transfer fungal 
antigens to LN-resident DCs for this function (Ersland, Wuthrich and Klein, 2010). In 
combination with the development of anti-fungal DC preparations, it is possible that 
CCR7-sorting cells could be used to direct cell migration to the LNs.  
 
7.5 Chemokine-based sorting can be adapted to other 
cell therapies 
7.5.1 Cytotoxic T cells 
Finally, the chemokine system is relevant to not only DC migration, but to the migration of 
several immune cell types with a potential for therapeutic use. Chemokine receptors are 
expressed by most, if not all cells of the immune system, and control migration to specific 
tissues in addition to having functional implications (Stein and Nombela-Arrieta, 2005). Of 
these immune cells, T cells may be the most therapeutically viable cells, and are currently 
used as therapies in a number of clinical contexts such as metastatic melanoma (Rosenberg 
et al., 2011). Tumours, and tumour-associated stroma, actively secrete chemokines and 
attract both pro- and anti-tumourigenic immune cells. In breast cancer for example, 
secretion of CCL2 and CCL5 is one of the initial driving mechanisms behind recruitment 
of macrophages to the developing tumour which become pro-tumourigenic TAMs and are 
prognostically very poor (Ben-Baruch, 2006). The same chemokines in ovarian cancer and 
melanoma, however, attract T cells and expression is beneficial to tumour control and 
regression (Harlin et al., 2009). T cells express a number of cancer-relevant chemokine 
receptors which control their tumourigenicity to a certain extent, including CCR1, 2, 3, 4, 
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5, 6, 7 and 8 and CXCR1, 2, 3, 4 and 5 (O’Garra, McEvoy and Zlotnik, 1998). Despite 
isolation of TILs from the actual tumour milieu, migration of these cells to primary or 
secondary sites after expansion and reinjection is lower than expected (Fisher et al., 1989). 
If tumour biopsies were analysed for their chemokine production, it could be possible to 
sort ex vivo-derived therapeutic T cells for expression of the matching chemokine receptors 
to target them directly to the tumour for function. This concept was first proposed by 
Kershaw et al. in 2002, who showed that matching cell expression of CXCR2 with 
secretion of CXCL1 by melanoma cells was sufficient to induce tumour tropism (Kershaw 
et al., 2002).  
This matching strategy was also shown to be successful in the directed migration of 
activated T cells expressing CCR2 to tumours highly expressing CCL2 in models of 
lymphoma and melanoma (Brown et al., 2007). In response to these studies, chemokine 
receptor upregulation by transduction has been highlighted as a potential improvement to 
therapeutic T cell homing to tumours: both CCR2 and CXCR2 have been transduced in T 
cells for successful treatment of melanoma (Garetto et al., 2016; Idorn et al., 2018). Idorn 
et al. also showed that the chemokine receptor repertoire of in vitro-expanded TILs stays 
relatively consistent over culture suggesting that cell sorting methods could be beneficial 
since the pre-expansion receptor expression is maintained during culture. Sorting T cells 
for the chemokine receptors which bind chemokines produced by the tumour, for example, 
CCL2 or CCL5, may help increase T cell migration to the tumour following injection and 
also remove T cells which cannot reach it (Ben-Baruch, 2006). The limited trafficking of 
engineered CAR T cells to tumours (Kakarla and Gottschalk, 2015) could also be 
supplemented with selection of cells for chemokine receptor expression. Current novel 
CAR therapies have used lentiviral transduction of CCR2 expression for CAR T cells to 
improve migration to the tumour as it was seen that after extended culture only 7% 
retained expression of the receptor (Moon et al., 2013). This improved tumour-specific 
migration, as the non-transfected control cells remained in the blood. Sorting the cells by 
expression of the receptor may prove beneficial, however, in overcoming the technical 
limitations of multiple rounds of lentiviral transfection for addition of the chimeric 
receptor, and then addition of the chemokine receptor; or may even be beneficial for 
isolating only the successfully transfected cells after these steps. 
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7.5.2 NK cells 
To circumvent the need for in vitro availability of a specific antigen, NK cells have 
become a recent attractive target for therapeutic use. In the context of cancer, NK cells are 
directly cytotoxic independent of MHC-recognition and contribute to tumour surveillance 
(Imai et al., 2000). Intratumoural NK cell infiltrate is associated with a good prognosis in 
gastric carcinoma (Ishigami et al., 2000), lung cancer (Villegas et al., 2002) and renal cell 
carcinoma (Geissler et al., 2015). Interestingly, T cell infiltrate into renal carcinoma 
lesions has been observed to be a poor prognostic factor (Igarashi et al., 2002), justifying 
the development of non T cell-based immunotherapies. Again, however, poor migration of 
NK cells derived from in vitro expansion to tumours limits their efficacy, although NK 
cells have been shown to express a number of relevant chemokine receptors for tumour-
specific migration including CCR2, CCR5, CXCR1 and CX3CR1 (Bernardini et al., 
2016). Additionally, expression of particular chemokine receptors is linked to cytotoxicity 
such as CXCR1 (Cooper, Fehniger and Caligiuri, 2001) so application of a chemokine 
sorting methodology may be beneficial to not only cell migration but cell function as 
shown here with dendritic cells.  Directed expression of chemokine receptors such as 
CXCR2 by viral transfection has been shown to improve cell homing to CXCL1 and 
CXCL5 produced in renal cell carcinoma (Kremer et al., 2017), which supports a focus on 
the chemokine receptor of potential NK cell therapies. 
 
7.6 Conclusion 
Dendritic cells are a valuable potential cancer therapy, although their efficacy is currently 
limited outside of a small percentage of clinical trials. A number of factors may account for 
this, but the lymph node migration of cells generated in vitro is poor and insufficient cell 
numbers reach the lymph node to induce an effective anti-tumour T cell response. Sorting 
dendritic cells for expression of the chemokine receptor CCR7, crucial for lymph node 
migration, allows more cells to reach the lymph node, improves cell function and the T cell 
response and this leads to a reduction in tumour growth in a model of subcutaneous 
melanoma. This modification to current clinically-used protocols may therefore inform and 
be incorporated into future clinical trials to help ensure a robust T cell response in all 
patients and may improve tumour survival as shown here. In addition to this, the 
chemokine sorting methodology presented in this thesis is broadly applicable to a number 
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of cell therapies in different disease contexts outside of DC therapy and has been shown to 
be relatively easy to accommodate at a GMP-compliant level. 
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Appendix I  
 
Generation and characterisation of the B16F10.ova 
cell line 
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A.1 Introduction and aims 
As described in the Introduction, a mouse model of metastatic melanoma was used to 
assess the potential benefit of CCL19-sorted DCs as a therapy for cancer. The main aims of 
this Chapter are to describe the generation of this cell line, its validation and 
characterisation as a model before use in the experiments detailed in Chapters 4 and 5. 
Mouse models of cancer are an extremely valuable tool for the development of new 
therapies and have been used in the field from as early as 1943 (Gross et al., 1943). The 
B16 melanoma is an example of one such model, which was first isolated from the 
C57BL/6 mouse strain and gave rise to two tumour cell lines known as B16F1 and 
B16F10. These lines are widely used as both solid primary tumour and secondary 
metastatic tumour models. The original cell line, B16F1, can produce subcutaneous 
tumours but very variable systemic metastases compared to the B16F10 cell line which has 
been selected over 10 generations for metastatic potential to the lung after IV injection in 
addition to subcutaneous tumour formation by injection into the skin (Ishiguro et al., 
1996). The B16F10 model was used in this study to allow study of both primary and 
secondary tumour development and will be the model discussed for the rest of this 
Chapter. The tumour is described as syngeneic given its C57BL/6 background, and as a 
result grows quickly in these mice receiving the tumour cells by injection either 
intravenously or subcutaneously. To allow in vivo targeting of the tumour by potential 
therapies, the cell line is commonly transduced to express a known foreign protein.  
For use in this project, the B16F10 cell line was engineered to express the chicken egg 
protein ovalbumin. Several methodologies exist for introduction of this antigen including 
transfection of the MHC-restricted epitopes of ovalbumin - OVA257-264 and OVA323-339 for 
MHC class I and II respectively - or an MHC-fused epitope, but in this project transfection 
of the whole protein coding sequence (cDNA) was chosen to elaborate the whole protein to 
allow processing and presentation of antigen by endogenous APCs during the progression 
of tumour development because this mirrors the clinical context (Huang et al., 1994). The 
transfection was validated also using microscopy, QPCR, flow cytometry and a functional 
T cell cytotoxicity assay. 
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A.2 Generation of B16F10.ova 
A.2.1 OVA gene source 
The plasmid vector pOVA, which encodes the full-length cDNA sequence of chicken 
ovalbumin, was a kind gift from Shoshana Levy (Addgene plasmid #31598). The plasmid 
was given transformed into Escherichia coli (E. coli), which were first expanded by 
streaking the bacteria along agar plates containing 50ng/ml ampicillin and incubating 
overnight at 37ºC. Colonies were then picked from the agar plates using sterile pipette tips 
and introduced into a conical flask containing 50ml of liquid agar broth containing 
50ng/ml ampicillin. The flask was incubated at 37ºC overnight on a moving plate mixer. 
The plasmid was then extracted from the bacterial cells using the PureLink HiPure Plasmid 
DNA Purification (Midiprep) Kit (Invitrogen) according to the manufacturer’s instructions, 
and the DNA content of the eluted fraction was quantified by nanodrop (Nanodrop 1000, 
Thermo Scientific). 
A.2.2 Subcloning OVA gene into an expression vector 
PCR outer primers for amplifying ovalbumin cDNA were designed to incorporate the 
EcoRI and ApaI restriction sites to allow ligation of the DNA fragment into the pEGFP-N3 
mammalian expression vector (BD Biosciences) under the control of the cytomegalovirus 
(CMV) gene promotor. As shown below, the ApaI reverse primer was additionally 
designed to include a STOP codon to prevent ligation of the ovalbumin cDNA sequence to 
the green fluorescent protein (GFP)-tag present in the plasmid during transcription. Primer 
sequences were designed based on the ovalbumin and primer sequences from Maecker et 
al., (1997) and McReynolds et al., (1978). These sequences are listed in Table A.1 below. 
Table A.1 - PCR primers used in cloning OVA into pEFGP-N3. Restriction sites for the specified 
restriction enzymes are highlighted in red. 
 
Ovalbumin cDNA was amplified from the pOVA eluate (A1.1) by PCR using the Q5 
High-Fidelity DNA Polymerase (Qiagen) as described in 2.4.2. The reactions were run in a 
thermal cycler using the following program, and are specific for amplification of the longer 
ovalbumin gene fragment: 
Primer Name Primer Sequence 
EcoRI-OVA (Forward) 5’- CCCCGGAATTCATGGGCTCCATCGGCGCAGC - 3’ 
ApaI-OVA (Reverse) 5’- TTATAGGGCCCTTAAGGGGAAACACATCTGC - 3’ 
193 
 
* Specific melting temperature of the primers designed, ** Extension time was for the 1200bp DNA 
fragment at a rate of 40 seconds/kb of DNA. 
 
The ovalbumin cDNA was then purified from the PCR reaction mixture using the PCR 
Purification Kit (Invitrogen) according to the manufacturer’s instructions. To validate the 
size of the fragment, the PCR product described previously was run on a 1% agarose 
electrophoresis gel which was prepared as described in 2.4.3. The fragment was sequenced 
for confirmation (Eurofin Genomics). 
To incorporate the cloned fragment into the plasmid, both the fragment and recipient 
plasmid (pEGFP-N3) were digested using the EcoRI and ApaI restriction enzymes. The 
digestion was prepared using the following enzyme mix, with one sample used as a no 
enzyme control reaction: 
 
 
ApaI was added first; the samples were vortexed briefly and incubated at 25ºC for 8 hours, 
after which EcoRI was added and the samples incubated at 37ºC overnight. Digestion of 
fragment and plasmid was validated by electrophoresis on a 0.8% agarose gel. Prior to 
introduction of the ovalbumin gene fragment, the plasmid prep was treated with 
phosphatase enzyme to reduce re-ligation of the plasmid before introduction of the 
plasmid. The enzyme mix for the ligation was set up as described below, with one sample 
used as a no insert control to assess for spontaneous re-ligation of the plasmid: 
  
Step Temperature (ºC) Time  
Initial denaturation 98 3 minutes  
Denaturation 98 10 seconds  
Annealing 63* 30 seconds Repeated for 35 cycles 
Elongation 72 55 seconds**  
Final elongation 72 10 minutes  
Hold 4 Indefinitely  
Ingredient Volume (μl/reaction) 
Restriction enzyme – EcoRI and ApaI 1 
Reaction buffer 10 
Template DNA  
 OVA gene fragment Up to 100 
or Plasmid 5 
 Double-distilled Nuclease-free Water Up to 100 
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* OVA gene fragment concentration was determined using the following formula:  
	 
     	   3  
 
The samples were then left at 4ºC for 20 hours to allow ligation. 
 
 
Figure A.2 - pEGFP-N3 OVA schematic.  
Functional regions (clockwise from top) are: Cytomegalovirus (CMV) promoter; Ovalbumin gene; 
eGFP gene present in plasmid but not expressed; sV40 pA; Bacterial and mammalian promoter; 
Neomycin resistance gene; HSV pA; pUC origin of replication. 
 
A.2.3 Expansion of construct in E. coli 
To amplify the constructed plasmid, chemically-competent E. coli were used (XL10-Gold 
cells, Agilent Technologies). The vial was defrosted from -80ºC storage on ice, and 5μl of 
each ligated and re-ligated plasmid was added. After a brief agitation of the contents using 
Ingredient Volume (μl)/Concentration 
Plasmid 100ng 
OVA gene fragment 76.13ng* 
Ligase enzyme 0.5 
Reaction buffer  1 
Double-distilled Nuclease-free Water Up to 10 
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a pipette, the vial was left on ice for 30min. Following this, the cells were heat-shocked by 
placing in a water bath at 42ºC for 45 seconds before immediate return to ice for 3min. 
250μl of super-rich agar broth was added to the vial, which was then incubated in a thermal 
mixer at 37ºC for 60min. The cells were streaked on two agar plates containing 25μg/ml 
kanamycin for selection of successfully transformed cells. One plate had 20μl of the broth 
streaked onto it; the remaining broth was centrifuged in a microcentrifuge at maximum 
speed (approx. 12000xg) for 30 seconds and the supernatant discarded. The pellet of 
bacteria was manually agitated to homogenise the concentration of bacteria in the 
remaining broth. This broth was then added undiluted to the agar plate in the event of 
minimal successful plasmid ligation. The plates were incubated at 37ºC overnight. From 
these plates, 12 clones were picked from the 20μl dilution plate, and were streaked onto 
new agar plates divided visually into 6 sections. 
A.2.4 Validation of construct 
The correct insertion of the ovalbumin cDNA was assessed by restriction enzyme digestion 
and gel electrophoresis as described previously. First, small colonies from each of the 12 
sections were picked using a sterile pipette tip and added to 50μl distilled water. These 
colony samples were ‘boiled’ for 10min in a thermal cycler, and 1μl of this preparation 
was amplified using PCR using insert-spanning primers (Table A.2) as described 
previously and validated by electrophoresis on a 0.8% agarose gel. 
Table A.2 - PCR primers used for plasmid validation.  
 
 
As shown in Figure A.3A, from one plate of 6 clones, 4 clones successfully incorporated 
the 1.42kb ovalbumin cDNA into the plasmid as indicated by the presence of bands 
between 1kb and 1.5kb (lanes 1, and 3-5). These clones were selected for overnight culture 
in 5ml liquid agar broth supplemented with 25μg/ml kanamycin. The plasmid was 
extracted from the expanded colonies using the QiaPure MiniPrep system (Qiagen), as per 
the manufacturer’s guidelines. To ensure the correct orientation of the insert within the 
plasmid, 3 restriction enzyme digests were prepared using the following enzyme mixes. 
 
Primer Name Primer Sequence 
CMV promoter (Forward) 5’-  TGGCACCAAAATCAACGGGACT - 3’ 
eGFP (Reverse) 5’-  CGTCGCCGTCCAGCTCGACCAG - 3’ 
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The samples were validated by electrophoresis on a 0.8% agarose gel as described 
previously. 
 
Figure A.3 - Validation of OVA plasmid.  
A) Detection of ovalbumin cDNA insertion by site-spanning primers in 4 of 6 selected clones (lanes 
1-6). B, C) Restriction enzyme digest with PvuII (B; lane 2), and EcoRV + AvrII (B; lane 3), or NotI-
HF (C; lane 3) for selected clone (in B and C, lane 1 is undigested plasmid control). 
 
To confirm the direction of the insert, three sets of restrictions were then performed to 
yield bands of known sizes. PvuII, which has three restriction sites on the plasmid 
construct, gave bands of 608bp, 2348bp and 2916bp (Figure A.3B). Similarly, the 
combination of EcoRV and AvrII restriction enzymes gave bands at 1015bp, 2113bp and 
2744bp. NotI-HF was also used as it cut the plasmid only once, resulting in a full-sized 
band of 5.8kb total (Figure A.3C). The direction of the ovalbumin coding sequence was 
therefore determined to be correct in the plasmid. The full plasmid was also sequenced 
(Eurofin Genomics) for confirmation of the gene sequence and the absence of minor 
genetic changes known as single nucleotide polymorphisms (SNPs). 
The selected clone was swabbed from the original plate and incubated at 37ºC in 5ml of 
agar broth supplemented with kanamycin, and subsequently expanded in 200ml of agar 
Ingredient Volume (μl)/Concentration 
Plasmid DNA 1ng 
Restriction enzyme – PvuII, EcoRV + AvrII, NotI-HF 0.5 
Reaction buffer 2 
Double-distilled Nuclease-free Water Up to 20 
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broth in a conical flask. The final plasmid was extracted from the bacterial cells using the 
Qiagen EndoFree Plasmid Maxi Kit (Qiagen) as per the manufacturer’s instructions and 
the concentration quantified by nanodrop. 
A.2.5 Stable transfection of B16F10 cells 
B16F10 cells were grown to 70-80% confluence in 25cm3 tissue culture flasks under 
normal culture conditions (described in 2.1). The transfection reaction mixture was created 
by first adding 2μl Lipofectamine 2000 to 25μl Opti-MEM medium (Invitrogen). A second 
mixture was prepared by adding 500ng linearised plasmid DNA to 25μl Opti-MEM 
medium. These values had been previously determined by optimisation. B16F10 cells were 
transfected with both the ovalbumin plasmid construct described previously to induce 
production and presentation of ovalbumin epitopes, and the mRuby2 plasmid to make the 
cells express this fluorescent protein. Each plasmid was linearised as described previously 
using the enzymes in Table A.3. 
Table A.3 - Restriction enzymes used for plasmid linearization. 
 
 
The two mixtures were then combined by pipetting and incubated at room temperature for 
5min to allow complex formation. The DNA-Lipofectamine 2000 complex was added into 
the flask in fresh DMEM, mixed by manual agitation to equally distribute the complexes, 
and then incubated under normal culture conditions. After 6 hours, the media was 
removed, the cells were washed with PBS and the media replaced. After 24 hours, the 
media was removed and replaced again. After a further 48 hours the cells were removed 
from the flask using trypsin as previously described and were split into 6 new 10cm3 
culture dishes with media supplemented with the selection antibiotic. For the B16F10 cell 
line, both blasticidin (5μg/ml, Invitrogen) and G418 (2.5mg/ml, ThermoFisher Scientific) 
were used to maintain the mRuby2 and OVA plasmid, and concentrations were optimised 
by survival curve analysis (data not shown). Transfected cells were maintained under 
selection for up to 2 weeks until individual colonies were visible by eye. The media was 
replaced every 3-4 days as necessary.  
Plasmid Enzyme used for linearisation 
pEGFP-N3-OVA ApaL1 
pEF6-mRuby2 Ssp1 
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A.2.6 Clonal selection of transfectants 
To ensure homogenous expression of the transfected vector within the cell population, it 
was important to isolate colonies outgrowing from a single antibiotic-resistant cell. When 
the colonies were first visible by eye, they were visually isolated by drawing around the 
colony edges on the underside of the culture dish in waterproof pen. The media was 
removed from the dish using a pastette and the cells were washed once with PBS to 
remove loosely-adherent cells and debris. 5ml of PBS was then added to the culture dish. 
Individual colonies were removed from the dish by manually scraping the cells with a 10μl 
pipette tip and then were transferred into individual wells of a 48-well plate. New selection 
media was added to each well and the colonies allowed to grow to confluence before 
analysis. Transfected clones were also assessed for their growth compared to the 
untransfected B16F10 cell line, with clones growing very quickly being excluded from 
further analysis. 
To quickly screen the colonies for presentation of ovalbumin, fully confluent colonies were 
prepared for flow cytometry by first lifting the cells using TryplE and washing in PEB as 
described previously. Cells were stained with 2μl of anti-SIINFEKL-MHC class I antibody 
conjugated to APC (BioLegend, clone: 25-D1.16), with untransfected B16F10 cells used as 
a control. This antibody binds the MHC class I-restricted ovalbumin epitope SIINFEKL in 
the context of MHC class I presentation. The samples were run on the MACSQuant and 
analysed using the FlowJo 10 software. A representative sample of the transfected clones is 
shown in Figure A.4 below. 
 
Figure A.4 - Clonal selection of B16F10.ova transfectants. 
In this representative sample, only two clones expressed the ovalbumin protein fragment presented 
on MHC class I higher than the untransfected control cells (red line). 
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Several clones with high ovalbumin presentation were selected for continued use, with one 
primary clone selected for further validation before use and designated as B16F10.ova 
forthwith. Cells were routinely assessed for maintenance of transfected proteins by flow 
cytometry. 
A.3 Characterisation of B16F10.ova 
A.3.1 Gene expression by QPCR 
Quantification of ovalbumin cDNA expression was done by QPCR. B16F10.ova cells were 
first lysed with RLT buffer containing β-mercaptoethanol. The RNA was then extracted 
using the RNeasy Mini Kit (Qiagen), as per manufacturer’s instructions, including the on-
column DNase digestion step using the RNase-free DNase kit (Qiagen). cDNA was 
generated from the RNA using the High Capacity RNA to cDNA Kit (Applied 
Biosystems) as per the manufacturer’s instructions, including samples containing no RT 
enzyme as a control for genomic contamination. QPCR for gene expression was done as 
described in 2.4.4, using the primers listed in Table 2.2.  
 
 
Figure A.5 - Expression of transfected genes in B16F10.ova cells by QPCR. 
B16F10 transfectants were compared to the untransfected no-plasmid control and showed 
induction of expression of Ovalbumin and mRuby2 as desired, as well as the antibiotic resistance 
genes for Kanamycin/Neomycin and Blasticidin compared to the controls.  
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Expression levels of each transfected gene are variable compared to the housekeeping gene 
GAPDH, however Figure A.5 shows clearly the expression of the 4 genes contained 
within the plasmids used for transfection of the B16F10 cell line compared to the no 
plasmid control. Variability in the expression of individual genes may be a result of the 
genes being under the control of two different promotors, ovalbumin under the CMV 
promotor and mRuby2 under the Elongation Factor alpha (EFα) promotor, which may be 
expressed by B16F10 cells may be at different levels. The kanamycin/neomycin resistance 
cassette is part of the ovalbumin plasmid construct and allows the selection of bacterial 
clones through kanamycin or neomycin resistance as well as selection of eukaryotic cell 
clones through resistance to the antibiotic G418. The blasticidin resistance cassette is 
present in the mRuby2 construct and confers resistance to the antibiotic blasticidin in 
eukaryotic cells. The presence of transcripts of each transfected gene is a validation of 
successful transfection with both plasmids. 
A.3.2 mRuby2 protein expression 
To assess expression of the mRuby2 fluorophore, both fluorescent microscopy and flow 
cytometry were used. For microscopy, B16F10.ova cells were seeded into 4-well chamber 
slides (ThermoFisher Nunc) and grown to confluence under normal culture conditions. 
Once the cells had reached 70-80% confluence the media was removed, and the wells 
rinsed with PBS. 0.5ml of 4% PFA in PBS (v/v) was added to each chamber to fix cells 
and incubated for 20min at room temperature. After this the PFA was removed and the 
chambers rinsed with 0.5ml PBS. The chamber walls were manually removed from the 
slide, which was then allowed to dry at room temperature. The slides were mounted using 
Vectashield Hardset Antifade mounting medium (Vector Laboratories). The slides were 
assessed for cell fluorescence using an epifluorescent microscope; mRuby2 has λex of 
559nm and λem of 600 (Lam et al., 2012). The images were captured and analysed using the 
Zen software. For flow cytometry, a sample of B16F10.ova cells in culture were removed 
during routine passaging, run on the LSRII (BD Biosciences) and analysed using the 
FlowJo 10 software. 
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Figure A.6 - Validation of B16F10.ova mRuby2 expression using microscopy and flow 
cytometry. 
Expression of the mRuby2 fluorescent protein was visible by microscopy (A) and by flow cytometry 
compared to the untransfected control cells (B).  
 
mRuby2 expression by B16F10.ova transfectants is strong enough for the fluorophore to 
be visible by both microscopy and flow cytometry as seen in Figure A.6. The cell 
population does heterogeneously express the fluorophore however, and this is something 
that needs to be taken into consideration in future experiments. The mRuby2 fluorophore 
expression is also stable over routine passage (data not shown). 
A.3.3 Ovalbumin protein expression 
Assessing ovalbumin expression in the B16F10 transfected cell line was expected to be 
difficult because of the poor expression of both MHC class I and MHC class II molecules 
on tumour cells is well characterised and has been reported in the B16F10 cell line (Seliger 
et al., 2001). The B16 model is a very commonly used tumour model and can still be 
targeted by CD8+ T cells in vitro and in vivo. To better understand the mechanism by 
which this is occurring, expression of MHC class I and II were tested following exposure 
to the inflammatory cytokine IFNγ.  
B16F10 cells were seeded onto 24-well culture plates and allowed to grow to confluence 
under normal culture conditions. Once confluence had been reached, the media in the wells 
was removed and replaced with 1ml of media containing IFNγ at 20ng/ml or 50ng/ml, or 
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no IFNγ as a control. After 48 hours, the cells were prepared for flow cytometry by lifting 
with TrypLE and washing into PEB as described in Chapter 2. Cells were stained with 2μl 
of anti-H-2kb antibody conjugated to AF647 (BioLegend, clone: AF6-88.5) and anti-I-A/I-
E antibody conjugated to AF488 (BioLegend, clone: M5/114.15.2). These antibodies stain 
MHC class I and II, respectively. The samples were run on the MACSQuant and analysed 
using the FlowJo 10 software. 
 
Figure A.7 - MHC class I and II expression of B16F10.ova cells under inflammatory 
conditions. 
B16F10 cells were exposed to increasing concentrations of IFNγ and show a clear increase in the 
expression of both MHC class I and MHC class II. 
 
As shown in Figure A.7, B16F10 cells are capable of upregulating MHC class I and II 
molecules during stimulation with as little as 20ng/ml IFNγ. General inflammation in the 
tumour microenvironment is likely to include IFNγ secretion by cells of the innate immune 
system such as NK cells, as well as by adaptive immune cells recruited to the site such as 
CD8+ T cells (Böhm et al., 1998), suggesting a potential mechanism for tumour rejection. 
A.3.4 CTL lysis assay 
To confirm that B16F10.ova cells present the ovalbumin epitope using MHC, a T cell 
killing assay was performed using ovalbumin-specific T cells. These T cells were isolated 
from the lymph nodes and spleens of OT-I mice, a strain of genetically modified mice with 
CD8+ T cells recognising only the MHC class I-restricted epitope of ovalbumin, 
SIINFEKL. In vitro, this can be used to quantify the full potential T cell responses to a 
known antigen. To do this, T cells were isolated from OT-I mice and expanded as 
described previously in 2.5.3.2 and 2.6.5.  
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After 7 days in culture, the cells were then collected using TrypLE for use. B16F10.ova 
cells were also collected from routine culture using TrypLE and plated on 12-well tissue 
culture plates at a concentration of 2x105 B16F10.ova cells with T cells added at ratios of 
1:5, 1:10, 1:20 and 1:40 in a total volume of 1ml complete RPMI/well. After 4 hours of 
culture, the cells were prepared for flow cytometry by lifting with TrypLE and washing 
into Annexin Binding Buffer (BioLegend) at a 1x106 cells/ml. Cells were stained with 5μl 
of Annexin V conjugated to FITC (BioLegend) for 15min at room temperature, and 1μl of 
DRAQ7 (Biostatus) was added immediately prior to flow cytometry. 
 
Figure A.8 - B16F10.ova targeting by activated antigen-specific T cells.  
B16F10.ova cells were incubated with activated ova-specific T cells at increasing concentrations of 
T cells. Cells in culture were gated on expression of mRuby2 and Annexin V/DRAQ7 to distinguish 
cells undergoing early/late apoptosis; showing B16F10.ova cells undergo more apoptosis with 
increasing T cell concentration. 
 
Annexin-V binds to phosphatidylserine (PS) on the cell membrane, which translocates to 
the extracellular membrane leaflet as the cell membrane loses its asymmetric architecture 
during early apoptosis. As apoptosis progresses, the cell membrane loses integrity and 
Annexin-V can also bind PS within the cell. DRAQ7, in contrast, binds double stranded 
DNA (dsDNA) which is only accessible for binding during late, and not early, apoptosis. A 
combination of Annexin-V and DRAQ7 staining can therefore be used to distinguish live 
cells from early and late apoptotic cells. As shown in Figure A.8, increasing the ratio of T 
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cells to B16F10.ova cells resulted in a dose-dependent T-cell mediated induction of 
apoptosis in the melanoma cells. Since all of the T cells present in the culture are specific 
for the SIINFEKL residue presented on MHC class I, B16F10.ova cells must both produce 
this protein endogenously and present it on the cell surface highly enough for recognition 
by T cells.  
 
A.4 Conclusion 
This Chapter details the process for construction of the ovalbumin plasmid for transfection 
of the B16F10 cell line, as well as the protocol used for the transfection of the cells. The 
cells were also transfected with mRuby2 to allow visualisation of the tumours in vitro. 
B16F10.ova cells were validated for successful transfection with the plasmids using QPCR 
for expression of the plasmid genes, and fluorescence microscopy and flow cytometry for 
expression of the proteins. The cells were also assessed functionally, by induction of 
apoptosis using antigen-specific T cells in vitro, showing that although MHC class I and II 
machinery is not highly expressed at rest, under inflammatory conditions the cells can be 
effectively targeted by the adaptive immune system. Taking these data together, the 
B16F10.ova cell line was successfully created and is a viable cancer model for this project. 
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